EP3925614A2

Melanocortin receptor ligands

Abstract

The present invention is directed to compounds according to the formula (R2R3)-A1-c (A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1, and pharmaceutically acceptable salts thereof that act as ligands for one or more of the melanocortin receptors, to methods of using such compounds to treat mammals and to pharmaceutical compositions comprising said compounds.

EP3925614A2, drawing sheet 1 — Sheet 1 of 303

Term

Term ended

Projected expiry passed 10 July 2026, 0.2 years ago.

15 claims: 4 independent, 11 dependent

1
A compound according to formula (I):(R 2 R 3 )-A 1 -c(A 2 -A 3 -A 4 -A 5 -A 6 -A 7 -A 6 -A 9 )-A 10 -R 1 wherein: A 1 is Acc, HN-(CH 2 ) m -C(O), L- or D-amino acid or deleted;A 2 is Cys, D-Cys, hCys, D-hCys, Pen, D-Pen, Asp or Glu;A 3 is Gly, Ala, β-Ala, Gaba, Aib, D-amino acid or deleted;A 4 is His, 2-Pal, 3-Pal, 4-Pal, Taz, 2-Thi, 3-Thi or (X 1 ,X 2 ,X 3 ,X 4 ,X 5 )Phe;A 5 is D-Phe, D-1-Nal, D-2-Nal, D-Trp, D-Bal, D-(X 1 ,X 2 ,X 3 ,X 4 ,X 5 )Phe, L-Phe or D-(Et)Tyr;A 6 is Arg, hArg, Dab, Dap, Lys, Orn or HN-CH((CH 2 ) n -N(R 4 R 5 ))-C(O);A 7 is Trp, 1-Nal, 2-Nal, Bal, Bip, D-Trp, D-1-Nal, D-2-Nal, D-Bal or D-Bip;A 8 is Gly, D-Ala, Acc, Ala, β-Ala, Gaba, Apn, Ahx, Aha, HN-(CH 2 ) s -C(O) or deleted;A 9 is Cys, D-Cys, hCys, D-hCys, Pen, D-Pen, Dab, Dap, Orn or Lys;A 10 is Acc, HN-(CH 2 ) t -C(O), L- or D-amino acid or deleted;R 1 is -OH or -NH 2 ;R 2 and R 3 is, independently for each occurrence, H, (C 1 -C 30 )alkyl, (C 1 -C 30 )heteroalkyl, (C 1 -C 30 )acyl, (C 2 -C 30 )alkenyl, (C 2 -C 30 )alkynyl, aryl(C 1 -C 30 )alkyl, aryl(C 1 -C 30 )acyl, substituted (C 1 -C 30 )alkyl, substituted (C 1 -C 30 )heteroalkyl, substituted (C 1 -C 30 )acyl, substituted (C 2 -C 30 )alkenyl, substituted (C 2 -C 30 )alkynyl, substituted aryl(C 1 -C 30 )alkyl or substituted aryl(C 1 -C 30 )acyl;R 4 and R 5 is, independently for each occurrence, H, (C 1 -C 40 )alkyl, (C 1 -C 40 )heteroalkyl, (C 1 -C 40 )acyl, (C 2 -C 40 )alkenyl, (C 2 -C 40 )alkynyl, aryl(C 1 -C 40 )alkyl, aryl(C 1 -C 40 )acyl, substituted (C 1 -C 40 )alkyl, substituted (C 1 -C 40 )heteroalkyl, substituted (C 1 -C 40 )acyl, substituted (C 2 -C 40 )alkenyl, substituted (C 2 -C 40 )alkynyl, substituted aryl(C 1 -C 40 )alkyl, substituted aryl(C 1 -C 40 )acyl, (C 1 -C 40 )alkylsulfonyl or -C(NH)-NH 2 ;m is, independently for each occurrence, 1, 2, 3, 4, 5, 6 or 7;n is, independently for each occurrence, 1, 2, 3, 4 or 5;s is, independently for each occurrence, 1, 2, 3, 4, 5, 6 or 7;t is, independently for each occurrence, 1, 2, 3, 4, 5, 6 or 7;and X 1 , X 2 , X 3 , X 4 , and X 5 each is, independently for each occurrence, H, F, Cl, Br, I, (C 1-10 )alkyl, substituted (C 1-10 )alkyl, (C 2-10 )alkenyl, substituted (C 2-10 )alkenyl, (C 2-10 )alkynyl, substituted (C 2-10 )alkynyl, aryl, substituted aryl, OH, NH 2 , NO 2 , or CN;provided that (I). when R 4 is (C 1 -C 40 )acyl, aryl(C 1 -C 40 )acyl, substituted (C 1 -C 40 )acyl, substituted aryl(C 1 -C 40 )acyl, (C 1 -C 40 )alkylsulfonyl or -C(NH)-NH 2 , then R 5 is H, (C 1 -C 40 )alkyl, (C 1 -C 40 )heteroalkyl, (C 2 -C 40 )alkenyl, (C 2 -C 40 )alkynyl, aryl(C 1 -C 40 )alkyl, substituted (C 1 -C 40 )alkyl, substituted (C 1 -C 40 )heteroalkyl, substituted (C 2 -C 40 )alkenyl, substituted (C 2 -C 40 )alkynyl or substituted aryl(C 1 -C 40 )alkyl;(II). when R 2 is (C 1 -C 30 )acyl, aryl(C 1 -C 30 )acyl, substituted (C 1 -C 30 )acyl or substituted aryl(C 1 -C 30 )acyl, then R 3 is H, (C 1 -C 30 )alkyl, (C 1 -C 30 )heteroalkyl, (C 2 -C 30 )alkenyl, (C 2 -C 30 )alkynyl, aryl(C 1 -C 30 )alkyl, substituted (C 1 -C 30 )alkyl, substituted (C 1 -C 30 )heteroalkyl, substituted (C 2 -C 30 )alkenyl, substituted (C 2 -C 30 )alkynyl or substituted aryl(C 1 -C 30 )alkyl;(III). either A 3 or A 8 or both must be present in said compound;(IV). when A 2 is Cys, D-Cys, hCys, D-hCys, Pen or D-Pen, then A 9 is Cys, D-Cys, hCys, D-hCys, Pen or D-Pen;(V). when A 2 is Asp or Glu, then A 9 is Dab, Dap, Orn or Lys;(VI). when A 8 is Ala or Gly, then A 1 is not Nle;and (VII). when A 1 is deleted, then R 2 and R 3 cannot both be H;or a pharmaceutically acceptable salt thereof.
3
A compound according to any one of claims 1 and 2, wherein:R 2 and R 3 is, independently for each occurrence, H, acyl, n-propanoyl or n-butanoyl;or a pharmaceutically acceptable salt thereof.
4
A compound according to any one of claims 1-3, wherein:A 1 is Acc, Arg, D-Arg, Cha, D-Cha, hCha, Chg, D-Chg, Gaba, Ile, Leu, hLeu, β- hMet, 2-Nal, D-2-Nal, Nip, Nle, Oic, Phe, D-Phe, hPhe, hPro, Val or deleted;A 2 is Cys, D-Cys, Pen or Asp;A 3 is Gly, Ala, β-Ala, Gaba, Aib, D-Ala, D-Abu, D-Cha, D-Ile, D-Leu, D-Tle, D-Val or deleted;A 4 is His or 3-Pal;A 5 is D-Phe, D-2-Nal or D-(Et)Tyr;A 6 is Arg or hArg;A 7 is Trp, 1-Nal, 2-Nal, Bal, Bip or D-Trp;A 8 is Gly, D-Ala, Acc, Ala, β-Ala, Gaba, Apn, Ahx, Aha or deleted;A 9 is Cys, D-Cys, Pen or Lys;and A 10 is Thr or deleted;provided that either A 3 or A 8 is deleted, but not both;or a pharmaceutically acceptable salt thereof.
6
A compound according to any one of claims 1-5, wherein R 2 and R 3 is, independently for each occurrence, H or acyl;A 1 is Arg, D-Arg, Cha, hCha, Chg, D-Chg, Ile, Leu, 2-Nal, Nle, Phe, D-Phe, hPhe, Val or deleted;A 2 is Cys, D-Cys, hCys, D-hCys, Pen, or D-Pen;A 3 is Gly, Ala, D-Ala, D-Glu, β-Ala, Gaba, Aib or deleted;A 4 is His;A 5 is D-Phe;A 6 is Arg or hArg;A 7 is Trp, 2-Nal, Bal, Bip or D-Trp;A 8 is Gly, Ala, β-Ala, Gaba, Apn, Ahx or deleted;A 9 is Cys, D-Cys, or Pen;and A 10 is Thr or deleted, or a pharmaceutically acceptable salt thereof.
8
A compound according to formula (II):(R 2 R 3 )-A 1 -c(A 2 -A 3 -A 4 -A 5 -A 6 -A 7 -A 8 -A 9 )-NH 2 wherein: A 1 is Nle or deleted;A 2 is Cys or Asp;A 3 is Glu or D-Ala;A 4 is His;A 5 is D-Phe;A 6 is Arg;A 7 is Trp, 2-Nal or Bal;A 8 is Gly, Ala, D-Ala, β-Ala, Gaba or Apn;A 9 is Cys or Lys;each of R 2 and R 3 is independently selected from the group consisting of H or (C 1 -C 6 )acyl;provided that (I). when R 2 is (C 1 -C 6 )acyl, then R 3 is H;and (II). when A 2 is Cys, then A 9 is Cys, or a pharmaceutically acceptable salt thereof.
10
A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.

Independent claims6

158 paragraphs in 5 sections, as filed

BACKGROUND OF THE INVENTION

0001The present invention is directed to peptides which are ligands of one or more of the melanocortin receptors (MC-R), the pharmaceutically-acceptable salts thereof, to methods of using such peptides to treat mammals and to useful pharmaceutical compositions comprising said peptides.

0002Melanocortins are a family of regulatory peptides which are formed by post-translational processing of pro-hormone pro-opiomelanocortin (POMC; 131 amino acids in length). POMC is processed into three classes of hormones; the melanocortins, adrenocorticotropin hormone, and various endorphins (e.g. lipotropin) (<nplcit id="ncit0001" npl-type="s"><text>Cone, et al., Recent Prog. Horm. Res., 51:287-317, (1996</text></nplcit>); <nplcit id="ncit0002" npl-type="s"><text>Cone et al., Ann. N.Y. Acad. Sci., 31:342-363, (1993</text></nplcit>)).

0003Melanocortins have been found in a wide variety of normal human tissues including the brain, adrenal, skin, testis, spleen, kidney, ovary, lung, thyroid, liver, colon, small intestine and pancreas (<nplcit id="ncit0003" npl-type="s"><text>Tatro, J. B. et al., Endocrinol. 121:1900-1907 (1987</text></nplcit>); <nplcit id="ncit0004" npl-type="s"><text>Mountjoy, K. G. et al., Science 257:1248-1251 (1992</text></nplcit>); <nplcit id="ncit0005" npl-type="s"><text>Chhajlani, V. et al., FEBS Lett. 309:417-420 (1992</text></nplcit>); <nplcit id="ncit0006" npl-type="s"><text>Gantz, I. et al. J. Biol. Chem. 268:8246-8250 (1993</text></nplcit>) and <nplcit id="ncit0007" npl-type="s"><text>Gantz, I. et al., J. Biol. Chem. 268:15174-15179 (1993</text></nplcit>)).

0004Melanocortin peptides have been shown to exhibit a wide variety of physiological activities including the control of behavior and memory, affecting neurotrophic and antipyretic properties, as well as affecting the modulation of the immune system. Aside from their well known effects on adrenal cortical functions (adrenocorticotropic hormone, ACTH) and on melanocytes (melanocyte stimulating hormone, MSH), melanocortins have also been shown to control the cardiovascular system, analgesia, thermoregulation and the release of other neurohumoral agents including prolactin, luteinizing hormone and biogenic amines (<nplcit id="ncit0008" npl-type="s"><text>De Wied, D. et al., Methods Achiev. Exp. Pathol. 15:167-199 (1991</text></nplcit>); <nplcit id="ncit0009" npl-type="s"><text>De Wied, D. et al., Physiol. Rev. 62:977-1059 (1982</text></nplcit>); <nplcit id="ncit0010" npl-type="s"><text>Guber, K.A. et al., Am. J. Physiol. 257:R681-R694 (1989</text></nplcit>); <nplcit id="ncit0011" npl-type="s"><text>Walker J.M. et al., Science 210:1247-1249 (1980</text></nplcit>); <nplcit id="ncit0012" npl-type="s"><text>Murphy, M. T. et al., Science 221:192-193 (1983</text></nplcit>); <nplcit id="ncit0013" npl-type="s"><text>Ellerkmann, E. et al., Endocrinol. 130:133-138 (1992</text></nplcit>) and <nplcit id="ncit0014" npl-type="s"><text>Versteeg, D. H. G. et al., Life Sci. 38:835-840 (1986</text></nplcit>)).

0005It has also been shown that binding sites for melanocortins are distributed in many different tissue types including lachrymal and submandibular glands, pancreas, adipose, bladder, duodenum, spleen, brain and gonadal tissues as well as malignant melanoma tumors. Five melanocortin receptors (MC-R) have been characterized to date. These include melanocyte-specific receptor (MC1-R), corticoadrenal-specific ACTH receptor (MC2-R), melacortin-3 (MC3-R), melanocortin-4 (MC4-R) and melanocortin-5 receptor (MC5-R). All of the melanocortin receptors respond to the peptide hormone class of melanocyte stimulating hormones (MSH) (<nplcit id="ncit0015" npl-type="s"><text>Cone, R. D. et al., Ann. N.Y. Acad. Sci., 680:342-363 (1993</text></nplcit>); <nplcit id="ncit0016" npl-type="s"><text>Cone, R. D. et al., Recent Prog. Horm. Res., 51:287-318 (1996</text></nplcit>)).

0006MC1-R, known in the art as Melanocyte Stimulating Hormone Receptor (MSH-R), Melanotropin Receptor or Melanocortin-1 Receptor, is a 315 amino acid transmembrane protein belonging to the family of G-Protein coupled receptors. MC1-R is a receptor for both MSH and ACTH. The activity of MC1-R is mediated by G-proteins which activate adenylate cyclase. MC1-R receptors are found in melanocytes and corticoadrenal tissue as well as various other tissues such as adrenal gland, leukocytes, lung, lymph node, ovary, testis, pituitary, placenta, spleen and uterus. MC2-R, also called Adrenocorticotropic hormone receptor (ACTH-R), is a 297 amino acid transmembrane protein found in melanocytes and the corticoadrenal tissue. MC2-R mediates the corticotrophic effect of ACTH. In humans, MC3-R is a 360 AA protein found in brain tissue; in mice and rats MC3-R is a 323 AA protein. MC4-R is a 332 amino acid transmembrane protein which is also expressed in brain as well as placental and gut tissues. MC5-R is a 325 amino acid transmembrane protein expressed in the adrenals, stomach, lung and spleen and very low levels in the brain. MC5-R is also expressed in the three layers of adrenal cortex, predominantly in the aldosterone-producing zona glomerulosa cells.

0007The five known melanocortin receptors differ, however, in their functions. For example, MC1-R is a G-protein coupled receptor that regulates pigmentation in response to α-MSH, a potent agonist of MC1-R. Agonism of the MC1-R receptor results in stimulation of the melanocytes which causes eumelanin and increases the risk for cancer of the skin. Agonism of MC1-R can also have neurological effects. Stimulation of MC2-R activity can result in carcinoma of adrenal tissue. Recent pharmacological confirmation has established that central MC4-R receptors are the prime mediators of the anorexic and orexigenic effects reported for melanocortin agonists and antagonists, respectively. The effects of agonism of the MC3-R and MC5-R are not yet known.

0008There has been great interest in melanocortin (MC-R) receptors as targets for the design of novel therapeutics to treat disorders of body weight such as obesity and cachexia. Both genetic and pharmacological evidence points toward central MC4-R receptors as the principal target (<nplcit id="ncit0017" npl-type="s"><text>Giraudo, S. Q. et al., Brain Res., 809:302-306 (1998</text></nplcit>); <nplcit id="ncit0018" npl-type="s"><text>Farooqi, I. S. et al., NE J Med., 348:1085-1095 (2003</text></nplcit>); <nplcit id="ncit0019" npl-type="s"><text>MacNeil, D. J. et al., Eu. J. Pharm., 44:141-157 (2002</text></nplcit>); <nplcit id="ncit0020" npl-type="s"><text>MacNeil, D. J. et al., Eu. J. Pharm., 450:93-109 (2002</text></nplcit>); <nplcit id="ncit0021" npl-type="s"><text>Kask, A. et al., NeuroReport, 10:707-711 (1999</text></nplcit>)). The current progress with receptor-selective agonists and antagonists evidences the therapeutic potential of melanocortin receptor activation, particularly MC4-R.

0009Agonist, antagonist or other ligand compounds activating one or more melanocortin receptor would be useful for treating a wide variety of indications in a subject in need thereof or at risk thereof including acute and chronic inflammatory diseases such as general inflammation (<patcit id="pcit0001" dnum="US6613874B"><text>U.S. Patent No. 6,613,874</text></patcit>; <nplcit id="ncit0022" npl-type="s"><text>Catania, A. et al., Pharm. Rev., 56:1-29 (2004</text></nplcit>)), inflammatory bowel disease (<patcit id="pcit0002" dnum="US6713487B"><text>U.S. Patent No. 6,713,487</text></patcit>; <nplcit id="ncit0023" npl-type="s"><text>Catania, A. et al., Pharm. Rev., 56:1-29 (2004</text></nplcit>)), brain inflammation (<nplcit id="ncit0024" npl-type="s"><text>Catania, A. et al., Pharm. Rev., 56:1-29 (2004</text></nplcit>)), sepsis (<patcit id="pcit0003" dnum="US6613874B"><text>U.S. Patent No. 6,613,874</text></patcit>; <patcit id="pcit0004" dnum="US6713487B"><text>U.S. Patent No. 6,713,487</text></patcit>; <nplcit id="ncit0025" npl-type="s"><text>Catania, A. et al., Pharm. Rev., 56:1-29 (2004</text></nplcit>)) and septic shock (<patcit id="pcit0005" dnum="US6613874B"><text>U.S. Patent No. 6,613,874</text></patcit>; <nplcit id="ncit0026" npl-type="s"><text>Catania, A. et al., Pharm. Rev., 56:1-29 (2004</text></nplcit>)); diseases with an autoimmune component such as rheumatoid arthritis (<patcit id="pcit0006" dnum="US6713487B"><text>U.S. Patent No. 6,713,487</text></patcit>; <nplcit id="ncit0027" npl-type="s"><text>Catania, A. et al., Pharm. Rev., 56:1-29 (2004</text></nplcit>)), gouty arthritis (<nplcit id="ncit0028" npl-type="s"><text>Catania, A. et al., Pharm. Rev., 56:1-29 (2004</text></nplcit>), <nplcit id="ncit0029" npl-type="s"><text>Getting, S. J. et al., Curr. Opin. Investig. Drugs, 2:1064-1069 (2001</text></nplcit>)), and multiple sclerosis ((<patcit id="pcit0007" dnum="US6713487B"><text>U.S. Patent No. 6,713,487</text></patcit>); metabolic diseases and medical conditions accompanied by weight gain such as obesity (U.S. <patcit id="pcit0008" dnum="US6613874B"><text>6,613,874</text></patcit>; <patcit id="pcit0009" dnum="US6600015B"><text>U.S. Patent No. 6,600,015</text></patcit>; <nplcit id="ncit0030" npl-type="s"><text>Fehm, H. L. et al., J. Clin. Endo. & Metab., 86:1144-1148 (2001</text></nplcit>); <nplcit id="ncit0031" npl-type="s"><text>Hansen, M. J. et al., Brain Res., 1039:137-145 (2005</text></nplcit>); <nplcit id="ncit0032" npl-type="s"><text>Ye, Z. et al., Peptides, 26:2017-2025 (2005</text></nplcit>); <nplcit id="ncit0033" npl-type="s"><text>Farooqi, I. S. et al., NE J Med., 348:1085-1095 (2003</text></nplcit>); <nplcit id="ncit0034" npl-type="s"><text>MacNeil, D. J. et al., Eu. J. Pharm., 44:141-157 (2002</text></nplcit>); <nplcit id="ncit0035" npl-type="s"><text>MacNeil, D. J. et al., Eu. J. Pharm., 450:93-109 (2002</text></nplcit>); <nplcit id="ncit0036" npl-type="s"><text>Kask, A. et al., NeuroReport, 10:707-711 (1999</text></nplcit>); <nplcit id="ncit0037" npl-type="s"><text>Schwartz, M. W., J. Clin. Invest., 108:963-964 (2001</text></nplcit>), <nplcit id="ncit0038" npl-type="s"><text>Gura, T., Science, 287:1738-1740 (2000</text></nplcit>), <nplcit id="ncit0039" npl-type="s"><text>Raffin-Sanson, M. L., Eu. J. Endo., 144:207-208 (2001</text></nplcit>), <nplcit id="ncit0040" npl-type="s"><text>Hamilton, B. S. et al., Obesity Res. 10:182-187 (2002</text></nplcit>)), feeding disorders (<patcit id="pcit0010" dnum="US6720324B"><text>U.S. Patent No. 6,720,324</text></patcit>; <nplcit id="ncit0041" npl-type="s"><text>Fehm, H. L. et al., J. Clin. Endo. & Metab., 86:1144-1148 (2001</text></nplcit>); <nplcit id="ncit0042" npl-type="s"><text>Pontillo, J. et al., Bioorganic & Med. Chem. Ltrs., 15:2541-2546 (2005</text></nplcit>)) and Prader-Willi Syndrome (<nplcit id="ncit0043" npl-type="s"><text>GE, Y. et al., Brain Research, 957:42-45 (2002</text></nplcit>)); metabolic diseases and medical conditions accompanied by weight loss such as anorexia (<patcit id="pcit0011" dnum="US6613874B"><text>U.S. Patent No. 6,613,874</text></patcit>; <nplcit id="ncit0044" npl-type="s"><text>Wisse, B. R. et al., Endo., 142:3292-3301 (2001</text></nplcit>)), bulimia (<patcit id="pcit0012" dnum="US6720324B"><text>U.S. Patent No. 6,720,324</text></patcit>), AIDS wasting (<nplcit id="ncit0045" npl-type="s"><text>Marsilje, T. H. et al., Bioorg. Med. Chem. Lett., 14:3721-3725 (2004</text></nplcit>); <nplcit id="ncit0046" npl-type="s"><text>Markison, S. et al., Endocrinology, 146:2766-2773 (2005</text></nplcit>)), cachexia (<patcit id="pcit0013" dnum="US6613874B"><text>U.S. Patent No. 6,613,874</text></patcit>; <nplcit id="ncit0047" npl-type="s"><text>Lechan, R. M. et al., Endo., 142:3288-3291 (2001</text></nplcit>); <nplcit id="ncit0048" npl-type="s"><text>Pontillo, J. et al., Bioorganic & Med. Chem. Ltrs., 15:2541-2546 (2005</text></nplcit>)), cancer cachexia (<patcit id="pcit0014" dnum="US6639123B"><text>U.S. Patent No. 6,639,123</text></patcit>) and wasting in frail elderly (<patcit id="pcit0015" dnum="US6639123B"><text>U.S. Patent No. 6,639,123</text></patcit>); diabetes (<patcit id="pcit0016" dnum="US6713487B"><text>U.S. Patent No. 6,713,487</text></patcit>) and diabetalogical related conditions and complications of diabetes such as retinopathy (<patcit id="pcit0017" dnum="US6525019B"><text>U.S. Patent No. 6,525,019</text></patcit>); neoplastic proliferation (<patcit id="pcit0018" dnum="US6713487B"><text>U.S. Patent No. 6,713,487</text></patcit>) such as skin cancer (<nplcit id="ncit0049" npl-type="s"><text>Sturm, R.A., Melanoma Res., 12:405-416 (2002</text></nplcit>); <nplcit id="ncit0050" npl-type="s"><text>Bastiens, M. T. et al., Am. J. Hum. Genet., 68:884-894 (2001</text></nplcit>)), and prostate cancer (<nplcit id="ncit0051" npl-type="s"><text>Luscombe, C. J. et al., British J. Cancer, 85:1504-1509 (2001</text></nplcit>); reproductive or sexual medical conditions such as endometriosis (<patcit id="pcit0019" dnum="US6713487B"><text>U.S. Patent No. 6,713,487</text></patcit>) and uterine bleeding in women (<patcit id="pcit0020" dnum="US6613874B"><text>U.S. Patent No. 6,613,874</text></patcit>), sexual dysfunction (<patcit id="pcit0021" dnum="US6720324B"><text>U.S. Patent No. 6,720,324</text></patcit>; <nplcit id="ncit0052" npl-type="s"><text>Van der Ploeg, L. H. T. et al., PNAS, 99:11381-11386 (2002</text></nplcit>), <nplcit id="ncit0053" npl-type="s"><text>Molinoff, P. B. et al., Ann. N.Y. Acad. Sci., 994:96-102 (2003</text></nplcit>), <nplcit id="ncit0054" npl-type="s"><text>Hopps, C. V. et al., BJU International, 92:534-538 (2003</text></nplcit>)), erectile dysfunction ((<patcit id="pcit0022" dnum="US6613874B"><text>U.S. Patent No. 6,613,874</text></patcit>; <nplcit id="ncit0055" npl-type="s"><text>Diamond, L. E. et al., Urology, 65:755-759 (2005</text></nplcit>), <nplcit id="ncit0056" npl-type="s"><text>Wessells, H. et al., Int. J. Impotence Res., 12:S74-S79 (2000</text></nplcit>), <nplcit id="ncit0057" npl-type="s"><text>Andersson K-E. et al., Int. J. Impotence Res., 14:S82-S92 (2002</text></nplcit>), <nplcit id="ncit0058" npl-type="b"><text>Bertolini, A. et. al., Sexual Behavior: Pharmacology and Biochemistry, Raven Press, NY, p 247-257</text></nplcit> (1975); <nplcit id="ncit0059" npl-type="s"><text>Wessells, H. et al., Neuroscience, 118:755-762 (2003</text></nplcit>), <nplcit id="ncit0060" npl-type="s"><text>Wessells, H. et al., Urology, 56:641-646 (2000</text></nplcit>), <nplcit id="ncit0061" npl-type="s"><text>Shadiack, A. M. et al., Society for Neuroscience Abstract, (2003</text></nplcit>); <nplcit id="ncit0062" npl-type="s"><text>Wessells, H. et al., J. Urology, 160:389-393 (1998</text></nplcit>), <nplcit id="ncit0063" npl-type="s"><text>Rosen, R. C. et al., Int. J. Impotence Res., 16:135-142 (2004</text></nplcit>), <nplcit id="ncit0064" npl-type="s"><text>Wessells, H. et al., Peptides, 26:1972-1977 (2005</text></nplcit>)) and decreased sexual response in females (<patcit id="pcit0023" dnum="US6713487B"><text>U.S. Patent No. 6,713,487</text></patcit>; <nplcit id="ncit0065" npl-type="s"><text>Fourcroy, J. L., Drugs, 63:1445-1457 (2003</text></nplcit>)); diseases or conditions resulting from treatment or insult to the organism such as organ transplant rejection (<patcit id="pcit0024" dnum="US6713487B"><text>U.S. Patent No. 6,713,487</text></patcit>; <nplcit id="ncit0066" npl-type="s"><text>Catania, A. et al., Pharm. Rev., 56:1-29 (2004</text></nplcit>)), ischemia and reperfusion injury (<nplcit id="ncit0067" npl-type="s"><text>Mioni, C. et al., Eu. J. Pharm., 477:227-234 (2003</text></nplcit>); <nplcit id="ncit0068" npl-type="s"><text>Catania, A. et al., Pharm. Rev., 56:1-29 (2004</text></nplcit>)), treatment of spinal cord injury and to accelerate wound healing (<nplcit id="ncit0069" npl-type="s"><text>Sharma H. S. et al., Acta. Nerochir. Suppl., 86:399-405 (2003</text></nplcit>); <nplcit id="ncit0070" npl-type="s"><text>Sharma H.S., Ann. N.Y. Acad. Sci. 1053: 407-421 (2005</text></nplcit>); <patcit id="pcit0025" dnum="US6525019B"><text>U.S. Patent No. 6,525,019</text></patcit>), as well as weight loss caused by chemotherapy, radiation therapy, temporary or permanent immobilization (<nplcit id="ncit0071" npl-type="s"><text>Harris, R. B. et al., Physiol. Behav., 73:599-608 (2001</text></nplcit>)) or dialysis; cardiovascular diseases or conditions such as hemorrhagic shock (<nplcit id="ncit0072" npl-type="s"><text>Catania, A. et al., Pharm. Rev., 56:1-29 (2004</text></nplcit>)), cardiogenic shock (<patcit id="pcit0026" dnum="US6613874B"><text>U.S. Patent No. 6,613,874</text></patcit>), hypovolemic shock (<patcit id="pcit0027" dnum="US6613874B"><text>U.S. Patent No. 6,613,874</text></patcit>), cardiovascular disorders (<patcit id="pcit0028" dnum="US6613874B"><text>U.S. Patent No. 6,613,874</text></patcit>) and cardiac cachexia (<nplcit id="ncit0073" npl-type="s"><text>Markison, S. et al., Endocrinology, 146:2766-2773 (2005</text></nplcit>); pulmonary diseases or conditions such as acute respiratory distress syndrome (<patcit id="pcit0029" dnum="US6350430B"><text>U.S. Patent No. 6,350,430</text></patcit>; <nplcit id="ncit0074" npl-type="s"><text>Catania, A. et al., Pharm. Rev., 56:1-29 (2004</text></nplcit>)), chronic obstructive pulmonary disease (<patcit id="pcit0030" dnum="US6713487B"><text>U.S. Patent No. 6,713,487</text></patcit>), asthma (<patcit id="pcit0031" dnum="US6713487B"><text>U.S. Patent No. 6,713,487</text></patcit>) and pulmonary fibrosis; to enhance immune tolerance (<nplcit id="ncit0075" npl-type="s"><text>Luger, T. A. et al., Pathobiology, 67:318-321 (1999</text></nplcit>)) and to combat assaults to the immune system such as those associated with certain allergies (<patcit id="pcit0032" dnum="US6713487B"><text>U.S. Patent No. 6,713,487</text></patcit>) or organ transplant rejection (<patcit id="pcit0033" dnum="US6713487B"><text>U.S. Patent No. 6,713,487</text></patcit>; <nplcit id="ncit0076" npl-type="s"><text>Catania, A. et al., Pharm. Rev., 56:1-29 (2004</text></nplcit>)); treatment of dermatological diseases and conditions such as psoriasis (<patcit id="pcit0034" dnum="US6713487B"><text>U.S. Patent No. 6,713,487</text></patcit>), skin pigmentation depletion (<patcit id="pcit0035" dnum="US6713487B"><text>U.S. Patent No. 6,713,487</text></patcit>; <nplcit id="ncit0077" npl-type="s"><text>Ye, Z. et al., Peptides, 26:2017-2025 (2005</text></nplcit>)), acne (<nplcit id="ncit0078" npl-type="s"><text>Hatta, N. et al., J. Invest. Dermatol., 116:564-570 (2001</text></nplcit>); <nplcit id="ncit0079" npl-type="s"><text>Bohm, M. et al., J. Invest. Dermatol., 118:533-539 (2002</text></nplcit>)), keloid formation (<patcit id="pcit0036" dnum="US6525019B"><text>U.S. Patent No. 6,525,019</text></patcit>) and skin cancer (<nplcit id="ncit0080" npl-type="s"><text>Sturm, R.A., Melanoma Res., 12:405-416 (2002</text></nplcit>); <nplcit id="ncit0081" npl-type="s"><text>Bastiens, M. T. et al., Am. J. Hum. Genet., 68:884-894 (2001</text></nplcit>)); behavioral, central nervous system or neuronal conditions and disorders such as anxiety (<patcit id="pcit0037" dnum="US6720324B"><text>U.S. Patent No. 6,720,324</text></patcit>; <nplcit id="ncit0082" npl-type="s"><text>Pontillo, J. et al., Bioorganic & Med. Chem. Ltrs., 15:2541-2546 (2005</text></nplcit>)), depression (<nplcit id="ncit0083" npl-type="s"><text>Chaki, S. et al., Peptides, 26:1952-1964 (2005</text></nplcit>), <nplcit id="ncit0084" npl-type="s"><text>Bednarek, M. A. et al., Expert Opinion Ther. Patents, 14:327-336 (2004</text></nplcit>); <patcit id="pcit0038" dnum="US6720324B"><text>U.S. Patent No. 6,720,324</text></patcit>), memory and memory dysfunction (<patcit id="pcit0039" dnum="US6613874B"><text>U.S. Patent No. 6,613,874</text></patcit>; <nplcit id="ncit0085" npl-type="s"><text>Voisey, J. et al., Curr. Drug Targets, 4:586-597 (2003</text></nplcit>)), modulating pain perception (<patcit id="pcit0040" dnum="US6613874B"><text>U.S. Patent No. 6,613,874</text></patcit>; <nplcit id="ncit0086" npl-type="s"><text>Bertolini, A. et al., J. Endocrinol. Invest., 4:241-251 (1981</text></nplcit>); <nplcit id="ncit0087" npl-type="s"><text>Vrinten, D. et al., J. Neuroscience, 20:8131-8137 (2000</text></nplcit>)) and treating neuropathic pain (<nplcit id="ncit0088" npl-type="s"><text>Pontillo, J. et al., Bioorganic & Med. Chem. Ltrs., 15:2541-2546 (2005</text></nplcit>)); conditions and diseases associated with alcohol consumption, alcohol abuse and/or alcoholism (<patcit id="pcit0041" dnum="WO05060985A"><text>WO 05/060985</text></patcit>; <nplcit id="ncit0089" npl-type="s"><text>Navarro, M. et al., Alcohol Clin. Exp. Res., 29:949-957 (2005</text></nplcit>)); and renal conditions or diseases such as the treatment of renal cachexia (<nplcit id="ncit0090" npl-type="s"><text>Markison, S. et al., Endocrinology, 146:2766-2773 (2005</text></nplcit>)) or natriuresis (<patcit id="pcit0042" dnum="US6613874B"><text>U.S. Patent No. 6,613,874</text></patcit>).

0010Ligand compounds activating one or more melanocortin receptor would be useful for modulating a wide variety of normalizing or homeostatic activities in a subject in need thereof including thyroxin release (<patcit id="pcit0043" dnum="US6613874B"><text>U.S. Patent No. 6,613,874</text></patcit>), aldosterone synthesis and release (<patcit id="pcit0044" dnum="US6613874B"><text>U.S. Patent No. 6,613,874</text></patcit>), body temperature (<patcit id="pcit0045" dnum="US6613874B"><text>U.S. Patent No. 6,613,874</text></patcit>), blood pressure (<patcit id="pcit0046" dnum="US6613874B"><text>U.S. Patent No. 6,613,874</text></patcit>), heart rate (<patcit id="pcit0047" dnum="US6613874B"><text>U.S. Patent No. 6,613,874</text></patcit>), vascular tone (<patcit id="pcit0048" dnum="US6613874B"><text>U.S. Patent No. 6,613,874</text></patcit>), brain blood flow (<patcit id="pcit0049" dnum="US6613874B"><text>U.S. Patent No. 6,613,874</text></patcit>), blood glucose levels (<patcit id="pcit0050" dnum="US6613874B"><text>U.S. Patent No. 6,613,874</text></patcit>), bone metabolism, bone formation or development (<nplcit id="ncit0091" npl-type="s"><text>Dumont, L. M. et al., Peptides, 26:1929-1935 (2005</text></nplcit>), ovarian weight (<patcit id="pcit0051" dnum="US6613874B"><text>U.S. Patent No. 6,613,874</text></patcit>), placental development (<patcit id="pcit0052" dnum="US6613874B"><text>U.S. Patent No. 6,613,874</text></patcit>), prolactin and FSH secretion (<patcit id="pcit0053" dnum="US6613874B"><text>U.S. Patent No. 6,613,874</text></patcit>), intrauterine fetal growth (<patcit id="pcit0054" dnum="US6613874B"><text>U.S. Patent No. 6,613,874</text></patcit>), parturition (<patcit id="pcit0055" dnum="US6613874B"><text>U.S. Patent No. 6,613,874</text></patcit>), spermatogenesis (<patcit id="pcit0056" dnum="US6613874B"><text>U.S. Patent No. 6,613,874</text></patcit>), sebum and pheromone secretion (<patcit id="pcit0057" dnum="US6613874B"><text>U.S. Patent No. 6,613,874</text></patcit>), neuroprotection (<patcit id="pcit0058" dnum="US6639123B"><text>U.S. Patent No. 6,639,123</text></patcit>) and nerve growth (<patcit id="pcit0059" dnum="US6613874B"><text>U.S. Patent No. 6,613,874</text></patcit>) as well as modulating motivation (<patcit id="pcit0060" dnum="US6613874B"><text>U.S. Patent No. 6,613,874</text></patcit>), learning (<patcit id="pcit0061" dnum="US6613874B"><text>U.S. Patent No. 6,613,874</text></patcit>) and other behaviors (<patcit id="pcit0062" dnum="US6613874B"><text>U.S. Patent No. 6,613,874</text></patcit>).

0011It is, therefore, an objective of the present invention to provide ligands for the melanocortin receptors which exhibit greater stability and selectivity for melanocortin receptors than native melanocortin receptor ligands.

SUMMARY OF THE INVENTION

0012In one aspect, the present invention is directed to a compound according formula (I): (R2R3)-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1 wherein: <ul id="ul0001" list-style="none" compact="compact"><li>A1 is Acc, HN-(CH2)m-C(O), L- or D-amino acid, or deleted;</li><li>A2 is Cys, D-Cys, hCys, D-hCys, Pen, D-Pen, Asp, or Glu;</li><li>A3 is Gly, Ala, β-Ala, Gaba, Aib, D-amino acid, or deleted;</li><li>A4 is His, 2-Pal, 3-Pal, 4-Pal, Taz, 2-Thi, 3-Thi, or (X1,X2,X3,X4,X5)Phe;</li><li>A5 is D-Phe, D-1-Nal, D-2-Nal, D-Trp, D-Bal, D-(X1,X2,X3. X4,X5)Phe, L-Phe or D-(Et)Tyr;</li><li>A6 is Arg, hArg, Dab, Dap, Lys, Orn, or HN-CH((CH2)n-N(R4R5))-C(O);</li><li>A7 is Trp, 1-Nal, 2-Nal, Bal, Bip, D-Trp, D-1-Nal, D-2-Nal, D-Bal or D-Bip;</li><li>A8 is Gly, D-Ala, Acc, Ala, β-Ala, Gaba, Apn, Ahx, Aha, HN-(CH2)s-C(O), or deleted;</li><li>A9 is Cys, D-Cys, hCys, D-hCys, Pen, D-Pen, Dab, Dap, Orn, or Lys;</li><li>A10 is Acc, HN-(CH2)t-C(O), L- or D-amino acid, or deleted;</li><li>R1 is -OH, or -NH2;</li><li>each of R2 and R3 is independently for each occurrence selected from the group consisting of H, (C1-C30)alkyl, (C1-C30)heteroalkyl, (C1-C30)acyl, (C2-C30)alkenyl, (C2-C30)alkynyl, aryl(C1-C30)alkyl, aryl(C1-C30)acyl, substituted (C1-C30)alkyl, substituted (C1-C30)heteroalkyl, substituted (C1-C30)acyl, substituted (C2-C30)alkenyl, substituted (C2-C30)alkynyl, substituted aryl(C1-C30)alkyl, and substituted aryl(C1-C30)acyl;</li><li>R4 and R5 each is, independently for each occurrence, H, (C1-C40)alkyl, (C1-C40)heteroalkyl, (C1-C40)acyl, (C2-C40)alkenyl, (C2-C40)alkynyl, aryl(C1-C40)alkyl, aryl(C1-C40)acyl, substituted (C1-C40)alkyl, substituted (C1-C40)heteroalkyl, substituted C1-C40)acyl, substituted (C2-C40)alkenyl, substituted (C2-C40)alkynyl, substituted aryl(C1-C40)alkyl, substituted aryl(C1-C40)acyl, (C1-C40)alkylsulfonyl, or -C(NH)-NH2;</li><li>m is, independently for each occurrence, 1, 2, 3, 4, 5, 6 or 7;</li><li>n is, independently for each occurrence, 1, 2, 3, 4 or 5;</li><li>s is, independently for each occurrence, 1, 2, 3, 4, 5, 6, or 7;</li><li>t is, independently for each occurrence, 1, 2, 3, 4, 5, 6, or 7;</li><li>X1, X2, X3, X4, and X5 each is, independently for each occurrence, H, F, Cl, Br, I, (C1-10)alkyl, substituted (C1-10)alkyl, (C2-10)alkenyl, substituted (C2-10)alkenyl, (C2-10)alkynyl, substituted (C2-10)alkynyl, aryl, substituted aryl, OH, NH2, NO2, or CN;</li></ul> provided that <ol id="ol0001" compact="compact"><li>(I). when R4 is (C1-C40)acyl, aryl(C1-C40)acyl, substituted (C1-C40)acyl, substituted aryl(C1-C40)acyl, (C1-C40)alkylsulfonyl, or -C(NH)-NH2, then R5 is H or (C1-C40)alkyl, (C1-C40)heteroalkyl, (C2-C40)alkenyl, (C2-C40)alkynyl, aryl(C1-C40)alkyl, substituted (C1-C40)alkyl, substituted (C1-C40)heteroalkyl, substituted (C2-C40)alkenyl, substituted (C2-C40)alkynyl, or substituted aryl(C1-C40) alkyl;</li><li>(II). when R2 is (C1-C30)acyl, aryl(C1-C30)acyl, substituted (C1-C30)acyl, or substituted aryl(C1-C30)acyl, then R3 is H, (C1-C30)alkyl, (C1-C30)heteroalkyl, (C2-C30)alkenyl, (C2-C30)alkynyl, aryl(C1-C30)alkyl, substituted (C1-C30)alkyl, substituted (C1-C30)heteroalkyl, substituted (C2-C30)alkenyl, substituted (C2-C30)alkynyl, or substituted aryl(C1-C30)alkyl;</li><li>(III). either A3 or A8 or both must be present in said compound;</li><li>(IV). when A2 is Cys, D-Cys, hCys, D-hCys, Pen, or D-Pen, then A9 is Cys, D-Cys, hCys, D-hCys, Pen, or D-Pen;</li><li>(V). when A2 is Asp or Glu, then A9 is Dab, Dap, Orn, or Lys;</li><li>(VI). when A8 is Ala or Gly, then A1 is not Nle; and</li><li>(VII). when A1 is deleted, then R2 and R3 cannot both be H;</li></ol> or a pharmaceutically acceptable salt thereof.

0013A preferred group of compounds of the immediate foregoing formula, is where A1 is A6c, Gaba, Nle, Met, Phe, D-Phe, D-2-Nal, hPhe, Chg, D-Chg, Cha, <ul id="ul0002" list-style="none" compact="compact"><li>hCha, hPro, hLeu, Nip, β-hMet, or Oic;</li><li>A2 is Cys, D-Cys, hCys, D-hCys, Pen, D-Pen, Asp, or Glu;</li><li>A3 is Gly, Ala, D-Ala, D-Glu, β-Ala, Gaba, Aib, or deleted;</li><li>A4 is His;</li><li>A5 is D-Phe, D-1-Nal, D-2-Nal, D-Trp, D-Bal, or D-(Et)Tyr;</li><li>A6 is Arg, or hArg;</li><li>A7 is Trp, Bip, D-Trp, 1-Nal, or 2-Nal;</li><li>A8 is A6c, Ala, β-Ala, Gaba, Apn, or Ahx;</li><li>A9 is Cys, D-Cys, hCys, D-hCys, Pen, D-Pen, or Lys;</li><li>A10 is Thr, or deleted</li></ul> or a pharmaceutically acceptable salt thereof.

0014A preferred group of compounds of the immediately foregoing group of compounds is where R2 and R3 each is, independently, H, acyl, n-propanoyl, or n-butanoyl or a pharmaceutically acceptable salt thereof.

0015A more preferred compound of formula (I) is where said compound is of the formula: <ul id="ul0003" list-style="none" compact="compact"><li>A1 is Acc, Arg, D-Arg, Cha, D-Cha, hCha, Chg, D-Chg, Gaba, Ile, Leu, hLeu, β-hMet, 2-Nal, D-2-Nal, Nip, Nle, Oic, Phe, D-Phe, hPhe, hPro, Val or deleted;</li><li>A2 is Cys, D-Cys, Pen or Asp;</li><li>A3 is Gly, Ala, β-Ala, Gaba, Aib, D-Ala, D-Abu, D-Cha, D-Ile, D-Leu, D-Tle, D-Val or deleted;</li><li>A4 is His or 3-Pal;</li><li>A5 is D-Phe, D-2-Nal or D-(Et)Tyr;</li><li>A6 is Arg or hArg;</li><li>A7 is Trp, 1-Nal, 2-Nal, Bal, Bip or D-Trp;</li><li>A8 is Gly, D-Ala, Acc, Ala, β-Ala, Gaba, Apn, Ahx, Aha or deleted;</li><li>A9 is Cys, D-Cys, Pen or Lys;</li><li>A10 is Thr or deleted;</li><li>wherein at least one of A3 or A8 is deleted, but not both,</li></ul> or a pharmaceutically acceptable salt thereof.

0016More preferred compounds of the immediately foregoing group of compounds is where said compound is of the formula: <ul id="ul0004" list-style="none" compact="compact"><li>Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-β-Ala-Lys)-NH2;</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-A6c-Lys)-NH2;</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-NH2;</li><li>D-Phe-c(Cys-His-D-Phe-Arg-Trp-Ala-D-Cys)-Thr-NH2;</li><li>D-Phe-c(Cys-His-D-Phe-Arg-Trp-β-Ala-D-Cys)-Thr-NH2;</li><li>D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-Thr-NH2;</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH2;</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Apn-Lys)-NH2;</li><li>Ac-A6c-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-D-2-Nal-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(Cys-β-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(Cys-Gaba-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(Cys-Aib-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(Cys-Gly-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(D-Cys-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(D-Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(D-Cys-β-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(D-Cys-Gaba-His-D- Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(D-Cys-Aib-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(D-Cys-Gly-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2;</li><li>Ac-Nle-c(Cys-β-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2;</li><li>Ac-Nle-c(Cys-Gaba-His-D-Phe-Arg-Trp-D-Cys)-NH2;</li><li>Ac-Nle-c(Cys-Aib-His-D-Phe-Arg-Trp-D-Cys)-NH2;</li><li>Ac-Nle-c(Cys-Gly-His-D-Phe-Arg-Trp-D-Cys)-NH2;</li><li>Ac-Nle-c(D-Cys-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2;</li><li>Ac-Nle-c(D-Cys-D-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2;</li><li>Ac-Nle-c(D-Cys-β-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2;</li><li>Ac-Nle-c(D-Cys-Gaba-His-D-Phe-Arg-Trp-D-Cys)-NH2;</li><li>Ac-Nle-c(D-Cys-Aib-His-D-Phe-Arg-Trp-D-Cys)-NH2;</li><li>Ac-Oic-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-D-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-Nip-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-hPro-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-hLeu-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-Phe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-D-Phe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>n-butanoyl-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-β-hMet-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-Gaba-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-Cha-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2;</li><li>Ac-hCha-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2;</li><li>Ac-Leu-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2;</li><li>Ac-hLeu-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2;</li><li>Ac-Phe-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2;</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-D-Ala-Lys)-NH2;</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-β-Ala-Lys)-NH2;</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Gaba-Lys)-NH2;</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Aha-Lys)-NH2;</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Apn-Lys)-NH2;</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Apn-Cys)-NH2;</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Gaba-Cys)-NH2;</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-NH2;</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-p-Ala-Cys)-NH2;</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-D-Ala-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-2-Nal-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-1-Nal-Cys)-NH2;</li><li>n-butanoyl-Nle-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Cys)-NH2;</li><li>n-butanoyl-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-l-Nal-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Bal-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-D-Ala-Lys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Bal-Cys)-NH2;</li><li>Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;</li><li>Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;</li><li>D-Phe-c(Cys-His-D-Phe-hArg-Trp-β-Ala-D-Cys)-Thr-NH2;</li><li>D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Thr-NH2;</li><li>D-Phe-c(Cys-His-D-Phe-Arg-Bip-β-Ala-D-Cys)-Thr-NH2;</li><li>D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-NH2;</li><li>D-Phe-c(Cys-His-D-Phe-hArg-Bip-β-Ala-D-Cys)-Thr-NH2;</li><li>D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-p-Ala-D-Cys)-Thr-NH2;</li><li>Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH2;</li><li>Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Trp-Lys)-NH2;</li><li>Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Bal-Lys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-OH;</li><li>Ac-Nle-c(Cys-D-Abu-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Val-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ile-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Tle-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2;</li><li>Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2;</li><li>Ac-Leu-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;</li><li>Ac-Cha-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;</li><li>Ac-Ile-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;</li><li>Ac-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;</li><li>Ac-Val-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;</li><li>Ac-2-Nal-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;</li><li>Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;</li><li>Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;</li><li>Ac-Nle-c(Cys-3-Pal-D-Phe-Arg-Trp-Gaba-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH;</li><li>Ac-Nle-c(Cys-His-Phe-Arg-D-Trp-Gaba-Cys)-NH2;</li><li>Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Ala-Lys)-NH2;</li><li>Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-β-Ala-Lys)-NH2;</li><li>Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Gaba-Cys)-NH2;</li><li>Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Ahx-Cys)-NH2;</li><li>Ac-hPhe-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-Cha-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-β-Ala-Lys)-OH;</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-OH;</li><li>D-Phe-c(Cys-His-D-Phe-Arg-Trp-Ala-D-Cys)-Thr-OH;</li><li>D-Phe-c(Cys-His-D-Phe-Arg-Trp-β-Ala-D-Cys)-Thr-OH;</li><li>D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-Thr-OH;</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-OH;</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Apn-Lys)-OH;</li><li>Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH;</li><li>Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;</li><li>Ac-D-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;</li><li>Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;</li><li>Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;</li><li>Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Gaba-Cys)-OH;</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-OH;</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-β-Ala-Cys)-OH;</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-D-Ala-Cys)-OH;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-OH;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-2-Nal-Cys)-OH;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-1-Nal-Cys)-OH;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Bal-Cys)-OH;</li><li>Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-OH;</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-OH; or</li><li>Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2; or</li></ul> or pharmaceutically acceptable salts thereof.

0017More preferred of the immediately foregoing group of compounds is a compound of the formula: <ul id="ul0005" list-style="none" compact="compact"><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-OH; or</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-OH;</li></ul> or pharmaceutically acceptable salts thereof.

0018A more preferred compound of formula (I) is where said compound is of the formula: <ul id="ul0006" list-style="none" compact="compact"><li>A1 is Arg, D-Arg, Cha, hCha, Chg, D-Chg, Ile, Leu, 2-Nal, Nle, Phe, D-Phe, hPhe, Val or deleted;</li><li>A2 is Cys, Pen or Asp;</li><li>A3 is D-Ala, D-Abu, D-Cha, D-Ile, D-Leu, D-Tle, D-Val or deleted;</li><li>A4 is His or 3-Pal;</li><li>A5 is D-Phe, D-2-Nal or D-(Et)Tyr;</li><li>A6 is Arg or hArg;</li><li>A7 is Trp, 2-Nal, Bal, Bip or D-Trp;</li><li>A8 is Gly, Ala, β-Ala, Gaba, Apn, Ahx, or deleted;</li><li>A9 is Cys, D-Cys, Pen or Lys;</li><li>A10 is Thr or deleted;</li><li>each of R2 and R3 is independently selected from the group consisting of H or acyl;</li></ul> or a pharmaceutically acceptable salt thereof.

0019More preferred of the immediately foregoing group of compounds is a compound of the formula: <ul id="ul0007" list-style="none" compact="compact"><li>Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;</li><li>Ac-D-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2;</li><li>Ac-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NHz;</li><li>Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;</li><li>Ac-D-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH2;</li><li>Ac-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Thr-NH2;</li><li>Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH2;</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2;</li><li>Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-β-Ala-Lys)-NH2;</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-NH2;</li><li>D-Phe-c(Cys-His-D-Phe-Arg-Trp-β-Ala-D-Cys)-Thr-NH2;</li><li>D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-Thr-NH2;</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH2;</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Apn-Lys)-NH2;</li><li>Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-p-Ala-Cys)-NH2;</li><li>Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;</li><li>D-Phe-c(Cys-His-D-Phe-hArg-Trp-β-Ala-D-Cys)-Thr-NH2;</li><li>D-Phe-c(Cys-His-D-Phe-Arg-Bip-β-Ala-D-Cys)-Thr-NH2;</li><li>D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-NH2;</li><li>D-Phe-c(Cys-His-D-Phe-hArg-Bip-β-Ala-D-Cys)-Thr-NH2;</li><li>D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-NH2;</li><li>Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Trp-Lys)-NH2;</li><li>Ac-Nle-c(Asp-D-Ala -His-D-Phe-Arg-Bal-Lys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-OH;</li><li>Ac-Nle-c(Cys-D-Abu-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Val-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ile-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Tle-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;</li><li>Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2;</li><li>Ac-Leu-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;</li><li>Ac-Cha-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;</li><li>Ac-Ile-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;</li><li>Ac-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;</li><li>Ac-Val-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;</li><li>Ac-2-Nal-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;</li><li>Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;</li><li>Ac-Nle-c(Cys-3Pal-D-Phe-Arg-Trp-Gaba-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH;</li><li>Ac-Nle-c(Cys-His-Phe-Arg-D-Trp-Gaba-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-2-Nal-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Bal-Cys)-NH2;</li><li>Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Ala-Lys)-NH2;</li><li>Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-β-Ala-Lys)-NH2;</li><li>Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Gaba-Cys)-NH2;</li><li>Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Ahx-Cys)-NH2;</li><li>Ac-hPhe-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-Cha-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH2; or</li><li>Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2;</li></ul> or a pharmaceutically acceptable salt thereof.

0020A more preferred compound of formula (I) is where said compound is of the formula: A1 is Arg, D-Arg, hArg or D-hArg; or a pharmaceutically acceptable salt thereof.

0021A more preferred compound of the immediately foregoing group of compounds is where said compound is of the formula: <ul id="ul0008" list-style="none" compact="compact"><li>A2 is Cys, D-Cys, hCys, D-hCys, Pen, D-Pen, Asp, or Glu;</li><li>A3 is Gly, Ala, D-Ala, D-Glu, β-Ala, Gaba, Aib, or deleted;</li><li>A4 is His;</li><li>A5 is D-Phe, D-1-Nal, D-2-Nal, D-Trp, D-Bal, or D-(Et)Tyr;</li><li>A6 is Arg, or hArg;</li><li>A7 is Trp, Bip, D-Trp, 1-Nal, or 2-Nal;</li><li>A8 is A6c, Ala, β-Ala, Gaba, Apn, or Ahx;</li><li>A9 is Cys, D-Cys, hCys, D-hCys, Pen, D-Pen, or Lys;</li><li>A10 is Thr, or deleted;</li></ul> or a pharmaceutically acceptable salt thereof.

0022A more preferred compound of the immediately foregoing group of compounds is where R2 and R3 each is, independently, H, acyl, n-propanoyl, or n-butanoyl or a pharmaceutically acceptable salt thereof.

0023A more preferred compound of the immediately foregoing group of compounds is where said compound is of the formula: <ul id="ul0009" list-style="none" compact="compact"><li>A2 is Cys or Asp;</li><li>A3 is D-Ala or deleted;</li><li>A4 is His;</li><li>A5 is D-Phe or D-2-Nal;</li><li>A6 is Arg;</li><li>A7 is Trp;</li><li>A8 is Ala, Gaba or deleted;</li><li>A9 is Cys, Pen or Lys;</li><li>A10 is deleted;</li></ul> or a pharmaceutically acceptable salt thereof.

0024A more preferred compound of the immediately foregoing group of compounds is where R2 and R3 each is, independently, H or acyl; or a pharmaceutically acceptable salt thereof.

0025More preferred of the immediately foregoing group of compounds is a compound of the formula: <ul id="ul0010" list-style="none" compact="compact"><li>Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;</li><li>Ac-D-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2;</li><li>Ac-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2;</li><li>Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;</li><li>Ac-D-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH2;</li><li>Ac-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH2; or</li><li>Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2;</li></ul> or pharmaceutically acceptable salts thereof.

0026More preferred of the immediately foregoing group of compounds is a compound of the formula: <ul id="ul0011" list-style="none" compact="compact"><li>Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2; or</li><li>Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2;</li></ul> or a pharmaceutically acceptable salt thereof.

0027More preferred of the immediately foregoing group of compounds is a compound of the formula: Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; or a pharmaceutically acceptable salt thereof.

0028More preferred of the immediately foregoing group of compounds is a compound of the formula: Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2; or a pharmaceutically acceptable salt thereof.

0029More preferred of the immediately foregoing group of compounds is a compound of the formula: Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2; or a pharmaceutically acceptable salt thereof.

0030In one aspect, the present invention is directed to a compound according formula (II): (R2R3)-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-NH2 wherein: <ul id="ul0012" list-style="none" compact="compact"><li>A1 is Nle or deleted;</li><li>A2 is Cys or Asp;</li><li>A3 is Glu or D-Ala;</li><li>A4 is His;</li><li>A5 is D-Phe;</li><li>A6 is Arg;</li><li>A7 is Trp, 2-Nal or Bal;</li><li>A8 is Gly, Ala, D-Ala, β-Ala, Gaba or Apn;</li><li>A9 is Cys or Lys;</li><li>each of R2 and R3 is independently selected from the group consisting of H or (C1-C6)acyl;</li><li>provided that <ol id="ol0002" compact="compact"><li>(I). when R2 is (C1-C6)acyl, then R3 is H; and</li><li>(II). when A2 is Cys, then A9 is Cys,</li></ol></li></ul> or a pharmaceutically acceptable salt thereof.

0031More preferred of the immediately foregoing group of compounds is a compound of the formula: <ul id="ul0013" list-style="none" compact="compact"><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gly-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-D-Ala-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-β-Ala-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Apn-Cys)-NH2;</li><li>Ac-c(Cys-Glu-His-D-Phe-Arg-Trp-Ala-Cys)-NH2;</li><li>Ac-c(Cys-Glu-His-D-Phe-Arg-2-Nal-Ala-Cys)-NH2;</li><li>Ac-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Ala-Cys)-NH2;</li><li>Ac-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Ala-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Ala-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-(3-Ala-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2; or</li><li>Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Bal-Ala-Lys)-NH2;</li></ul> or a pharmaceutically acceptable salt thereof.

0032Another more preferred compound of formula (I) or formula (II) is each of the compounds that are specifically enumerated herein below in the Examples section of the present disclosure, or a pharmaceutically acceptable salt thereof.

0033In another aspect, the present invention provides a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.

0034In another aspect, the present invention provides a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, wherein said compound is a selective melanocortin-4 receptor agonist.

0035In another aspect, the present invention provides a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, wherein said compound is a selective melanocortin 4 receptor agonist with a functional activity characterized by an EC50 at least 15- fold more selective for the human melanocortin 4 receptor than for the human melanocortin 1 receptor, the human melanocortin 3 receptor and the human melanocortin 5 receptor.

0036In yet another aspect, the present invention provides a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, wherein said compound is a selective melanocortin 4 receptor agonist with a functional activity characterized by an ECso at least 17-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 3 receptor, an EG50 at least 90-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 3 receptor, an ECso at least 200-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 5 receptor, or an EC50 at least 3000-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 5 receptor.

0037In another aspect, the present invention provides a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, useful for treating an acute or chronic inflammatory disease or medical condition such as general inflammation, inflammatory bowel disease, brain inflammation, sepsis and septic shock.

0038In another aspect, the present invention provides a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, useful for treating a disease or medical condition with an autoimmune component such as rheumatoid arthritis, gouty arthritis and multiple sclerosis.

0039In another aspect, the present invention provides a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, useful for treating a metabolic disease or medical condition accompanied by weight gain such as obesity, feeding disorders and Prader-Willi Syndrome. In a further aspect, the disease or condition treated is obesity. In yet a further aspect, the disease or condition treated is a feeding disorder.

0040In another aspect, the present invention provides a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, useful for decreasing food intake, for decreasing body weight or a combination thereof. In a preferred embodiment, the present invention provides a pharmaceutical composition comprising an effective amount of a compound of formula (I) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, which is useful for diminishing food intake, decreasing body weight, or a combination thereof, wherein the active ingredient is one or more of the following compounds: Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2, Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2, Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2, Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2, Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2, D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Thr-NH2, Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2 or Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2. In yet another preferred embodiment, the present invention provides a pharmaceutical composition comprising an effective amount of a compound of formula (I) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, which is useful for diminishing food intake, decreasing body weight, or a combination thereof, wherein the active ingredient is_Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2. In yet another preferred embodiment, the present invention provides a pharmaceutical composition comprising an effective amount of a compound of formula (I) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, which is useful for diminishing food intake, decreasing body weight, or a combination thereof, wherein the active ingredient is Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2. In yet another preferred embodiment, the present invention provides a pharmaceutical composition comprising an effective amount of a compound of formula (I) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, which is useful for diminishing food intake, decreasing body weight, or a combination thereof, wherein the active ingredient is Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2.

0041In another aspect, the present invention provides a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically-acceptable carrier or diluent, which is useful for decreasing appetite without compromising body weight. In yet another aspect, the present invention provides a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically-acceptable carrier or diluent, useful for decreasing food consumption while increasing body weight.

0042In another aspect, the present invention provides a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, useful for treating a metabolic disease or medical condition accompanied by weight loss such as anorexia, bulimia, AIDS wasting, cachexia, cancer cachexia and wasting in frail elderly. In a further aspect, the disease or condition treated is anorexia. In a further aspect, the disease or condition treated is bulimia. In a further aspect, the disease or condition treated is AIDS wasting or wasting in frail elderly. In a further aspect, the disease or condition treated is cachexia or cancer cachexia.

0043In another aspect, the present invention provides a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, useful for treating a neoplastic disease or medical condition such as skin cancer and cancer cachexia.

0044In another aspect, the present invention provides a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, useful for treating a reproductive or sexual medical condition such as endometriosis, uterine bleeding, sexual dysfunction, erectile dysfunction and decreased sexual response in females.

0045In another aspect, the present invention provides a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, useful for treating a disease or medical condition resulting from treatment or insult to an organism such as organ transplant rejection, ischemia and reperfusion injury, wounding and spinal cord injury, and weight loss due to a medical procedure selected from the group consisting of chemotherapy, radiation therapy, temporary or permanent immobilization and dialysis.

0046In another aspect, the present invention provides a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, useful for treating a cardiovascular disease or medical condition such as hemorrhagic shock, cardiogenic shock, hypovolemic shock, cardiovascular disorders and cardiac cachexia.

0047In another aspect, the present invention provides a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, useful for treating a pulmonary disease or medical condition such as acute respiratory distress syndrome, pulmonary fibrosis, chronic obstructive pulmonary disease and asthma.

0048In another aspect, the present invention provides a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, useful for enhancing immune tolerance and treating allergies.

0049In another aspect, the present invention provides a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, useful for treating a dermatological disease or medical condition such as psoriasis, skin pigmentation depletion, acne and keloid formation.

0050In another aspect, the present invention provides a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically-acceptable carrier or diluent, useful for treating a behavioral or central nervous system or neuronal disease or medical condition such as anxiety, depression, memory dysfunction and neuropathic pain.

0051In another aspect, the present invention provides a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically-acceptable carrier or diluent, useful for treating a renal disease or medical condition such as renal cachexia and natriuresis.

0052In another aspect, the present invention provides a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically-acceptable carrier or diluent, useful for modulating ovarian weight, placental development, prolactin secretion, FSH secretion, intrauterine fetal growth, parturition, spermatogenesis, thyroxin release, aldosterone synthesis and release, body temperature, blood pressure, heart rate, vascular tone, brain blood flow, blood glucose levels, sebum secretion, pheromone secretion, motivation, learning and behavior, pain perception, neuroprotection and nerve growth.

0053In another aspect, the present invention provides a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically-acceptable carrier or diluent, useful for modulating bone metabolism, bone formation and bone development.

0054In another aspect, the present invention provides a pharmaceutical composition comprising an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically-acceptable carrier or diluent, useful for inhibiting alcohol consumption, for reducing alcohol consumption, for treating alcoholism, or for treating alcohol abuse. In a further aspect, the compound of the composition useful for inhibiting alcohol consumption, for reducing alcohol consumption, for treating alcoholism, or for treating alcohol abuse is a selective melanocortin 4 receptor agonist. In yet a further aspect, the compound of the composition useful for inhibiting alcohol consumption is a selective melanocortin 4 receptor agonist, or a pharmaceutically acceptable salt thereof, with a functional activity characterized by an ECso at least 15-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 1 receptor, the human melanocortin 3 receptor and the human melanocortin 5 receptor. In yet another aspect, the compound of the composition useful for inhibiting alcohol consumption is a selective melanocortin 4 receptor agonist, or a pharmaceutically acceptable salt thereof, with a functional activity characterized by an ECso at least 17-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 3 receptor, an EC50 at least 90-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 3 receptor, an ECso at least 200-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 5 receptor, or an ECso at least 3000-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 5 receptor.

0055In another aspect, the present invention provides the use of a therapeutically effective amount of a melanocortin 4 receptor agonist compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament useful for inhibiting alcohol consumption, for reducing alcohol consumption, for treating alcoholism, or for treating alcohol abuse in a subject in need of such treatment.

0056In yet another aspect, the present invention provides a method of eliciting an agonist or an antagonist effect from a melanocortin receptor in a subject in need thereof which comprises administering to said subject an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.

0057In another aspect, the present invention provides a method of eliciting an agonist or an antagonist effect from a melanocortin receptor in a subject in need thereof which comprises administering to said subject an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, wherein said compound is a selective melanocortin 4 receptor agonist.

0058In another aspect, the present invention provides a method of eliciting an agonist or an antagonist effect from a melanocortin receptor in a subject in need thereof which comprises administering to said subject an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, wherein said compound is a selective melanocortin 4 receptor agonist with a functional activity characterized by an ECso at least 15- fold more selective for the human melanocortin 4 receptor than for the human melanocortin 1 receptor, the human melanocortin 3 receptor and the human melanocortin 5 receptor.

0059In yet another aspect, the present invention provides a method of eliciting an agonist or an antagonist effect from a melanocortin receptor in a subject in need thereof which comprises administering to said subject an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, wherein said compound is a selective melanocortin 4 receptor agonist with a functional activity characterized by an ECso at least 17-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 3 receptor, an ECso at least 90-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 3 receptor, an ECso at least 200-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 5 receptor, or an ECso at least 3000-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 5 receptor.

0060In another aspect, the present invention provides a method of treating an acute or chronic inflammatory disease or medical condition such as general inflammation, inflammatory bowel disease, brain inflammation, sepsis and septic shock by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.

0061In another aspect, the present invention provides a method of treating a disease or medical condition with an autoimmune component such as rheumatoid arthritis, gouty arthritis and multiple sclerosis by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.

0062In another aspect, the present invention provides a method of treating a metabolic disease or medical condition accompanied by weight gain such as obesity, feeding disorders and Prader-Willi Syndrome by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof. In a further aspect of the foregoing method, the disease or condition treated is obesity. In yet a further aspect of the foregoing method, the disease or condition treated is a feeding disorder.

0063In another aspect, the present invention provides a method of decreasing food intake, decreasing body weight or a combination thereof, by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof. In a preferred embodiment, the present invention provides a method of decreasing food intake, decreasing body weight or a combination thereof, by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein said compound is Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2, Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2, Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2, Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2, Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2, D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Thr-NH2, Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2, or Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2. In another preferred embodiment, the present invention provides a method of decreasing food intake, decreasing body weight or a combination thereof, by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein said compound is Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2. In another preferred embodiment, the present invention provides a method of decreasing food intake, decreasing body weight or a combination thereof, by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein said compound is Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2. In another preferred embodiment, the present invention provides a method of decreasing food intake, decreasing body weight or a combination thereof, by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein said compound is Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2.

0064In another aspect, the present invention provides a method of decreasing appetite without compromising body weight by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof. In another aspect, the present invention provides a method of decreasing food consumption while increasing body weight by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.

0065In another aspect, the present invention provides a method of treating a metabolic disease or medical condition accompanied by weight loss such as anorexia, bulimia, AIDS wasting, cachexia, cancer cachexia and wasting in frail elderly by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof. In a further aspect, the foregoing method is used to treat anorexia. In a further aspect, the foregoing method is used to treat bulimia. In a further aspect, the foregoing method is used to treat AIDS wasting or wasting in frail elderly. In a further aspect, the foregoing method is used to treat cachexia or cancer cachexia.

0066In another aspect, the present invention provides a method of treating a neoplastic disease or medical condition such as skin cancer and cancer cachexia by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.

0067In another aspect, the present invention provides a method of treating a reproductive or sexual medical condition such as endometriosis, uterine bleeding, sexual dysfunction, erectile dysfunction and decreased sexual response in females by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.

0068In another aspect, the present invention provides a method of treating a disease or medical condition resulting from treatment or insult to an organism such as organ transplant rejection, ischemia and reperfusion injury, wounding and spinal cord injury, and weight loss due to a medical procedure selected from the group consisting of chemotherapy, radiation therapy, temporary or permanent immobilization and dialysis by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.

0069In another aspect, the present invention provides a method of treating a cardiovascular disease or medical condition such as hemorrhagic shock, cardiogenic shock, hypovolemic shock, cardiovascular disorders and cardiac cachexia by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.

0070In another aspect, the present invention provides a method of treating a pulmonary disease or medical condition such as acute respiratory distress syndrome, pulmonary fibrosis, chronic obstructive pulmonary disease and asthma by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.

0071In another aspect, the present invention provides a method of enhancing immune tolerance or treating allergies by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.

0072In another aspect, the present invention provides a method of treating dermatological disease or medical condition such as psoriasis, skin pigmentation depletion, acne and keloid formation by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.

0073In another aspect, the present invention provides a method of treating a behavioral or central nervous system or neuronal disease or medical condition such as anxiety, depression, memory dysfunction and neuropathic pain by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.

0074In another aspect, the present invention provides a method of treating a renal disease or medical condition such as renal cachexia and natriuresis by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.

0075In another aspect, the present invention provides a method of modulating a normalizing or homeostatic activity such as ovarian weight, placental development, prolactin secretion, FSH secretion, intrauterine fetal growth, parturition, spermatogenesis, thyroxin release, aldosterone synthesis and release, body temperature, blood pressure, heart rate, vascular tone, brain blood flow, blood glucose levels, sebum secretion, pheromone secretion, motivation, learning and behavior, pain perception, neuroprotection and nerve growth by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.

0076In another aspect, the present invention provides a method of modulating a normalizing or homeostatic activity such as bone metabolism, bone formation and bone development by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof.

0077In another aspect, the present invention provides a method of inhibiting alcohol consumption, for reducing alcohol consumption, for treating alcoholism, or for treating alcohol abuse by eliciting an agonist or antagonist effect from a melanocortin receptor by administering an effective amount of a compound of formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof. In a further aspect of the foregoing method, the compound is a selective melanocortin 4 receptor agonist. In yet a further aspect of the immediately foregoing method, the compound of the composition useful for inhibiting alcohol consumption is a selective melanocortin 4 receptor agonist, or a pharmaceutically acceptable salt thereof, with a functional activity characterized by an ECso at least 15- fold more selective for the human melanocortin 4 receptor than for the human melanocortin 1 receptor, the human melanocortin 3 receptor and the human melanocortin 5 receptor. In yet another aspect of the foregoing method, the compound of the composition useful for inhibiting alcohol consumption is a selective melanocortin 4 receptor agonist, or a pharmaceutically acceptable salt thereof, with a functional activity characterized by an ECso at least 17-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 3 receptor, an ECso at least 90-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 3 receptor, an ECso at least 200-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 5 receptor, or an ECso at least 3000-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 5 receptor.

0078In a further aspect, the present invention provides the use of a therapeutically effective amount of a melanocortin 4 receptor agonist or antagonist compound according formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament useful to treat a disease and/or medical condition selected from the group consisting of acute and chronic inflammatory diseases such as general inflammation, inflammatory bowel disease, brain inflammation, sepsis and septic shock; diseases with an autoimmune component such as rheumatoid arthritis, gouty arthritis and multiple sclerosis; metabolic diseases and medical disorders accompanied by weight gain such as obesity, feeding disorders and Prader-Willi Syndrome; metabolic diseases and medical disorders accompanied by weight loss such as anorexia, bulimia, AIDS wasting, cachexia, cancer cachexia and wasting in frail elderly; diabetes, diabetalogical related conditions and complications of diabetes such as retinopathy; neoplastic proliferation such as skin cancer and prostate cancer; reproductive or sexual medical conditions such as endometriosis and uterine bleeding in women, sexual dysfunction, erectile dysfunction and decreased sexual response in females; diseases or conditions resulting from treatment or insult to the organism such as organ transplant rejection, ischemia and reperfusion injury, spinal cord injury and wounding, as well as weight loss caused chemotherapy, radiation therapy, temporary or permanent immobilization or dialysis; cardiovascular diseases or conditions such as hemorrhagic shock, cardiogenic shock, hypovolemic shock, cardiovascular disorders and cardiac cachexia; pulmonary diseases or conditions such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma and pulmonary fibrosis; to enhance immune tolerance and to combat assaults to the immune system such as those associated with certain allergies or organ transplant rejection; treatment of dermatological diseases and conditions such as psoriasis, skin pigmentation depletion, acne, keloid formation and skin cancer; behavioral, central nervous system and neuronal disorders such as anxiety, depression, memory dysfunction, and neuropathic pain; and renal conditions or diseases such as the treatment of renal cachexia and natriuresis.

0079In a further aspect, the present invention provides the use of a therapeutically effective amount of a melanocortin 4 receptor agonist or antagonist compound according formula (I) or formula (II) as defined hereinabove, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament useful to modulate normalizing or homeostatic activities such as ovarian weight, placental development, prolactin secretion, FSH secretion, intrauterine fetal growth, parturition, spermatogenesis, thyroxin release, aldosterone synthesis and release, body temperature, blood pressure, heart rate, vascular tone, brain blood flow, blood glucose levels, sebum secretion, pheromone secretion, motivation, learning and behavior, pain perception, neuroprotection, nerve growth, bone metabolism, bone formation and bone development.

0080It will be appreciated that therapeutic interventions addressing both normal physiological and pathophysiological processes which utilize the melanocortin receptors are also contemplated.

0081Additional objects, advantages, and features of the present invention will become apparent from the following description and appended claims, taken in conjunction with the accompanying drawings.

0082The compounds of formulae (I) or (II) are ligands for at least one of the melanocortin receptors (MC1-R, MC2-R, MC3-R, MC4-R and MC5-R) and a selection thereof were tested for their ability to act as a ligand in the in vitro assay described below.

BRIEF DESCRIPTION OF THE DRAWINGS:

0083<ul id="ul0014" list-style="none" compact="compact"><li><figref idref="f0001">Figure 1A</figref>: Mean difference in food consumed from vehicle in fasted rats 6 hours after administration of 100 nmole/Kg of selected compounds.</li><li><figref idref="f0002">Figure 1B</figref>. Mean difference in food consumed from vehicle in fasted rats 6 hours after administration of 500 nmole/Kg of selected compounds.</li><li><figref idref="f0003">Figure 2A</figref>. Cumulative difference in mean food intake from vehicle in rats after administration of various concentrations of Compound A.</li><li><figref idref="f0004">Figure 2B</figref>. Cumulative mean body weight difference from vehicle in rats after administration of various concentrations of Compound A.</li><li><figref idref="f0005">Figure 3A</figref>. Cumulative difference in mean food intake from vehicle in rats after administration of selected compounds.</li><li><figref idref="f0006">Figure 3B</figref>. Cumulative mean body weight difference from vehicle in rats after administration of selected compounds.</li><li><figref idref="f0007">Figure 4A</figref>. Cumulative difference in mean food intake from vehicle in rats after administration of selected compounds.</li><li><figref idref="f0008">Figure 4B</figref>. Cumulative mean body weight difference from vehicle in rats after administration of selected compounds.</li></ul>

DETAILED DESCRIPTION OF THE INVENTION

0084The nomenclature used to define the peptides is that typically used in the art wherein the amino group at the N-terminus appears to the left and the carboxyl group at the C-terminus appears to the right. Where the amino acid has isomeric forms, it is the L form of the amino acid that is represented unless otherwise explicitly indicated. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Also, all publications, patent applications, patents and other references mentioned herein are incorporated by reference. <tables id="tabl0001" num="0001"><table frame="top"><title>Nomenclature and Abbreviations</title><tgroup cols="2" colsep="0"><colspec colnum="1" colname="col1" colwidth="22mm" /><colspec colnum="2" colname="col2" colwidth="115mm" /><thead valign="top"><row><entry>Symbol</entry><entry>Meaning</entry></row></thead><tbody><row rowsep="0"><entry>Abu</entry><entry>α-ammobutyric acid</entry></row><row rowsep="0"><entry>Ac</entry><entry>acyl group</entry></row><row rowsep="0"><entry>Acc</entry><entry>1-amino-1-cyclo(C3-C9)alkyl carboxylic acid</entry></row><row rowsep="0"><entry>A3c</entry><entry>1-amino-1-cyclopropanecarboxylic acid</entry></row><row rowsep="0"><entry>A4c</entry><entry>1-amino-1-cyclobutanecarboxylic acid</entry></row><row rowsep="0"><entry>A5c</entry><entry>1-amino-1-cyclopentanecarboxylic acid</entry></row><row rowsep="0"><entry>A6c</entry><entry>1-amino-1-cyclohexanecarboxylic acid</entry></row><row rowsep="0"><entry>Aha</entry><entry>7-aminoheptanoic acid</entry></row><row rowsep="0"><entry>Ahx</entry><entry>6-aminohexanoic acid</entry></row><row rowsep="0"><entry>Aib</entry><entry>α-ammoisobutyric acid</entry></row><row rowsep="0"><entry>Ala or A</entry><entry>alanine</entry></row><row rowsep="0"><entry>β-Ala</entry><entry>β-alanine</entry></row><row rowsep="0"><entry>Apn</entry><entry>5-aminopentanoic acid (HN-(CH2)4-C(O)</entry></row><row rowsep="0"><entry>Arg or R</entry><entry>arginine</entry></row><row rowsep="0"><entry>hArg</entry><entry>homoarginine</entry></row><row rowsep="0"><entry>Asn or N</entry><entry>asparagine</entry></row><row rowsep="0"><entry>Asp or D</entry><entry>aspartic acid</entry></row><row rowsep="0"><entry>Bal</entry><entry>3-benzothienylalanine</entry></row><row rowsep="0"><entry>Bip</entry><entry>4,4'-biphenylalanine/ represented by the structure</entry></row><row rowsep="0"><entry /><entry><chemistry id="chem0001" num="0001"><img file="EP3925614A2_D0001.tif" /></chemistry></entry></row><row rowsep="0"><entry>Bpa</entry><entry>4-benzoylphenylalanine</entry></row><row rowsep="0"><entry>4-Br-Phe</entry><entry>4-bromo-phenylalanine</entry></row><row rowsep="0"><entry>Cha</entry><entry>β-cyclohexylalanine</entry></row><row rowsep="0"><entry>hCha</entry><entry>homo-cyclohexylalanine</entry></row><row rowsep="0"><entry>Chg</entry><entry>cyclohexylglycine</entry></row><row rowsep="0"><entry>Cys or C</entry><entry>cysteine</entry></row><row rowsep="0"><entry>hCys</entry><entry>homocysteine</entry></row><row rowsep="0"><entry>Dab</entry><entry>2,4-diaminobutyric acid</entry></row><row rowsep="0"><entry>Dap</entry><entry>2,3-diaminopropionic acid</entry></row><row rowsep="0"><entry>Dip</entry><entry>β,β-diphenylalanine</entry></row><row rowsep="0"><entry>Doc</entry><entry>8-amino-3,6-dioxaoctanoic acid with the structure of:</entry></row><row rowsep="0"><entry /><entry><chemistry id="chem0002" num="0002"><img file="EP3925614A2_D0002.tif" /></chemistry></entry></row><row rowsep="0"><entry>2-Fua</entry><entry>β-(2-furyl)-alanine</entry></row><row rowsep="0"><entry>Gaba</entry><entry>4-aminobutyric acid</entry></row><row rowsep="0"><entry>Gln or Q</entry><entry>glutamine</entry></row><row rowsep="0"><entry>Glu or E</entry><entry>glutamic acid</entry></row><row rowsep="0"><entry>Gly or G</entry><entry>glycine</entry></row><row rowsep="0"><entry>His or H</entry><entry>histidine</entry></row><row rowsep="0"><entry>3-Hyp</entry><entry>trans-3-hydroxy-L-proline, i.e., (2S, 3S)-3-hydroxypyrrolidine-2-carboxylic acid</entry></row><row rowsep="0"><entry>4-Hyp</entry><entry>4-hydroxyproline, i.e., (2S, 4R)-4-hydroxypyrrolidine-2-carboxylic acid</entry></row><row rowsep="0"><entry>Ile or I</entry><entry>isoleucine</entry></row><row rowsep="0"><entry>Leu or L</entry><entry>leucine</entry></row><row rowsep="0"><entry>hLeu</entry><entry>homoleucine</entry></row><row rowsep="0"><entry>Lys or K</entry><entry>lysine</entry></row><row rowsep="0"><entry>Met or M</entry><entry>methionine</entry></row><row rowsep="0"><entry>β-hMet</entry><entry>β-homomethionine</entry></row><row rowsep="0"><entry>1-Nal</entry><entry>β-(1-naphthyl)alanine:</entry></row><row rowsep="0"><entry>2-Nal</entry><entry>β-(2-naphthyl)alanine</entry></row><row rowsep="0"><entry>Nip</entry><entry>nipecotic acid</entry></row><row rowsep="0"><entry>Nle</entry><entry>norleucine</entry></row><row rowsep="0"><entry>Oic</entry><entry>octahydroindole-2-carboxylic acid</entry></row><row rowsep="0"><entry>Orn</entry><entry>ornithine</entry></row><row rowsep="0"><entry>2-Pal</entry><entry>β-(2-pyridiyl)alanine</entry></row><row rowsep="0"><entry>3-Pal</entry><entry>β-(3-pyridiyl)alanine</entry></row><row rowsep="0"><entry>4-Pal</entry><entry>β-(4-pyridiyl)alanine</entry></row><row rowsep="0"><entry>Pen</entry><entry>penicillamine</entry></row><row rowsep="0"><entry>Phe or F</entry><entry>phenylalanine</entry></row><row rowsep="0"><entry>hPhe</entry><entry>homophenylalanine</entry></row><row rowsep="0"><entry>Pro or P</entry><entry>proline</entry></row><row rowsep="0"><entry>hPro</entry><entry>homoproline</entry></row><row rowsep="0"><entry>Ser or S</entry><entry>serine</entry></row><row rowsep="0"><entry>Tle</entry><entry>tert-Leucine</entry></row><row rowsep="0"><entry>Taz</entry><entry>β-(4-thiazolyl)alanine</entry></row><row rowsep="0"><entry>2-Thi</entry><entry>β-(2-thienyl)alanine</entry></row><row rowsep="0"><entry>3-Thi</entry><entry>β-(3-thienyl)alanine</entry></row><row rowsep="0"><entry>Thr or T</entry><entry>threonine</entry></row><row rowsep="0"><entry>Trp or W</entry><entry>tryptophan</entry></row><row rowsep="0"><entry>Tyr or Y</entry><entry>tyrosine</entry></row><row rowsep="0"><entry>D-(Et)Tyr</entry><entry>has a structure of</entry></row><row rowsep="0"><entry /><entry><chemistry id="chem0003" num="0003"><img file="EP3925614A2_D0003.tif" /></chemistry></entry></row><row rowsep="0"><entry>Val or V</entry><entry>valine</entry></row><row rowsep="0"><entry align="center" /><entry>Certain other abbreviations used herein are defined as follows:</entry></row><row rowsep="0"><entry>Boc:</entry><entry>tert-butyloxycarbonyl</entry></row><row rowsep="0"><entry>Bzl:</entry><entry>benzyl</entry></row><row rowsep="0"><entry>DCM:</entry><entry>dichloromethane</entry></row><row rowsep="0"><entry>DIC:</entry><entry>N, N-diisopropylcarbodiimide</entry></row><row rowsep="0"><entry>DIEA:</entry><entry>diisopropylethyl amine</entry></row><row rowsep="0"><entry>Dmab:</entry><entry>4-{N-(1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl)-amino} benzyl</entry></row><row rowsep="0"><entry>DMAP:</entry><entry>4-(dimethylamino)pyridine</entry></row><row rowsep="0"><entry>DMF</entry><entry>dimethylformamide</entry></row><row rowsep="0"><entry>DNP:</entry><entry>2,4-dinitrophenyl</entry></row><row rowsep="0"><entry>Fm:</entry><entry>fluorenylmethyl</entry></row><row rowsep="0"><entry>Fmoc:</entry><entry>fluorenylmethyloxycarbonyl</entry></row><row rowsep="0"><entry>For:</entry><entry>formyl</entry></row><row rowsep="0"><entry>HBTU:</entry><entry>2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate</entry></row><row rowsep="0"><entry>cHex</entry><entry>cyclohexyl</entry></row><row rowsep="0"><entry>HOAT:</entry><entry>O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate</entry></row><row rowsep="0"><entry>HOBt:</entry><entry>1-hydroxy-benzotriazole</entry></row><row rowsep="0"><entry>MBHA</entry><entry>4-methylbenzhydrylamine</entry></row><row rowsep="0"><entry>Mmt:</entry><entry>4-methoxytrityl</entry></row><row rowsep="0"><entry>NMP:</entry><entry>N-methylpyrrolidone</entry></row><row rowsep="0"><entry>O-tBu</entry><entry>oxy-tert-butyl</entry></row><row rowsep="0"><entry>Pbf:</entry><entry>2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl</entry></row><row rowsep="0"><entry>PyBroP</entry><entry>bromo-tris-pyrrolidino-phosphonium hexafluorophosphate</entry></row><row rowsep="0"><entry>tBu:</entry><entry>tert-butyl</entry></row><row rowsep="0"><entry>TIS:</entry><entry>triisopropylsilane</entry></row><row rowsep="0"><entry>TOS:</entry><entry>tosyl</entry></row><row rowsep="0"><entry>Trt</entry><entry>trityl</entry></row><row rowsep="0"><entry>TFA:</entry><entry>trifluoro acetic acid</entry></row><row rowsep="0"><entry>TFFH:</entry><entry>tetramethylfluoroforamidinium hexafluorophosphate</entry></row><row rowsep="0"><entry>Z:</entry><entry>benzyloxycarbonyl</entry></row></tbody></tgroup></table></tables>

0085Unless otherwise indicated, with the exception of the N-terminal amino acid, all abbreviations (e.g. Ala) of amino acids in this disclosure stand for the structure of -NH-C(R)(R')-CO-, wherein R and R' each is, independently, hydrogen or the side chain of an amino acid (e.g., R = CH3 and R' = H for Ala), or R and R' may be joined to form a ring system.

0086For the N-terminal amino acid, the abbreviation stands for the structure of: <chemistry id="chem0004" num="0004"><img file="EP3925614A2_D0004.tif" /></chemistry>

0087The designation "NH2" in e.g., Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2, indicates that the C-terminus of the peptide is amidated. Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys), or alternatively Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)- OH, indicates that the C-terminus is the free acid.

0088"-c(Cys-Cys)-" or "-cyclo(Cys-Cys)-" denotes the structure: <chemistry id="chem0005" num="0005"><img file="EP3925614A2_D0005.tif" /></chemistry>

0089"-c(Cys-Pen)-" or "-cyclo(Cys-Pen)-" denotes the structure: <chemistry id="chem0006" num="0006"><img file="EP3925614A2_D0006.tif" /></chemistry>

0090"-c(Asp-Lys)-" or "-cyclo(Asp-Lys)-" denotes the structure: <chemistry id="chem0007" num="0007"><img file="EP3925614A2_D0007.tif" /></chemistry>

0091"Acyl" refers to R"-C(O)-, where R" is H, alkyl, substituted alkyl, heteroalkyl, substituted heteroalkyl, alkenyl, substituted alkenyl, aryl, alkylaryl, or substituted alklyaryl, and is indicated in the general formula of a particular embodiment as "Ac".

0092"Alkyl" refers to a hydrocarbon group containing one or more carbon atoms, where multiple carbon atoms if present are joined by single bonds. The alkyl hydrocarbon group may be straight-chain or contain one or more branches or cyclic groups.

0093"Hydroxyalkyl" refers to an alkyl group wherein one or more hydrogen atoms of the hydrocarbon group are substituted with one or more hydroxy radicals, such as hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl and the like.

0094"Substituted alkyl" refers to an alkyl wherein one or more hydrogen atoms of the hydrocarbon group are replaced with one or more substituents selected from the group consisting of halogen, (i.e., fluorine, chlorine, bromine, and iodine), -OH, -CN, -SH, -NH2, -NHCH3, -NO2, and -C1-20 alkyl, wherein said -C1-20 alkyl optionally may be substituted with one or more substituents selected, independently for each occurrence, from the group consisting of halogens, -CF3, -OCH3, -OCF3, and -(CH2)0-20-COOH. In different embodiments 1, 2, 3 or 4 substituents are present. The presence of -(CH2)0-20-COOH results in the production of an alkyl acid. Non-limiting examples of alkyl acids containing, or consisting of, -(CH2)0-20-COOH include 2-norbornane acetic acid, tert-butyric acid, 3-cyclopentyl propionic acid, and the like.

0095The term "halo" encompasses fluoro, chloro, bromo and iodo.

0096"Heteroalkyl" refers to an alkyl wherein one of more of the carbon atoms in the hydrocarbon group is replaced with one or more of the following groups: amino, amido, -O-, -S- or carbonyl. In different embodiments 1 or 2 heteroatoms are present.

0097"Substituted heteroalkyl" refers to a heteroalkyl wherein one or more hydrogen atoms of the hydrocarbon group are replaced with one or more substituents selected from the group consisting of halogen, (i.e., fluorine, chlorine, bromine, and iodine), -OH, -CN, -SH, -NH2, -NHCH3, -NO2, and -C1-20 alkyl, wherein said -C1-20 alkyl optionally may be substituted with one or more substituents selected, independently for each occurrence, from the group consisting of halogens, -CF3, -OCH3, -OCF3, and -(CH2)0-20-COOH. In different embodiments 1, 2, 3 or 4 substituents are present.

0098"Alkenyl" refers to a hydrocarbon group made up of two or more carbons where one or more carbon-carbon double bonds are present. The alkenyl hydrocarbon group may be straight-chain or contain one or more branches or cyclic groups.

0099"Substituted alkenyl" refers to an alkenyl wherein one or more hydrogens are replaced with one or more substituents selected from the group consisting of halogen (i.e., fluorine, chlorine, bromine, and iodine), -OH, -CN, -SH, -NH2, -NHCH3, -NO2, and -C1-20 alkyl, wherein said -C1-20 alkyl optionally may be substituted with one or more substituents selected, independently for each occurrence, from the group consisting of halogens, -CF3, -OCH3, -OCF3, and -(CH2)0-20-COOH. In different embodiments 1, 2, 3 or 4 substituents are present.

0100"Aryl" refers to an optionally substituted aromatic group with at least one ring having a conjugated pi-electron system, containing up to three conjugated or fused ring systems. Aryl includes carbocyclic aryl, heterocyclic aryl and biaryl groups. Preferably, the aryl is a 5- or 6-membered ring. Preferred atoms for a heterocyclic aryl are one or more sulfur, oxygen, and/or nitrogen. Non-limiting examples of aryl include phenyl, 1-naphthyl, 2-naphthyl, indole, quinoline, 2-imidazole, 9-anthracene, and the like. Aryl substituents are selected from the group consisting of -C1-20 alkyl, -C1-20 alkoxy, halogen (i.e., fluorine, chlorine, bromine, and iodine), -OH, -CN, -SH, -NH2, -NO2, -C1-20 alkyl substituted with halogens, -CF3, -OCF3, and -(CH2)0-20-COOH. In different embodiments the aryl contains 0, 1, 2, 3, or 4 substituents.

0101"Alkylaryl" refers to an "alkyl" joined to an "aryl".

0102The term "(C1-C12)hydrocarbon moiety" encompasses alkyl, alkenyl and alkynyl and in the case of alkenyl and alkynyl there is C2-C12.

0103As used herein, the term "normalizing" functions or activities refers to those types of functions which may be considered to be involved in normal body function or homeostasis of an organism. Such functions include but are not limited to activities and functions affecting body temperature, blood pressure, heart rate, vascular tone, brain blood flow, blood glucose levels and the like.

0104As used herein, compounds which are considered to be "selective" for a particular melanocortin receptor are those compounds with a functional activity characterized by an ECso at least about 2-fold, at least about 5-fold, at least about 10-fold, at least about 15-fold, at least about 17-fold; at least about 90-fold, at least about 200-fold, at least about 3000-fold or at least about 10,000-fold, or even greater, selectivity for any melanocortin receptor as compared to any other melanocortin receptor. For example, a selective melanocortin 4 receptor agonist of the invention exhibits a functional activity characterized by an ECso at least about 15-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 1 receptor, the human melanocortin 3 receptor and the human melanocortin 5 receptor. Also for example, a selective melanocortin 4 receptor agonist of the invention exhibits a functional activity characterized by an ECso at least 17-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 3 receptor.

Synthesis

0105The peptides of this invention can be prepared by standard solid phase peptide synthesis. See, e.g., <nplcit id="ncit0092" npl-type="b"><text>Stewart, J.M., et al., Solid Phase Synthesis (Pierce Chemical Co., 2d ed. 1984</text></nplcit>). The substituents R2 and R3 of the above generic formula may be attached to the free amine of the N-terminal amino acid by standard methods known in the art. For example, alkyl groups, e.g., (C1-C30)alkyl, may be attached using reductive alkylation. Hydroxyalkyl groups, e.g., (C1-C30)hydroxyalkyl, may also be attached using reductive alkylation wherein the free hydroxyl group is protected with a t-butyl ester. Acyl groups, e.g., COE1, may be attached by coupling the free acid, e.g., E1COOH, to the free amine of the N-terminal amino acid by mixing the completed resin with 3 molar equivalents of both the free acid and diisopropylcarbodiimide in methylene chloride for one hour. If the free acid contains a free hydroxyl group, e.g., p-hydroxyphenylpropionic acid, then the coupling should be performed with an additional 3 molar equivalents of HOBt.

0106When R1 is -NH2, the synthesis of the peptide starts with an Fmoc-amino acid which is coupled to the Rink Amide MBHA resin. If R1 is -OH, the synthesis of the peptide starts with a Fmoc-amino acid which is coupled to Wang resin.

0107In the synthesis of a peptide of this invention containing A6c and/or Aib, the coupling time is 2 hours for these residues and the residue immediately following them.

0108The following examples describe synthetic methods for making a peptide of this invention, which methods are well-known to those skilled in the art. Other methods are also known to those skilled in the art. The examples are provided for the purpose of illustration and are not meant to limit the scope of the present invention in any manner.

EXAMPLES

Example 1: Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH

2

0109The title peptide was synthesized on an Advanced ChemTech model 396® multiple peptide synthesizer (Louisville, KY 40228) using Fluorenylmethyloxycarbonyl (Fmoc) chemistry. A Rink Amide 4-methylbenzylhydrylamine (MBHA) resin (Novabiochem®, San Diego, CA) with substitution of 0.58 mmol/g was used. The Fmoc amino acids (Novabiochem®, CA and Chem-Impex®, IL) used were Fmoc-Nle-OH, Fmoc-Cys(Trt)-OH, Fmoc-D-Ala-OH, Fmoc-His(Trt)-OH, Fmoc-D-Phe-OH, Fmoc-Arg(Pbf)-OH, and Fmoc-Trp(Boc)-OH. The synthesis was carried out on a 0.035 mmol scale. The Fmoc groups were removed by treatment with 25% piperidine in N,N-dimethylformamide (DMF) for 30 minutes. In each coupling step, the Fmoc amino acid (10 eq, 0.35 mmol), N, N-diisopropylcarbodiimide (DIC) (10 eq, 0.35 mmol), and 1-hydroxy-benzotriazole (HOBt) (10 eq, 0.35 mmol) were used in DMF (1.4 mL). After washing with DMF, double-coupling was performed with the Fmoc-amino acid (10 eq, 0.35 mmol), 2-(1-H-benzotriazole-1-yl)-1,1,2,3-tetramethyluronium hexafluorophosphate (HBTU) (8 eq, 0.28 mmol), HOBT (10 eq, 0.35 mmol), and diisopropylethyl amine (DIEA) (20 eq, 0.7 mmol) in DMF (1.26 mL). The ACT 396® multiple peptide synthesizer was programmed to perform the following reaction cycle: (1) washing with DMF, (2) removing Fmoc protecting group with 25% piperidine in DMF for 30 minutes, (3) washing with DMF, (4) coupling with Fmoc amino acid in the presence of DIC and HOBT for 1 hour, (5) washing with DMF, (6) double-coupling with the same Fmoc amino acid in step 4 in the presence of HBTU, HOBt, and DIEA for 1 hour. The resin was coupled successively according to the sequence of the title peptide. After the peptide chain was assembled and the last Fmoc- protecting group was removed, the resin was washed completely by using DMF and dichloromethane (DCM).

0110To cleave the title peptide, the resin was treated with a solution (1.5 mL) of TFA, H2O and triisopropylsilane (TIS) (v/v/v: 90/6.2/3.8) for 2 hours at room temperature. The resin was filtered off and the filtrate was poured into 30 mL of ether. The precipitate was collected by centrifugation. This crude product was dissolved in water (∼7 mL) and the pH of the aqueous solution was adjusted to ∼7.5 by adding 2N NH4HCO3. The solution was opened to the air for 72 hours at room temperature. The resulting crude product was purified on a reverse-phase preparative HPLC system with a column (4 x 43 cm) of C18 DYNAMAX-100® A0 (Varian®, Walnut Creek, CA). The column was eluted over approximately 1 hour using a linear gradient of 85% A:15% B to 30% A:70% B, where A was 0.1% TFA in water and B was 0.1% TFA in acetonitrile. The fractions were checked by analytical HPLC and those containing pure product were pooled and lyophilized to dryness to give 10.3 mg (27% yield) of a white solid. Purity was assayed using HPLC and found to be approximately 88%. Electro-spray ionization mass spectrometry (ESI-MS) analysis gave the molecular weight at 1073.6 (in agreement with the calculated molecular weight of 1074.3).

Example 2: Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH

2

0111The title peptide was synthesized on an Applied Biosystems® (Foster City, CA) model 430A peptide synthesizer which was modified to do accelerated Boc-chemistry solid phase peptide synthesis. See <nplcit id="ncit0093" npl-type="s"><text>Schnolzer, et al., Int. J. Peptide Protein Res., 40:180 (1992</text></nplcit>). 4-methylbenzhydrylamine (MBHA) resin (Peninsula®, Belmont, CA) with the substitution of 0.91 mmol/g was used. The Boc amino acids (Novabiochem®, San Diego, CA and Chem-Impex®, Wood Dale, IL) used were: Boc-Cha-OH, Boc-Asp(OFm)-OH, Boc-His(DNP)-OH, Boc-D-Phe-OH, Boc-Arg(Tos)-OH, Boc-Trp(For)-OH, Boc-Gaba-OH, and Boc-Lys(Fmoc)-OH. The synthesis was carried out on a 0.20 mmol scale. The Boc groups were removed by treatment with 100% TFA for 2 x 1 minute. Boc amino acids (2.5 mmol) were pre-activated with HBTU (2.0 mmol) and DIEA (1.0 mL) in 4 mL of DMF and were coupled without prior neutralization of the peptide-resin TFA salt. Coupling times were 5 minutes.

0112At the end of the assembly of Boc-Asp(OFm)-His(DNP)-D-Phe-Arg(Tos)-Trp(For)-Gaba-Lys(Fmoc)-MBHA, the peptide-resin was transferred into a reaction vessel on a shaker. The resin was treated twice with 25% piperidine in DMF for 15 minutes per session, washed with DMF, and shaken with bromo-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBrOP) (6 eq, 0.3 mmol), DIEA (1 mL), and 4-(dimethylamino)pyridine (DMAP) (24 mg) in DMF (2 mL) for 12 hours. After washing with DMF, the resin was treated twice with 100% TFA for 2 minutes per treatment, washed with DMF and DCM, and then dried under reduced pressure. One fourth of the peptide-resin (0.05 mmol) was used for the next coupling with Boc-Cha-OH (10 eq, 0.5 mmol) in the presence of HBTU (9 eq, 0.45 mmol) and DIEA (0.25 mL) in DMF for 10 minutes. After the deprotection with 100% TFA in two sessions lasting approximately 2 minutes each, the peptide-resin was then washed with DMF. The final capping step was done by shaking the resin with acetic anhydride (40 eq, 2.0 mmol) and DIEA (20 eq, 1.0 mmol) in DMF for 1 hour. After washing with DMF, the resin was treated twice with a solution of 20% mercaptoethanol/10% DIEA in DMF, each treatment lasting approximately 30 minutes, to remove the DNP group on the Histidine side chain. The formyl group on the side chain of Tryptophan was removed by shaking with a solution of 15% ethanolamine/ 15% water/ 70% DMF twice for 30 minutes per shaking. The peptide-resin was washed with DMF and DCM and dried under reduced pressure. The final cleavage was done by stirring the peptide-resin in 10 mL of HF containing 1 mL of anisole and dithiothreitol (30 mg) at 0°C for 75 minutes. HF was removed by a flow of nitrogen. The residue was washed with ether (6 x 10 mL) and extracted with 4N HOAc (6 x 10 mL).

0113The peptide mixture in the aqueous extract was purified on reverse-phase preparative high pressure liquid chromatography (HPLC) using a reverse phase VYDAC® C18 column (Nest Group®, Southborough, MA). The column was eluted with a linear gradient (10% to 50% of solution B over 40 minutes) at a flow rate of 10 mL/minute (Solution A = water containing 0.1% TFA; Solution B = acetonitrile containing 0.1% of TFA). Fractions were collected and checked on analytical HPLC. Those containing pure product were combined and lyophilized to dryness. 5.1 mg of a white solid was obtained. Yield was 8.9%. Purity was 94.5% based on analytical HPLC analysis. Electro-spray mass spectrometer (MS(ES))S analysis gave the molecular weight at 1148.5 (in agreement with the calculated molecular weight of 1148.3).

0114Other peptides of the invention can be prepared by a person of ordinary skill in the art using synthetic procedures analogous to those disclosed generally hereinabove and/or to those disclosed specifically in the foregoing examples, as were the compounds depicted in Tables 1A and 1B.

0115Other peptides of the invention can be prepared by a person of ordinary skill in the art using synthetic procedures analogous to those disclosed generally hereinabove and/or to those disclosed specifically in the foregoing examples, as were the compounds depicted in Tables 1A and 1B.

0116The following examples can be made according to the appropriate procedures described above: <ul id="ul0015" list-style="none" compact="compact"><li>Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-β-Ala-Lys)-NH2;</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-A6c-Lys)-NH2;</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-NH2;</li><li>D-Phe-c(Cys-His-D-Phe-Arg-Trp-Ala-D-Cys)-Thr-NH2;</li><li>D-Phe-c(Cys-His-D-Phe-Arg-Trp-β-Ala-D-Cys)-Thr-NH2;</li><li>D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-Thr-NH2;</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH2;</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Apn-Lys)-NH2;</li><li>Ac-A6c-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-D-2-Nal-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-Nle-c(Cys-β-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(Cys-Gaba-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(Cys-Aib-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(Cys-Gly-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(D-Cys-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(D-Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(D-Cys-β-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(D-Cys-Gaba-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(D-Cys-Aib-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(D-Cys-Gly-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2;</li><li>Ac-Nle-c(Cys-p-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2;</li><li>Ac-Nle-c(Cys-Gaba-His-D-Phe-Arg-Trp-D-Cys)-NH2;</li><li>Ac-Nle-c(Cys-Aib-His-D-Phe-Arg-Trp-D-Cys)-NH2;</li><li>Ac-Nle-c(Cys-Gly-His-D-Phe-Arg-Trp-D-Cys)-NH2;</li><li>Ac-Nle-c(D-Cys-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2;</li><li>Ac-Nle-c(D-Cys-D-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2;</li><li>Ac-Nle-c(D-Cys-β-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2;</li><li>Ac-Nle-c(D-Cys-Gaba-His-D-Phe-Arg-Trp-D-Cys)-NH2;</li><li>Ac-Nle-c(D-Cys-Aib-His-D-Phe-Arg-Trp-D-Cys)-NH2;</li><li>Ac-Oic-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-D-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-Nip-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-hPro-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-hLeu-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-Phe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-D-Phe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>n-butanoyl-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-β-hMet-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-Gaba-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NHz;</li><li>Ac-Cha-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2;</li><li>Ac-hCha-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2;</li><li>Ac-Leu-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2;</li><li>Ac-hLeu-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2;</li><li>Ac-Phe-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2;</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-D-Ala-Lys)-NH2;</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-β-Ala-Lys)-NH2;</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Gaba-Lys)-NH2;</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Aha-Lys)-NH2;</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Apn-Lys)-NH2;</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Apn-Cys)-NH2;</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Gaba-Cys)-NH2;</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-NH2;</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-p-Ala-Cys)-NH2;</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-D-Ala-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-2-Nal-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-1-Nal-Cys)-NH2;</li><li>n-butanoyl-Nle-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Cys)-NH2;</li><li>n-butanoyl-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-1-Nal-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Bal-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Glu-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-D-Ala-Lys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Bal-Cys)-NH2;</li><li>Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;</li><li>Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;</li><li>D-Phe-c(Cys-His-D-Phe-hArg-Trp-p-Ala-D-Cys)-Thr-NH2;</li><li>D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Thr-NH2;</li><li>D-Phe-c(Cys-His-D-Phe-Arg-Bip-β-Ala-D-Cys)-Thr-NH2;</li><li>D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-NH2;</li><li>D-Phe-c(Cys-His-D-Phe-hArg-Bip-β-Ala-D-Cys)-Thr-NH2;</li><li>D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-p-Ala-D-Cys)-Thr-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gly-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-D-Ala-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-p-Ala-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Apn-Cys)-NH2;</li><li>Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH2;</li><li>Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Trp-Lys)- NH2;</li><li>Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Bal-Lys)-NH2;</li><li>Ac-c(Cys-Glu-His-D-Phe-Arg-Trp-Ala-Cys)-NH2;</li><li>Ac-c(Cys-Glu-His-D-Phe-Arg-2-Nal-Ala-Cys)-NH2;</li><li>Ac-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Ala-Cys)-NH2;</li><li>Ac-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Ala-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Ala-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-β-Ala-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-OH;</li><li>Ac-Nle-c(Cys-D-Abu-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Val-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ile-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Tle-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2;</li><li>Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2;</li><li>Ac-Leu-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;</li><li>Ac-Cha-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;</li><li>Ac-Ile-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;</li><li>Ac-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;</li><li>Ac-Val-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;</li><li>Ac-2-Nal-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;</li><li>Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;</li><li>Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2;</li><li>Ac-Nle-c(Cys-3-Pal-D-Phe-Arg-Trp-Gaba-Cys)-NH2;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH;</li><li>Ac-Nle-c(Cys-His-Phe-Arg-D-Trp-Gaba-Cys)-NH2;</li><li>Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Bal-Ala-Lys)-NH2;</li><li>Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Ala-Lys)-NH2;</li><li>Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-β-Ala-Lys)-NH2;</li><li>Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Gaba-Cys)-NH2;</li><li>Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Ahx-Cys)-NH2;</li><li>Ac-hPhe-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-Cha-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH2;</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-β-Ala-Lys)-OH;</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-OH;</li><li>D-Phe-c(Cys-His-D-Phe-Arg-Trp-Ala-D-Cys)-Thr-OH;</li><li>D-Phe-c(Cys-His-D-Phe-Arg-Trp-β-Ala-D-Cys)-Thr-OH;</li><li>D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-Thr-OH;</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-OH;</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Apn-Lys)-OH;</li><li>Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH;</li><li>Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;</li><li>Ac-D-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;</li><li>Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;</li><li>Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;</li><li>Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Gaba-Cys)-OH;</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-OH;</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-β-Ala-Cys)-OH;</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-D-Ala-Cys)-OH;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-OH;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-2-Nal-Cys)-OH;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-1-Nal-Cys)-OH;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Bal-Cys)-OH;</li><li>Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH;</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-OH;</li><li>Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;</li><li>Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;</li><li>Ac-D-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2;</li><li>Ac-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2;</li><li>Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;</li><li>Ac-D-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH2;</li><li>Ac-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH2;</li><li>Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2; and</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-OH.</li></ul>

0117Other peptides of the invention can be prepared by a person of ordinary skill in the art using synthetic procedures analogous to those disclosed generally hereinabove and/or to those disclosed specifically in the foregoing examples, as were the compounds depicted in Tables 1A and 1B.

TABLES 1A and 1B - Molecular Weight and Purity for Selected Embodiments

0118<tables id="tabl0002" num="0002"><table frame="all"><title>Table 1A</title><tgroup cols="4"><colspec colnum="1" colname="col1" colwidth="66mm" /><colspec colnum="2" colname="col2" colwidth="43mm" /><colspec colnum="3" colname="col3" colwidth="46mm" /><colspec colnum="4" colname="col4" colwidth="12mm" /><thead valign="middle"><row><entry>Compound</entry><entry>Calculated Molecular Weight</entry><entry>Experimental Molecular Weight</entry><entry>Purity</entry></row></thead><tbody valign="middle"><row><entry><img file="EP3925614A2_D0008.tif" /></entry><entry>1095.27</entry><entry>1095.2</entry><entry>96.4</entry></row><row><entry><img file="EP3925614A2_D0009.tif" /></entry><entry>1149.36</entry><entry>1149.05</entry><entry>96</entry></row><row><entry><img file="EP3925614A2_D0010.tif" /></entry><entry>1116.38</entry><entry>1115.8</entry><entry>98</entry></row><row><entry><img file="EP3925614A2_D0011.tif" /></entry><entry>1167.38</entry><entry>1167.3</entry><entry>99</entry></row><row><entry><img file="EP3925614A2_D0012.tif" /></entry><entry>1167.38</entry><entry>1167.5</entry><entry>93</entry></row><row><entry><img file="EP3925614A2_D0013.tif" /></entry><entry>1181.41</entry><entry>1181.9</entry><entry>99</entry></row><row><entry><img file="EP3925614A2_D0014.tif" /></entry><entry>1102.35</entry><entry>1103</entry><entry>99</entry></row><row><entry><img file="EP3925614A2_D0015.tif" /></entry><entry>1123.32</entry><entry>1123.9</entry><entry>99</entry></row><row><entry><img file="EP3925614A2_D0016.tif" /></entry><entry>1121.31</entry><entry>1121.2</entry><entry>93</entry></row><row><entry><img file="EP3925614A2_D0017.tif" /></entry><entry>1193.37</entry><entry>1193.2</entry><entry>92.6</entry></row><row><entry><img file="EP3925614A2_D0018.tif" /></entry><entry>1149.36</entry><entry>1149.4</entry><entry>94.5</entry></row><row><entry><img file="EP3925614A2_D0019.tif" /></entry><entry>1109.3</entry><entry>1109.2</entry><entry>91.5</entry></row><row><entry><img file="EP3925614A2_D0020.tif" /></entry><entry>1074.3</entry><entry>1074.6</entry><entry>98.3</entry></row><row><entry><img file="EP3925614A2_D0021.tif" /></entry><entry>1074.3</entry><entry>1074.4</entry><entry>91</entry></row><row><entry><img file="EP3925614A2_D0022.tif" /></entry><entry>1088.32</entry><entry>1088.4</entry><entry>93</entry></row><row><entry><img file="EP3925614A2_D0023.tif" /></entry><entry>1088.32</entry><entry>1088.4</entry><entry>80</entry></row><row><entry><img file="EP3925614A2_D0024.tif" /></entry><entry>1060.27</entry><entry>1060.4</entry><entry>90</entry></row><row><entry><img file="EP3925614A2_D0025.tif" /></entry><entry>1074.3</entry><entry>1074.4</entry><entry>93</entry></row><row><entry><img file="EP3925614A2_D0026.tif" /></entry><entry>1074.3</entry><entry>1074.4</entry><entry>81</entry></row><row><entry><img file="EP3925614A2_D0027.tif" /></entry><entry>1074.3</entry><entry>1074.4</entry><entry>92</entry></row><row><entry><img file="EP3925614A2_D0028.tif" /></entry><entry>1088.32</entry><entry>1088.4</entry><entry>94</entry></row><row><entry><img file="EP3925614A2_D0029.tif" /></entry><entry>1088.32</entry><entry>1088.4</entry><entry>91</entry></row><row><entry><img file="EP3925614A2_D0030.tif" /></entry><entry>1060.27</entry><entry>1060.4</entry><entry>96</entry></row><row><entry><img file="EP3925614A2_D0031.tif" /></entry><entry>1074.3</entry><entry>1074.4</entry><entry>66</entry></row><row><entry><img file="EP3925614A2_D0032.tif" /></entry><entry>1074.3</entry><entry>1074.2</entry><entry>94</entry></row><row><entry><img file="EP3925614A2_D0033.tif" /></entry><entry>1088.32</entry><entry>1088.2</entry><entry>93</entry></row><row><entry><img file="EP3925614A2_D0034.tif" /></entry><entry>1088.32</entry><entry>1088.4</entry><entry>90</entry></row><row><entry><img file="EP3925614A2_D0035.tif" /></entry><entry>1060.27</entry><entry>1060.4</entry><entry>91</entry></row><row><entry><img file="EP3925614A2_D0036.tif" /></entry><entry>1074.3</entry><entry>1074.4</entry><entry>65</entry></row><row><entry><img file="EP3925614A2_D0037.tif" /></entry><entry>1074.3</entry><entry>1074.2</entry><entry>93</entry></row><row><entry><img file="EP3925614A2_D0038.tif" /></entry><entry>1074.3</entry><entry>1074.4</entry><entry>92</entry></row><row><entry><img file="EP3925614A2_D0039.tif" /></entry><entry>1088.32</entry><entry>1088.4</entry><entry>90</entry></row><row><entry><img file="EP3925614A2_D0040.tif" /></entry><entry>1088.32</entry><entry>1088</entry><entry>95</entry></row><row><entry><img file="EP3925614A2_D0041.tif" /></entry><entry>1147.35</entry><entry>1147.4</entry><entry>97.5</entry></row><row><entry><img file="EP3925614A2_D0042.tif" /></entry><entry>1135.33</entry><entry>1135.1</entry><entry>99</entry></row><row><entry><img file="EP3925614A2_D0043.tif" /></entry><entry>1163.39</entry><entry>1163.4</entry><entry>99</entry></row><row><entry><img file="EP3925614A2_D0044.tif" /></entry><entry>1149.36</entry><entry>1149.2</entry><entry>99</entry></row><row><entry><img file="EP3925614A2_D0045.tif" /></entry><entry>1107.28</entry><entry>1107</entry><entry>98.9</entry></row><row><entry><img file="EP3925614A2_D0046.tif" /></entry><entry>1107.28</entry><entry>1107.4</entry><entry>99</entry></row><row><entry><img file="EP3925614A2_D0047.tif" /></entry><entry>1123.32</entry><entry>1123.2</entry><entry>99</entry></row><row><entry><img file="EP3925614A2_D0048.tif" /></entry><entry>1163.39</entry><entry>1163.6</entry><entry>94</entry></row><row><entry><img file="EP3925614A2_D0049.tif" /></entry><entry>1143.31</entry><entry>1143.3</entry><entry>96.9</entry></row><row><entry><img file="EP3925614A2_D0050.tif" /></entry><entry>1143.31</entry><entry>1143.3</entry><entry>96.5</entry></row><row><entry><img file="EP3925614A2_D0051.tif" /></entry><entry>1135.33</entry><entry>1135.4</entry><entry>99</entry></row><row><entry><img file="EP3925614A2_D0052.tif" /></entry><entry>1177.41</entry><entry>1177.5</entry><entry>88.6</entry></row><row><entry><img file="EP3925614A2_D0053.tif" /></entry><entry>1157.34</entry><entry>1157.2</entry><entry>70</entry></row><row><entry><img file="EP3925614A2_D0054.tif" /></entry><entry>1141.36</entry><entry>1141.2</entry><entry>89</entry></row><row><entry><img file="EP3925614A2_D0055.tif" /></entry><entry>1081.24</entry><entry>1080.9</entry><entry>92.5</entry></row><row><entry><img file="EP3925614A2_D0056.tif" /></entry><entry>1135.33</entry><entry>1135.2</entry><entry>85</entry></row><row><entry><img file="EP3925614A2_D0057.tif" /></entry><entry>1149.36</entry><entry>1149.1</entry><entry>87</entry></row><row><entry><img file="EP3925614A2_D0058.tif" /></entry><entry>1095.27</entry><entry>1095.4</entry><entry>98.6</entry></row><row><entry><img file="EP3925614A2_D0059.tif" /></entry><entry>1109.3</entry><entry>1109.2</entry><entry>93.8</entry></row><row><entry><img file="EP3925614A2_D0060.tif" /></entry><entry>1129.29</entry><entry>1129.2</entry><entry>81.9</entry></row><row><entry><img file="EP3925614A2_D0061.tif" /></entry><entry>1095.27</entry><entry>1095.3</entry><entry>97</entry></row><row><entry><img file="EP3925614A2_D0062.tif" /></entry><entry>1095.27</entry><entry>1095.3</entry><entry>82</entry></row><row><entry><img file="EP3925614A2_D0063.tif" /></entry><entry>1109.3</entry><entry>1109.1</entry><entry>99</entry></row><row><entry><img file="EP3925614A2_D0064.tif" /></entry><entry>1137.35</entry><entry>1137.4</entry><entry>98</entry></row><row><entry><img file="EP3925614A2_D0065.tif" /></entry><entry>1123.32</entry><entry>1123.3</entry><entry>97.3</entry></row><row><entry><img file="EP3925614A2_D0066.tif" /></entry><entry>1102.35</entry><entry>1102</entry><entry>99</entry></row><row><entry><img file="EP3925614A2_D0067.tif" /></entry><entry>1088.32</entry><entry>1087.8</entry><entry>97</entry></row><row><entry><img file="EP3925614A2_D0068.tif" /></entry><entry>1116.38</entry><entry>1116.2</entry><entry>99</entry></row><row><entry><img file="EP3925614A2_D0069.tif" /></entry><entry>1074.3</entry><entry>1073.8</entry><entry>99.9</entry></row><row><entry><img file="EP3925614A2_D0070.tif" /></entry><entry>1074.3</entry><entry>1073.8</entry><entry>99.9</entry></row><row><entry><img file="EP3925614A2_D0071.tif" /></entry><entry>1124.36</entry><entry>1123.6</entry><entry>96.1</entry></row><row><entry><img file="EP3925614A2_D0072.tif" /></entry><entry>1135.38</entry><entry>1134.5</entry><entry>99.1</entry></row><row><entry><img file="EP3925614A2_D0073.tif" /></entry><entry>1135.38</entry><entry>1134.6</entry><entry>94.8</entry></row><row><entry><img file="EP3925614A2_D0074.tif" /></entry><entry>1113.37</entry><entry>1112.6</entry><entry>95.7</entry></row><row><entry><img file="EP3925614A2_D0075.tif" /></entry><entry>1102.35</entry><entry>1101.5</entry><entry>99.9</entry></row><row><entry><img file="EP3925614A2_D0076.tif" /></entry><entry>1085.32</entry><entry>1084.4</entry><entry>97.7</entry></row><row><entry><img file="EP3925614A2_D0077.tif" /></entry><entry>1085.32</entry><entry>1084.5</entry><entry>96.6</entry></row><row><entry><img file="EP3925614A2_D0078.tif" /></entry><entry>1091.35</entry><entry>1090.4</entry><entry>96.2</entry></row><row><entry><img file="EP3925614A2_D0079.tif" /></entry><entry>1132.33</entry><entry>1131.5</entry><entry>99.9</entry></row><row><entry><img file="EP3925614A2_D0080.tif" /></entry><entry>1095.27</entry><entry>1094.6</entry><entry>99.9</entry></row><row><entry><img file="EP3925614A2_D0081.tif" /></entry><entry>1141.41</entry><entry>1140.5</entry><entry>95.6</entry></row><row><entry><img file="EP3925614A2_D0082.tif" /></entry><entry>1102.35</entry><entry>1101.6</entry><entry>99.9</entry></row><row><entry><img file="EP3925614A2_D0083.tif" /></entry><entry>1102.35</entry><entry>1101.6</entry><entry>99.9</entry></row><row><entry><img file="EP3925614A2_D0084.tif" /></entry><entry>1130.4</entry><entry>1129.6</entry><entry>99.9</entry></row><row><entry><img file="EP3925614A2_D0085.tif" /></entry><entry>1181.41</entry><entry>1181.7</entry><entry>96.9</entry></row><row><entry><img file="EP3925614A2_D0086.tif" /></entry><entry>1211.43</entry><entry>1211.7</entry><entry>97.1</entry></row><row><entry><img file="EP3925614A2_D0087.tif" /></entry><entry>1204.44</entry><entry>1204.6</entry><entry>99</entry></row><row><entry><img file="EP3925614A2_D0088.tif" /></entry><entry>1225.46</entry><entry>1225.7</entry><entry>97</entry></row><row><entry><img file="EP3925614A2_D0089.tif" /></entry><entry>1218.47</entry><entry>1218.8</entry><entry>99</entry></row><row><entry><img file="EP3925614A2_D0090.tif" /></entry><entry>1262.52</entry><entry>1263</entry><entry>99</entry></row><row><entry><img file="EP3925614A2_D0091.tif" /></entry><entry>1131.35</entry><entry>1131.2</entry><entry>96.8</entry></row><row><entry><img file="EP3925614A2_D0092.tif" /></entry><entry>1145.37</entry><entry>1145.3</entry><entry>96.4</entry></row><row><entry><img file="EP3925614A2_D0093.tif" /></entry><entry>1145.37</entry><entry>1145.2</entry><entry>98.2</entry></row><row><entry><img file="EP3925614A2_D0094.tif" /></entry><entry>1159.4</entry><entry>1159.2</entry><entry>95.1</entry></row><row><entry><img file="EP3925614A2_D0095.tif" /></entry><entry>1173.43</entry><entry>1173.3</entry><entry>96.8</entry></row><row><entry><img file="EP3925614A2_D0096.tif" /></entry><entry>1060.31</entry><entry>1060.3</entry><entry>98.5</entry></row><row><entry><img file="EP3925614A2_D0097.tif" /></entry><entry>1095.27</entry><entry>1094.7</entry><entry>96.2</entry></row><row><entry><img file="EP3925614A2_D0098.tif" /></entry><entry>1112.32</entry><entry>1111.7</entry><entry>96.5</entry></row><row><entry><img file="EP3925614A2_D0099.tif" /></entry><entry>1090.25</entry><entry>1089.6</entry><entry>99.9</entry></row><row><entry><img file="EP3925614A2_D0100.tif" /></entry><entry>1101.27</entry><entry>1100.6</entry><entry>98.3</entry></row><row><entry><img file="EP3925614A2_D0101.tif" /></entry><entry>1032.22</entry><entry>1031.5</entry><entry>95.2</entry></row><row><entry><img file="EP3925614A2_D0102.tif" /></entry><entry>1043.24</entry><entry>1042.5</entry><entry>95.6</entry></row><row><entry><img file="EP3925614A2_D0103.tif" /></entry><entry>1144.39</entry><entry>1144.6</entry><entry>95.3</entry></row><row><entry><img file="EP3925614A2_D0104.tif" /></entry><entry>1145.37</entry><entry>1144.6</entry><entry>97.3</entry></row><row><entry><img file="EP3925614A2_D0105.tif" /></entry><entry>1158.41</entry><entry>1158.6</entry><entry>96.5</entry></row><row><entry><img file="EP3925614A2_D0106.tif" /></entry><entry>1103.33</entry><entry>1103</entry><entry>99.9</entry></row><row><entry><img file="EP3925614A2_D0107.tif" /></entry><entry>1088.32</entry><entry>1087.6</entry><entry>99.9</entry></row><row><entry><img file="EP3925614A2_D0108.tif" /></entry><entry>1102.35</entry><entry>1101.7</entry><entry>99.9</entry></row><row><entry><img file="EP3925614A2_D0109.tif" /></entry><entry>1116.38</entry><entry>1115.7</entry><entry>99.9</entry></row><row><entry><img file="EP3925614A2_D0110.tif" /></entry><entry>1116.38</entry><entry>1115.8</entry><entry>97.4</entry></row><row><entry><img file="EP3925614A2_D0111.tif" /></entry><entry>1116.38</entry><entry>1115.5</entry><entry>96.5</entry></row><row><entry><img file="EP3925614A2_D0112.tif" /></entry><entry>1156.44</entry><entry>1155.6</entry><entry>96.4</entry></row><row><entry><img file="EP3925614A2_D0113.tif" /></entry><entry>1116.38</entry><entry>1115.7</entry><entry>95</entry></row><row><entry><img file="EP3925614A2_D0114.tif" /></entry><entry>1116.38</entry><entry>1115.5</entry><entry>99.9</entry></row><row><entry><img file="EP3925614A2_D0115.tif" /></entry><entry>1144.43</entry><entry>1144</entry><entry>99.9</entry></row><row><entry><img file="EP3925614A2_D0116.tif" /></entry><entry>1088.32</entry><entry>1088</entry><entry>96.7</entry></row><row><entry><img file="EP3925614A2_D0117.tif" /></entry><entry>1128.39</entry><entry>1128.4</entry><entry>95.8</entry></row><row><entry><img file="EP3925614A2_D0118.tif" /></entry><entry>1088.32</entry><entry>1088.4</entry><entry>95</entry></row><row><entry><img file="EP3925614A2_D0119.tif" /></entry><entry>1122.34</entry><entry>1122</entry><entry>95.2</entry></row><row><entry><img file="EP3925614A2_D0120.tif" /></entry><entry>1074.3</entry><entry>1074.6</entry><entry>95.4</entry></row><row><entry><img file="EP3925614A2_D0121.tif" /></entry><entry>1172.4</entry><entry>1172.2</entry><entry>95.2</entry></row><row><entry><img file="EP3925614A2_D0122.tif" /></entry><entry>1046.29</entry><entry>1046.4</entry><entry>97.6</entry></row><row><entry><img file="EP3925614A2_D0123.tif" /></entry><entry>1080.3</entry><entry>1080</entry><entry>95.8</entry></row><row><entry><img file="EP3925614A2_D0124.tif" /></entry><entry>1099.35</entry><entry>1099.6</entry><entry>96.6</entry></row><row><entry><img file="EP3925614A2_D0125.tif" /></entry><entry>1075.28</entry><entry>1075.2</entry><entry>99.9</entry></row><row><entry><img file="EP3925614A2_D0126.tif" /></entry><entry>1088.32</entry><entry>1088</entry><entry>95.8</entry></row><row><entry><img file="EP3925614A2_D0127.tif" /></entry><entry>1183.4</entry><entry>1182.85</entry><entry>99.9</entry></row><row><entry><img file="EP3925614A2_D0128.tif" /></entry><entry>1145.33</entry><entry>1145</entry><entry>99.99</entry></row><row><entry><img file="EP3925614A2_D0129.tif" /></entry><entry>1145.33</entry><entry>1145</entry><entry>99.99</entry></row><row><entry><img file="EP3925614A2_D0130.tif" /></entry><entry>1138.38</entry><entry>1137.8</entry><entry>99.99</entry></row><row><entry><img file="EP3925614A2_D0131.tif" /></entry><entry>1166.44</entry><entry>1166</entry><entry>99</entry></row><row><entry><img file="EP3925614A2_D0132.tif" /></entry><entry>1207.4</entry><entry>1206.9</entry><entry>99</entry></row><row><entry><img file="EP3925614A2_D0133.tif" /></entry><entry>1199.42</entry><entry>1198.8</entry><entry>100</entry></row><row><entry><img file="EP3925614A2_D0134.tif" /></entry><entry>1117.3</entry><entry>1116.9</entry><entry>95.10</entry></row><row><entry><img file="EP3925614A2_D0135.tif" /></entry><entry>1117.33</entry><entry>1116.8</entry><entry>99.2</entry></row><row><entry><img file="EP3925614A2_D0136.tif" /></entry><entry>1145.38</entry><entry>1144.9</entry><entry>96.4</entry></row><row><entry><img file="EP3925614A2_D0137.tif" /></entry><entry>1159.41</entry><entry>1158.9</entry><entry>99.9</entry></row><row><entry><img file="EP3925614A2_D0138.tif" /></entry><entry>1159.41</entry><entry>1159.1</entry><entry>99</entry></row><row><entry><img file="EP3925614A2_D0139.tif" /></entry><entry>1145.38</entry><entry>1145.1</entry><entry>99</entry></row><row><entry><img file="EP3925614A2_D0140.tif" /></entry><entry>1138.3</entry><entry>1138.0</entry><entry>98.0</entry></row><row><entry><img file="EP3925614A2_D0141.tif" /></entry><entry>1138.3</entry><entry>1138.1</entry><entry>99.0</entry></row></tbody></tgroup></table></tables><tables id="tabl0003" num="0003"><table frame="all"><title>Table 1B</title><tgroup cols="4"><colspec colnum="1" colname="col1" colwidth="58mm" /><colspec colnum="2" colname="col2" colwidth="45mm" /><colspec colnum="3" colname="col3" colwidth="49mm" /><colspec colnum="4" colname="col4" colwidth="14mm" /><thead valign="top"><row><entry>Compound</entry><entry>Calculated Molecular Weight</entry><entry>Experimental Molecular Weight</entry><entry>Purity</entry></row></thead><tbody valign="middle"><row><entry><img file="EP3925614A2_D0142.tif" /></entry><entry>1167.39</entry><entry>1167.40</entry><entry>99.9</entry></row></tbody></tgroup></table></tables>

Example 3: In vitro studies

0119Compounds of the present invention can be and were tested for activity as ligands of one or more of the melanocortin receptors according to the following procedures. One skilled in the art would know that procedures similar to those described herein may be used to assay the binding activities of the compounds of the invention to melanocortin receptor molecules.

Radioligand Binding Assays

0120Cellular membranes used for the in vitro receptor binding assays were obtained from transgenic CHO-K1 cells stably expressing hMC-R receptor subtypes 1, 3, 4 or 5. The CHO-K1 cells expressing the desired hMC-R receptor type were sonicated (Branson® setting 7, approximately 30 sec) in ice-cold 50 mM Tris-HCl at pH 7.4 and then centrifuged at 39,000 g for 10 minutes at approximately 4°C. The pellets were resuspended in the same buffer and centrifuged at 50,000 g for 10 minutes at approximately 4°C. The washed pellets containing the cellular membranes were stored at approximately - 80°C.

0121Competitive inhibition of [12SI](Tyr2)-(Nle4-D-Phe7)α-MSH ([125I]-NDP-α-MSH, Amersham Biosciences®) binding was carried out in polypropylene 96 well plates. Cell membranes (1-10 µg protein/well) prepared as described above were incubated in 50 mM Tris-HCl at pH 7.4 containing 0.2% bovine serum albumin (BSA), 5 mM MgCl2, 1 mM CaCl2 and 0.1 mg/mL bacitracin, with increasing concentrations of the test compound and 0.1-0.3 nM [125I]-NDP-α-MSH for approximately 90-120 minutes at approximately 37°C. Bound [125I]-NDP-α-MSH ligand was separated from free [125I]-NDP-α-MSH by filtration through GF/C glass fiber filter plates (Unifilter®; Packard) presoaked with 0.1 % (w/v) polyethylenimine (PEI), using a Packard Filtermate® harvester. Filters were washed three times with 50 mM Tris-HCl at pH 7.4 at a temperature of approximately 0-4°C and then assayed for radioactivity using a Packard Topcount® scintillation counter. Binding data were analyzed by computer-assisted non-linear regression analysis (XL fit; IDBS).

0122A selection of the preferred embodiments was tested using the above-discussed assay and the binding constants (Ki in nM) are reported in Tables 2A, 2B and 2C.

TABLES 2A, 2B and 2C - Radioligand Binding Assay Data for Selected Compounds

0123<tables id="tabl0004" num="0004"><table frame="all"><title>Table 2A</title><tgroup cols="6"><colspec colnum="1" colname="col1" colwidth="60mm" /><colspec colnum="2" colname="col2" colwidth="19mm" /><colspec colnum="3" colname="col3" colwidth="19mm" /><colspec colnum="4" colname="col4" colwidth="19mm" /><colspec colnum="5" colname="col5" colwidth="19mm" /><colspec colnum="6" colname="col6" colwidth="30mm" /><thead valign="middle"><row><entry>Compound</entry><entry>Ki hMC1-R</entry><entry>Ki hMC3-R</entry><entry>Ki hMC4-R</entry><entry>Ki hMC5-R</entry><entry>Ki hMC1-R/MC4-R</entry></row></thead><tbody valign="middle"><row><entry><img file="EP3925614A2_D0143.tif" /></entry><entry>3.87</entry><entry>10.1</entry><entry>2.09</entry><entry>430</entry><entry>1.9</entry></row><row><entry><img file="EP3925614A2_D0144.tif" /></entry><entry>4.01</entry><entry>12.1</entry><entry>1.76</entry><entry>352</entry><entry>2.3</entry></row><row><entry><img file="EP3925614A2_D0145.tif" /></entry><entry>8.29</entry><entry>13.3</entry><entry>2.78</entry><entry>816</entry><entry>3.0</entry></row><row><entry><img file="EP3925614A2_D0146.tif" /></entry><entry>3.93</entry><entry>172</entry><entry>11.0</entry><entry>538</entry><entry>0.36</entry></row><row><entry><img file="EP3925614A2_D0147.tif" /></entry><entry>1.81</entry><entry>20.5</entry><entry>4.57</entry><entry>502</entry><entry>0.4</entry></row><row><entry><img file="EP3925614A2_D0148.tif" /></entry><entry>9.67</entry><entry>22.0</entry><entry>4.2</entry><entry>1900</entry><entry>2.3</entry></row><row><entry><img file="EP3925614A2_D0149.tif" /></entry><entry>0.79</entry><entry>45.5</entry><entry>1.21</entry><entry>493</entry><entry>0.6</entry></row><row><entry><img file="EP3925614A2_D0150.tif" /></entry><entry>0.68</entry><entry>20.7</entry><entry>1.01</entry><entry>783</entry><entry>0.7</entry></row></tbody></tgroup></table></tables><tables id="tabl0005" num="0005"><table frame="all"><title>Table 2B</title><tgroup cols="6"><colspec colnum="1" colname="col1" colwidth="62mm" /><colspec colnum="2" colname="col2" colwidth="19mm" /><colspec colnum="3" colname="col3" colwidth="19mm" /><colspec colnum="4" colname="col4" colwidth="19mm" /><colspec colnum="5" colname="col5" colwidth="19mm" /><colspec colnum="6" colname="col6" colwidth="29mm" /><thead valign="middle"><row><entry>Compound</entry><entry>Ki hMC1-R</entry><entry>Ki hMC3-R</entry><entry>Ki hMC4-R</entry><entry>Ki hMC5-R</entry><entry>Ki hMC1-R/MC4-R</entry></row></thead><tbody><row><entry><img file="EP3925614A2_D0151.tif" /></entry><entry>114</entry><entry>63.9</entry><entry>3.07</entry><entry>1657</entry><entry>37.1</entry></row><row><entry><img file="EP3925614A2_D0152.tif" /></entry><entry>11</entry><entry>26</entry><entry>7.6</entry><entry>1800</entry><entry>1.4</entry></row><row><entry><img file="EP3925614A2_D0153.tif" /></entry><entry>0.05</entry><entry>9.3</entry><entry>1.1</entry><entry>2.9</entry><entry>0.0</entry></row><row><entry><img file="EP3925614A2_D0154.tif" /></entry><entry>0.07</entry><entry>4.1</entry><entry>0.85</entry><entry>8.8</entry><entry>0.1</entry></row><row><entry><img file="EP3925614A2_D0155.tif" /></entry><entry>0.12</entry><entry>10</entry><entry>0.43</entry><entry>0.42</entry><entry>0.3</entry></row><row><entry><img file="EP3925614A2_D0156.tif" /></entry><entry>0.05</entry><entry>1.3</entry><entry>0.47</entry><entry>0.2</entry><entry>0.1</entry></row><row><entry><img file="EP3925614A2_D0157.tif" /></entry><entry>0.0996</entry><entry>9318</entry><entry>0.617</entry><entry>10.9</entry><entry>0.16</entry></row><row><entry><img file="EP3925614A2_D0158.tif" /></entry><entry>.0132</entry><entry>16.1</entry><entry>1.23</entry><entry>0.359</entry><entry>0.11</entry></row><row><entry><img file="EP3925614A2_D0159.tif" /></entry><entry>0.207</entry><entry>43.2</entry><entry>2.58</entry><entry>344</entry><entry>0.08</entry></row><row><entry><img file="EP3925614A2_D0160.tif" /></entry><entry>0.420</entry><entry>106</entry><entry>4.75</entry><entry>1260</entry><entry>0.09</entry></row><row><entry><img file="EP3925614A2_D0161.tif" /></entry><entry>0.0951</entry><entry>9.33</entry><entry>0.894</entry><entry>13.4</entry><entry>0.11</entry></row><row><entry><img file="EP3925614A2_D0162.tif" /></entry><entry>0.999</entry><entry>300</entry><entry>11.1</entry><entry>431</entry><entry>0.09</entry></row><row><entry><img file="EP3925614A2_D0163.tif" /></entry><entry>0.106</entry><entry>11.8</entry><entry>1.49</entry><entry>110</entry><entry>0.07</entry></row><row><entry><img file="EP3925614A2_D0164.tif" /></entry><entry>0.0506</entry><entry>9.89</entry><entry>1.04</entry><entry>16.3</entry><entry>0.05</entry></row><row><entry><img file="EP3925614A2_D0165.tif" /></entry><entry>0.884</entry><entry>223</entry><entry>22.5</entry><entry>609</entry><entry>0.04</entry></row><row><entry><img file="EP3925614A2_D0166.tif" /></entry><entry>0.721</entry><entry>93.5</entry><entry>56.0</entry><entry>747</entry><entry>0.01</entry></row><row><entry><img file="EP3925614A2_D0167.tif" /></entry><entry>0.227</entry><entry>14.5</entry><entry>2.99</entry><entry>164</entry><entry>0.08</entry></row><row><entry><img file="EP3925614A2_D0168.tif" /></entry><entry>0.277</entry><entry>25.2</entry><entry>3.37</entry><entry>203</entry><entry>0.08</entry></row><row><entry><img file="EP3925614A2_D0169.tif" /></entry><entry>0.323</entry><entry>14.1</entry><entry>1.96</entry><entry>24.0</entry><entry>0.16</entry></row><row><entry><img file="EP3925614A2_D0170.tif" /></entry><entry>34.1</entry><entry>118</entry><entry>17.0</entry><entry>5560</entry><entry>2.01</entry></row><row><entry><img file="EP3925614A2_D0171.tif" /></entry><entry>29.1</entry><entry>22.8</entry><entry>3.84</entry><entry>2550</entry><entry>7.58</entry></row><row><entry><img file="EP3925614A2_D0172.tif" /></entry><entry>0.442</entry><entry>123</entry><entry>10.3</entry><entry>521</entry><entry>0.04</entry></row><row><entry><img file="EP3925614A2_D0173.tif" /></entry><entry>5.80</entry><entry>3370</entry><entry>583</entry><entry>1130</entry><entry>0.01</entry></row><row><entry><img file="EP3925614A2_D0174.tif" /></entry><entry>0.0567</entry><entry>31.4</entry><entry>14.7</entry><entry>9.27</entry><entry>0</entry></row><row><entry><img file="EP3925614A2_D0175.tif" /></entry><entry>1.68</entry><entry>1260</entry><entry>172</entry><entry>1220</entry><entry>0.01</entry></row><row><entry><img file="EP3925614A2_D0176.tif" /></entry><entry>0.128</entry><entry>85.6</entry><entry>36.9</entry><entry>38.0</entry><entry>0</entry></row><row><entry><img file="EP3925614A2_D0177.tif" /></entry><entry>0.352</entry><entry>149</entry><entry>3.01</entry><entry>339</entry><entry>0.12</entry></row><row><entry><img file="EP3925614A2_D0178.tif" /></entry><entry>3.93</entry><entry>876</entry><entry>48.0</entry><entry>4940</entry><entry>0.08</entry></row><row><entry><img file="EP3925614A2_D0179.tif" /></entry><entry>0.995</entry><entry>287</entry><entry>4.80</entry><entry>766</entry><entry>0.21</entry></row><row><entry><img file="EP3925614A2_D0180.tif" /></entry><entry>0.848</entry><entry>184</entry><entry>3.76</entry><entry>956</entry><entry>0.23</entry></row><row><entry><img file="EP3925614A2_D0181.tif" /></entry><entry>1.10</entry><entry>228</entry><entry>7.58</entry><entry>859</entry><entry>0.15</entry></row><row><entry><img file="EP3925614A2_D0182.tif" /></entry><entry>0.659</entry><entry>98.9</entry><entry>2.55</entry><entry>4.19</entry><entry>0.26</entry></row><row><entry><img file="EP3925614A2_D0183.tif" /></entry><entry>4.12</entry><entry>445</entry><entry>50.6</entry><entry>4300</entry><entry>0.08</entry></row><row><entry><img file="EP3925614A2_D0184.tif" /></entry><entry>111</entry><entry>1710</entry><entry>47.7</entry><entry>694</entry><entry>2.33</entry></row><row><entry><img file="EP3925614A2_D0185.tif" /></entry><entry>262</entry><entry>2500</entry><entry>96.4</entry><entry>1460</entry><entry>2.72</entry></row><row><entry><img file="EP3925614A2_D0186.tif" /></entry><entry>199</entry><entry>5990</entry><entry>96.7</entry><entry>> 10000</entry><entry>2.06</entry></row><row><entry><img file="EP3925614A2_D0187.tif" /></entry><entry>132</entry><entry>4560</entry><entry>40.7</entry><entry>8810</entry><entry>3.24</entry></row><row><entry><img file="EP3925614A2_D0188.tif" /></entry><entry>9.12</entry><entry>1130</entry><entry>22.1</entry><entry>2860</entry><entry>0.41</entry></row><row><entry><img file="EP3925614A2_D0189.tif" /></entry><entry>1.00</entry><entry>227</entry><entry>5.55</entry><entry>496</entry><entry>0.18</entry></row><row><entry><img file="EP3925614A2_D0190.tif" /></entry><entry>0.536</entry><entry>169</entry><entry>3.12</entry><entry>358</entry><entry>0.17</entry></row><row><entry><img file="EP3925614A2_D0191.tif" /></entry><entry>32.1</entry><entry>330</entry><entry>17.4</entry><entry>165</entry><entry>1.84</entry></row><row><entry><img file="EP3925614A2_D0192.tif" /></entry><entry>10.6</entry><entry>41.1</entry><entry>7.69</entry><entry>54.9</entry><entry>1.38</entry></row><row><entry><img file="EP3925614A2_D0193.tif" /></entry><entry>13.0</entry><entry>104</entry><entry>10.1</entry><entry>40</entry><entry>1.29</entry></row><row><entry><img file="EP3925614A2_D0194.tif" /></entry><entry>4.28</entry><entry>38.5</entry><entry>9.0</entry><entry>12.5</entry><entry>0.48</entry></row><row><entry><img file="EP3925614A2_D0195.tif" /></entry><entry>1.60</entry><entry>6.82</entry><entry>4.13</entry><entry>5.57</entry><entry>0.39</entry></row><row><entry><img file="EP3925614A2_D0196.tif" /></entry><entry>12.0</entry><entry>85.8</entry><entry>11.2</entry><entry>40</entry><entry>1.07</entry></row><row><entry><img file="EP3925614A2_D0197.tif" /></entry><entry>0.353</entry><entry>2.08</entry><entry>1.41</entry><entry>0.857</entry><entry>0.25</entry></row><row><entry><img file="EP3925614A2_D0198.tif" /></entry><entry>0.537</entry><entry>86.1</entry><entry>5.89</entry><entry>2.56</entry><entry>0.09</entry></row><row><entry><img file="EP3925614A2_D0199.tif" /></entry><entry>0.744</entry><entry>178</entry><entry>3.51</entry><entry>2.69</entry><entry>0.21</entry></row><row><entry><img file="EP3925614A2_D0200.tif" /></entry><entry>0.216</entry><entry>17.4</entry><entry>0.995</entry><entry>0.486</entry><entry>0.22</entry></row><row><entry><img file="EP3925614A2_D0201.tif" /></entry><entry>0.107</entry><entry>9.11</entry><entry>0.884</entry><entry>0.354</entry><entry>0.12</entry></row><row><entry><img file="EP3925614A2_D0202.tif" /></entry><entry>0.148</entry><entry>13.9</entry><entry>1.06</entry><entry>0.423</entry><entry>0.14</entry></row><row><entry><img file="EP3925614A2_D0203.tif" /></entry><entry>0.254</entry><entry>18.5</entry><entry>2.13</entry><entry>0.714</entry><entry>0.12</entry></row><row><entry><img file="EP3925614A2_D0204.tif" /></entry><entry>0.256</entry><entry>29.9</entry><entry>1.98</entry><entry>0.864</entry><entry>0.13</entry></row><row><entry><img file="EP3925614A2_D0205.tif" /></entry><entry>0.560</entry><entry>39.2</entry><entry>2.94</entry><entry>2.73</entry><entry>0.19</entry></row><row><entry><img file="EP3925614A2_D0206.tif" /></entry><entry>0.186</entry><entry>15.2</entry><entry>4.93</entry><entry>0.537</entry><entry>0.04</entry></row><row><entry><img file="EP3925614A2_D0207.tif" /></entry><entry>21.1</entry><entry>151</entry><entry>10.4</entry><entry>92.6</entry><entry>2.03</entry></row><row><entry><img file="EP3925614A2_D0208.tif" /></entry><entry>30.7</entry><entry>152</entry><entry>15.6</entry><entry>114</entry><entry>1.97</entry></row><row><entry><img file="EP3925614A2_D0209.tif" /></entry><entry>5.20</entry><entry>150</entry><entry>138</entry><entry>20.3</entry><entry>0.04</entry></row><row><entry><img file="EP3925614A2_D0210.tif" /></entry><entry>4.89</entry><entry>290</entry><entry>21.3</entry><entry>11.1</entry><entry>0.23</entry></row><row><entry><img file="EP3925614A2_D0211.tif" /></entry><entry>25.5</entry><entry>3.82</entry><entry>7.61</entry><entry>102</entry><entry>3.35</entry></row><row><entry><img file="EP3925614A2_D0212.tif" /></entry><entry>32.5</entry><entry>5.85</entry><entry>2.53</entry><entry>94.6</entry><entry>12.85</entry></row><row><entry><img file="EP3925614A2_D0213.tif" /></entry><entry>22.2</entry><entry>12.7</entry><entry>16.6</entry><entry>125</entry><entry>1.34</entry></row><row><entry><img file="EP3925614A2_D0214.tif" /></entry><entry>1.17</entry><entry>1.56</entry><entry>0.277</entry><entry>3.24</entry><entry>4.22</entry></row><row><entry><img file="EP3925614A2_D0215.tif" /></entry><entry>0.648</entry><entry>2.78</entry><entry>0.329</entry><entry>1.4</entry><entry>1.97</entry></row><row><entry><img file="EP3925614A2_D0216.tif" /></entry><entry>0.393</entry><entry>1.86</entry><entry>0.375</entry><entry>1.11</entry><entry>1.05</entry></row><row><entry><img file="EP3925614A2_D0217.tif" /></entry><entry>0.333</entry><entry>2.91</entry><entry>0.998</entry><entry>0.366</entry><entry>0.33</entry></row><row><entry><img file="EP3925614A2_D0218.tif" /></entry><entry>0.461</entry><entry>2.45</entry><entry>0.931</entry><entry>1.37</entry><entry>0.50</entry></row><row><entry><img file="EP3925614A2_D0219.tif" /></entry><entry>0.576</entry><entry>3.98</entry><entry>2.82</entry><entry>3.91</entry><entry>0.20</entry></row></tbody></tgroup></table></tables><tables id="tabl0006" num="0006"><table frame="all"><title>Table 2C</title><tgroup cols="6"><colspec colnum="1" colname="col1" colwidth="60mm" /><colspec colnum="2" colname="col2" colwidth="20mm" /><colspec colnum="3" colname="col3" colwidth="20mm" /><colspec colnum="4" colname="col4" colwidth="20mm" /><colspec colnum="5" colname="col5" colwidth="20mm" /><colspec colnum="6" colname="col6" colwidth="30mm" /><thead valign="middle"><row><entry>Compound</entry><entry>Ki hMC1-R</entry><entry>Ki hMC3-R</entry><entry>Ki hMC4-R</entry><entry>Ki hMC5-R</entry><entry>Ki hMC1-R/MC4-R</entry></row></thead><tbody><row><entry><img file="EP3925614A2_D0220.tif" /></entry><entry>17.9</entry><entry>1.68</entry><entry>0.256</entry><entry>23.4</entry><entry>69.9</entry></row></tbody></tgroup></table></tables>

cyclic AMP Bioassay

0124Intracellular cyclic AMP (cAMP) levels were determined by an electrochemiluminescence (ECL) assay (Meso Scale Discovery®, Gaithersburg, MD; referred to hereinafter as MSD). CHO-K1 cells stably expressing the hMC receptor subtypes were suspended in RMPI 1640® assay buffer (RMPI 1640 buffer contains 0.5 mM isobutylmethylxanthine (IBMX), and 0.2% protein cocktail (MSD blocker A)). Transgenic CHO-K1 cells stably expressing hMC receptor subtypes 1, 3, 4 or 5 were dispensed at a density of approximately 7,000 cells/well in 384-well Multi-Array® plates (MSD) containing integrated carbon electrodes and coated with anti-cAMP antibody. Increasing concentrations of the test compounds were added and the cells were incubated for approximately 40 minutes at approximately 37°C. Following this incubation, lysis buffer (HEPES-buffered saline solution with MgCl2 and Triton X-100® at ph 7.3) containing 0.2% protein cocktail and 2.5 nM TAG™ ruthenium-labeled cAMP (MSD) was added and the cells were incubated for approximately 90 minutes at room temperature. At the end of the second incubation period read buffer (Tris-buffered solution containing an ECL co-reactant and Triton X-100 at ph 7.8) was added and the cAMP levels in the cell lysates were immediately determined by ECL detection with a Sector Imager 6000 reader® (MSD). Data were analyzed using a computer-assisted non-linear regression analysis (XL fit; IDBS) and reported as either an ECso value or a Kb value.

0125ECso represents the concentration of an agonist compound needed to obtain 50% of the maximum reaction response, e.g., 50% of the maximum level of cAMP as determined using the assay described above. The Kb value reflects the potency of an antagonist and is determined by Schild analysis. In brief, concentration-response curves of an agonist are carried out in the presence of increasing concentrations of an antagonist. The Kb value is the concentration of antagonist which would produce a 2-fold shift in the concentration-response curve for an agonist. It is calculated by extrapolating the line on a Schild plot to zero on the y-axis.

0126A selection of compounds was tested using the above-discussed assays and the results are reported in Tables 3A, 3B, 3C, and 3D. TABLES 3A, 3B, 3C, and 3D - cAMP Bioassay Data for Selected Compounds <tables id="tabl0007" num="0007"><table frame="all"><title>Table 3A</title><tgroup cols="6"><colspec colnum="1" colname="col1" colwidth="52mm" /><colspec colnum="2" colname="col2" colwidth="22mm" /><colspec colnum="3" colname="col3" colwidth="22mm" /><colspec colnum="4" colname="col4" colwidth="22mm" /><colspec colnum="5" colname="col5" colwidth="22mm" /><colspec colnum="6" colname="col6" colwidth="28mm" /><thead valign="middle"><row><entry>Compound</entry><entry>EC50 hMC1-R</entry><entry>EC50 hMC3-R</entry><entry>EC50 hMC4-R</entry><entry>EC50 hMC5-R</entry><entry>EC50 hMC1-R/MC4-R</entry></row></thead><tbody valign="middle"><row><entry><img file="EP3925614A2_D0221.tif" /></entry><entry>5.79</entry><entry>5.25</entry><entry>0.313</entry><entry>1630</entry><entry>18.0</entry></row><row><entry><img file="EP3925614A2_D0222.tif" /></entry><entry>6.17</entry><entry>5.6</entry><entry>0.397</entry><entry>1020</entry><entry>16.0</entry></row><row><entry><img file="EP3925614A2_D0223.tif" /></entry><entry>26.5</entry><entry>10.5</entry><entry>0.493</entry><entry>2440</entry><entry>54.0</entry></row><row><entry><img file="EP3925614A2_D0224.tif" /></entry><entry>8.43</entry><entry>32.4</entry><entry>0.959</entry><entry>2140</entry><entry>9.0</entry></row><row><entry><img file="EP3925614A2_D0225.tif" /></entry><entry>4.23</entry><entry>8.09</entry><entry>0.719</entry><entry>23.2</entry><entry>6.0</entry></row><row><entry><img file="EP3925614A2_D0226.tif" /></entry><entry>48.3</entry><entry>13.3</entry><entry>0.79</entry><entry>10000</entry><entry>61.0</entry></row><row><entry><img file="EP3925614A2_D0227.tif" /></entry><entry>1.48</entry><entry>5.76</entry><entry>0.078</entry><entry>297</entry><entry>19.0</entry></row><row><entry><img file="EP3925614A2_D0228.tif" /></entry><entry>1.39</entry><entry>2.89</entry><entry>0.055</entry><entry>467</entry><entry>25.0</entry></row></tbody></tgroup><tgroup cols="6" rowsep="0"><colspec colnum="1" colname="col1" colwidth="52mm" align="justify" /><colspec colnum="2" colname="col2" colwidth="22mm" /><colspec colnum="3" colname="col3" colwidth="22mm" /><colspec colnum="4" colname="col4" colwidth="22mm" /><colspec colnum="5" colname="col5" colwidth="22mm" /><colspec colnum="6" colname="col6" colwidth="28mm" /><tbody><row><entry namest="col1" nameend="col6">ND = not determined</entry></row></tbody></tgroup></table></tables><tables id="tabl0008" num="0008"><table frame="all"><title>Table 3B</title><tgroup cols="6"><colspec colnum="1" colname="col1" colwidth="52mm" /><colspec colnum="2" colname="col2" colwidth="22mm" /><colspec colnum="3" colname="col3" colwidth="22mm" /><colspec colnum="4" colname="col4" colwidth="22mm" /><colspec colnum="5" colname="col5" colwidth="23mm" /><colspec colnum="6" colname="col6" colwidth="27mm" /><thead valign="top"><row><entry>Compound</entry><entry>EC50 hMC1-R</entry><entry>EC50 hMC3-R</entry><entry>EC50 hMC4-R</entry><entry>EC50 hMC5-R</entry><entry>EC50 hMC1-R/MC4-R</entry></row></thead><tbody valign="middle"><row><entry><img file="EP3925614A2_D0229.tif" /></entry><entry>2.4</entry><entry>0.33</entry><entry>0.078</entry><entry>420</entry><entry>31</entry></row><row><entry><img file="EP3925614A2_D0230.tif" /></entry><entry>0.35</entry><entry>1.1</entry><entry>0.11</entry><entry>0.37</entry><entry>3</entry></row><row><entry><img file="EP3925614A2_D0231.tif" /></entry><entry>0.31</entry><entry>0.27</entry><entry>0.018</entry><entry>3.1</entry><entry>17</entry></row><row><entry><img file="EP3925614A2_D0232.tif" /></entry><entry>0.28</entry><entry>0.24</entry><entry>0.028</entry><entry>3.9</entry><entry>10</entry></row><row><entry><img file="EP3925614A2_D0233.tif" /></entry><entry>0.37</entry><entry>0.1</entry><entry>0.021</entry><entry>1.7</entry><entry>18</entry></row><row><entry><img file="EP3925614A2_D0234.tif" /></entry><entry>0.834</entry><entry>0.145</entry><entry>0.128</entry><entry>2.79</entry><entry>6.52</entry></row><row><entry><img file="EP3925614A2_D0235.tif" /></entry><entry>0.76</entry><entry>0.199</entry><entry>0.0492</entry><entry>1.73</entry><entry>15.45</entry></row><row><entry><img file="EP3925614A2_D0236.tif" /></entry><entry>3.26</entry><entry>0.189</entry><entry>0.0949</entry><entry>30.2</entry><entry>34.35</entry></row><row><entry><img file="EP3925614A2_D0237.tif" /></entry><entry>1.37</entry><entry>0.628</entry><entry>0.131</entry><entry>3.48</entry><entry>10.46</entry></row><row><entry><img file="EP3925614A2_D0238.tif" /></entry><entry>2.27</entry><entry>3.32</entry><entry>7.24</entry><entry>415</entry><entry>0.31</entry></row><row><entry><img file="EP3925614A2_D0239.tif" /></entry><entry>ND</entry><entry>1.89</entry><entry>0.531</entry><entry>ND</entry><entry>ND</entry></row><row><entry><img file="EP3925614A2_D0240.tif" /></entry><entry>14.3</entry><entry>2.03</entry><entry>0.183</entry><entry>2240</entry><entry>78.14</entry></row><row><entry><img file="EP3925614A2_D0241.tif" /></entry><entry>0.345</entry><entry>2.71</entry><entry>5376</entry><entry>2.38</entry><entry>0.06</entry></row><row><entry><img file="EP3925614A2_D0242.tif" /></entry><entry>0.685</entry><entry>81.8</entry><entry>86.9</entry><entry>31.8</entry><entry>0.01</entry></row><row><entry><img file="EP3925614A2_D0243.tif" /></entry><entry>0.931</entry><entry>3.22</entry><entry>1.65</entry><entry>>10000</entry><entry>0.56</entry></row><row><entry><img file="EP3925614A2_D0244.tif" /></entry><entry>3.24</entry><entry>0.465</entry><entry>0.0915</entry><entry>78.5</entry><entry>35.41</entry></row><row><entry><img file="EP3925614A2_D0245.tif" /></entry><entry>0.819</entry><entry>0.541</entry><entry>0.453</entry><entry>45.3</entry><entry>1.81</entry></row></tbody></tgroup><tgroup cols="6" rowsep="0"><colspec colnum="1" colname="col1" colwidth="52mm" align="justify" /><colspec colnum="2" colname="col2" colwidth="22mm" /><colspec colnum="3" colname="col3" colwidth="22mm" /><colspec colnum="4" colname="col4" colwidth="22mm" /><colspec colnum="5" colname="col5" colwidth="23mm" /><colspec colnum="6" colname="col6" colwidth="27mm" /><tbody><row><entry namest="col1" nameend="col6">ND = not determined</entry></row></tbody></tgroup></table></tables><tables id="tabl0009" num="0009"><table frame="all"><title>Table 3C</title><tgroup cols="5"><colspec colnum="1" colname="col1" colwidth="51mm" /><colspec colnum="2" colname="col2" colwidth="26mm" /><colspec colnum="3" colname="col3" colwidth="22mm" /><colspec colnum="4" colname="col4" colwidth="21mm" /><colspec colnum="5" colname="col5" colwidth="26mm" /><thead valign="middle"><row><entry>Compound</entry><entry>EC50 hMC1-R</entry><entry>Kb hMC3-R</entry><entry>Kb MC4-R</entry><entry>EC50 hMC5-R</entry></row></thead><tbody valign="middle"><row><entry><img file="EP3925614A2_D0246.tif" /></entry><entry>17.6</entry><entry>12.4</entry><entry>38.8</entry><entry>11.8</entry></row><row><entry><img file="EP3925614A2_D0247.tif" /></entry><entry>0.619</entry><entry>2.98</entry><entry>0.109</entry><entry>0.189</entry></row><row><entry><img file="EP3925614A2_D0248.tif" /></entry><entry>0.913</entry><entry>0.536</entry><entry>0.346</entry><entry>0.489</entry></row><row><entry><img file="EP3925614A2_D0249.tif" /></entry><entry>0.231</entry><entry>18.4</entry><entry>0.782</entry><entry>0.153</entry></row><row><entry><img file="EP3925614A2_D0250.tif" /></entry><entry>0.581</entry><entry>10.8</entry><entry>0.967</entry><entry>0.126</entry></row><row><entry><img file="EP3925614A2_D0251.tif" /></entry><entry>0.413</entry><entry>9.32</entry><entry>0.824</entry><entry>0.307</entry></row><row><entry><img file="EP3925614A2_D0252.tif" /></entry><entry>1.27</entry><entry>3.02</entry><entry>0.442</entry><entry>0.736</entry></row><row><entry><img file="EP3925614A2_D0253.tif" /></entry><entry>383</entry><entry>61.5</entry><entry>53.6</entry><entry>2842</entry></row></tbody></tgroup></table></tables><tables id="tabl0010" num="0010"><table frame="all"><title>Table 3D</title><tgroup cols="5"><colspec colnum="1" colname="col1" colwidth="51mm" /><colspec colnum="2" colname="col2" colwidth="26mm" /><colspec colnum="3" colname="col3" colwidth="22mm" /><colspec colnum="4" colname="col4" colwidth="21mm" /><colspec colnum="5" colname="col5" colwidth="26mm" /><thead valign="middle"><row><entry>Compound</entry><entry>EC50 hMC1-R</entry><entry>Kb hMC3-R</entry><entry>Kb MC4-R</entry><entry>EC50 hMC5-R</entry></row></thead><tbody><row><entry><img file="EP3925614A2_D0254.tif" /></entry><entry>193</entry><entry>5.72</entry><entry>1.58</entry><entry>1111</entry></row></tbody></tgroup></table></tables>

Example 4: In vivo studies

0127Compounds of the present invention can be and were tested for an effect upon food intake and/or body weight according to the following procedures. One skilled in the art would know that procedures similar to those described herein may be used to assay the effect of the compounds of the invention upon food intake and/or body weight.

0128Ligand compounds activating melanocortin receptors tested in the in vivo studies were as follows (Table 4): <tables id="tabl0011" num="0011"><table frame="all"><title>Table 4</title><tgroup cols="2"><colspec colnum="1" colname="col1" colwidth="25mm" /><colspec colnum="2" colname="col2" colwidth="89mm" /><thead valign="top"><row><entry>Ligand Code</entry><entry>Structure</entry></row></thead><tbody><row><entry>Compound A</entry><entry>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2</entry></row><row><entry>Compound B</entry><entry>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2</entry></row><row><entry>Compound C</entry><entry>Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2</entry></row><row><entry>Compound D</entry><entry>D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-3-Ala-D-Cys)-Thr-NH2</entry></row><row><entry>Compound E</entry><entry>Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2</entry></row><row><entry>Compound F</entry><entry>Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2</entry></row><row><entry>Compound G</entry><entry>Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2</entry></row></tbody></tgroup></table></tables>

Acute feeding experiments (fasting)

0129Male Sprague Dawley rats (250g) were housed in individual cages and maintained under 12:12 hour light:dark conditions. The rats were fasted for 18 hours prior to the start of the experiment with water available ad libitum. At time 0, the rats were injected subcutaneously (sc) with selected compounds at doses of either 500 or 100 nmole/kg, or with vehicle, and were provided with food. Individual food consumption was measured at about 1, 2, 3, 4, 5 and 6 hours after injection. Data for selected compounds of the invention are reported in <figref idref="f0001">Figures 1A</figref> and <figref idref="f0002">1B</figref>.

Acute feeding experiments (non fasting)

0130Male Sprague Dawley rats (250g) are housed in individual cages and maintained under 12:12 hour light:dark conditions. Food and water is available ad libitum throughout the experiment. At time 0, the rats are injected sc with compound at doses of either 500 or 100 nmole/kg, or with vehicle. Individual food consumption is measured at about 1, 2, 3, 4, 5 and 6 hours after injection.

Chronic feeding experiments

0131Male Sprague Dawley rats (250g) were housed in individual cages and maintained under 12:12 hour light:dark conditions with both food and water available ad libitum. The rats were injected sc 3x/day (approximately 0800 hour, 1200 hour, and 1600 hour) with compound at various doses or with vehicle for 7 days. Individual body weight and food consumption were measured daily. Data for selected compounds of the invention are reported in <figref idref="f0003">Figures 2A</figref> and <figref idref="f0004">2B</figref>, <figref idref="f0005">Figures 3A</figref> and <figref idref="f0006">3B</figref>, and <figref idref="f0007">Figures 4A</figref> and <figref idref="f0008">4B</figref>.

Administration and Use

0132The peptides of this invention can be provided in the form of pharmaceutically acceptable salts. Examples of such salts include, but are not limited to, those formed with organic acids (e.g., acetic, lactic, maleic, citric, malic, ascorbic, succinic, benzoic, methanesulfonic, toluenesulfonic, or pamoic acid), inorganic acids (e.g., hydrochloric acid, sulfuric acid, or phosphoric acid), and polymeric acids (e.g., tannic acid, carboxymethyl cellulose, polylactic, polyglycolic, or copolymers of polylactic-glycolic acids). A typical method of making a salt of a peptide of the present invention is well known in the art and can be accomplished by standard methods of salt exchange. Accordingly, the TFA salt of a peptide of the present invention (the TFA salt results from the purification of the peptide by using preparative HPLC, eluting with TFA containing buffer solutions) can be converted into another salt, such as an acetate salt, by dissolving the peptide in a small amount of 0.25 N acetic acid aqueous solution. The resulting solution is applied to a semi-prep HPLC column (Zorbax®, 300 SB, C-8). The column is eluted with: (1) 0.1N ammonium acetate aqueous solution for 0.5 hours; (2) 0.25N acetic acid aqueous solution for 0.5 hours; and (3) a linear gradient (20% to 100% of solution B over 30 minutes) at a flow rate of 4 ml/min (solution A is 0.25N acetic acid aqueous solution; solution B is 0.25N acetic acid in acetonitrile/water, 80:20). The fractions containing he peptide are collected and lyophilized to dryness.

0133As is well known to those skilled in the art, the known and potential uses of peptides with melanocortin receptor (MC-R) agonist or antagonist activity is varied md multitudinous, thus the administration of the compounds of this invention for purposes of eliciting an agonist effect can have the same effects and uses as melanocortin itself.

0134Accordingly, the present invention includes within its scope pharmaceutical compositions comprising, as an active ingredient, at least one of the compounds of formula (I) in association with a pharmaceutically acceptable carrier.

0135The dosage of active ingredient in the compositions of this invention may be varied; however, it is necessary that the amount of the active ingredient be such that a suitable dosage form is obtained. The selected dosage depends upon the desired therapeutic effect, on the route of administration, and on the duration of the treatment. In general, an effective dosage for the activities of this invention is in the range of 1x10-7 to 200 mg/kg/day, preferably 1x10-4 to 100 mg/kg/day which can be administered as a single dose or divided into multiple doses.

0136The compounds of this invention can be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous or subcutaneous injection, or implant), nasal, vaginal, rectal, sublingual or topical routes of administration and can be formulated with pharmaceutically acceptable carriers to provide dosage forms appropriate for each route of administration.

0137Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound is admixed with at least one inert pharmaceutically acceptable carrier such as sucrose, lactose, or starch. Such dosage forms can also comprise, as is normal practice, additional substances other than such inert diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.

0138Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, the elixirs containing inert diluents commonly used in the art, such as water. Besides such inert diluents, compositions can also include adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring and perfuming agents.

0139Preparations according to this invention for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, or emulsions. Examples of non-aqueous solvents or vehicles are propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and corn oil, gelatin, and injectable organic esters such as ethyl oleate. Such dosage forms may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents. Preparations may be sterilized by, for example, filtration through a bacteria-retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions. Preparations can also be manufactured in the form of sterile solid compositions which can be dissolved in sterile water or some other sterile injectable medium immediately before use.

0140Compositions for rectal or vaginal administration are preferably suppositories which may contain, in addition to the active substance, excipients such as cocoa butter or a suppository wax.

0141Compositions for nasal or sublingual administration are also prepared with standard excipients well known in the art.

0142Further, a compound of this invention can be administered in a sustained release composition such as those described in the following patents and patent applications. <patcit id="pcit0063" dnum="US5672659A"><text>U.S. Patent No. 5,672,659</text></patcit> teaches sustained release compositions comprising a bioactive agent and a polyester. <patcit id="pcit0064" dnum="US5595760A"><text>U.S. Patent No. 5,595,760</text></patcit> teaches sustained release compositions comprising a bioactive agent in a gelable form. <patcit id="pcit0065" dnum="US5821221A"><text>U.S. Patent No. 5,821,221</text></patcit> teaches polymeric sustained release compositions comprising a bioactive agent and chitosan. <patcit id="pcit0066" dnum="US5916883A"><text>U.S. Patent No. 5,916,883</text></patcit> teaches sustained release compositions comprising a bioactive agent and cyclodextrin. The teachings of the foregoing patents and applications are incorporated herein by reference.

0143The following numbered paragraphs are not claims but merely serve to further define particular aspects of the invention. <ol id="ol0003"><li>1. A compound according to formula (I): (R2R3)-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1 wherein: <ul id="ul0016" list-style="none" compact="compact"><li>A1 is Acc, HN-(CH2)m-C(O), L- or D-amino acid or deleted;</li><li>A2 is Cys, D-Cys, hCys, D-hCys, Pen, D-Pen, Asp or Glu;</li><li>A3 is Gly, Ala, β-Ala, Gaba, Aib, D-amino acid or deleted;</li><li>A4 is His, 2-Pal, 3-Pal, 4-Pal, Taz, 2-Thi, 3-Thi or (X1,X2,X3,X4,X5)Phe;</li><li>A5 is D-Phe, D-1-Nal, D-2-Nal, D-Trp, D-Bal, D-(X1,X2,X3,X4,X5)Phe, L-Phe or D-(Et)Tyr;</li><li>A6 is Arg, hArg, Dab, Dap, Lys, Orn or HN-CH((CH2)n-N(R4R5))-C(O);</li><li>A7 is Trp, 1-Nal, 2-Nal, Bal, Bip, D-Trp, D-1-Nal, D-2-Nal, D-Bal or D-Bip;</li><li>A8 is Gly, D-Ala, Acc, Ala, β-Ala, Gaba, Apn, Ahx, Aha, HN-(CH2)s-C(O) or deleted;</li><li>A9 is Cys, D-Cys, hCys, D-hCys, Pen, D-Pen, Dab, Dap, Orn or Lys;</li><li>A10 is Acc, HN-(CH2)t-C(O), L- or D-amino acid or deleted;</li><li>R1 is -OH or -NH2;</li><li>R2 and R3 is, independently for each occurrence, H, (C1-C30)alkyl, (C1-C30)heteroalkyl, (C1-C30)acyl, (C2-C30)alkenyl, (C2-C30)alkynyl, aryl(C1-C30)alkyl, aryl(C1-C30)acyl, substituted (C1-C30)alkyl, substituted (C1-C30)heteroalkyl, substituted (C1-C30)acyl, substituted (C2-C30)alkenyl, substituted (C2-C30)alkynyl, substituted aryl(C1-C30)alkyl or substituted aryl(C1-C30)acyl;</li><li>R4 and R5 is, independently for each occurrence, H, (C1-C40)alkyl, (C1-C40)heteroalkyl, (C1-C40)acyl, (C2-C40)alkenyl, (C2-C40)alkynyl, aryl(C1-C40)alkyl, aryl(C1-C40)acyl, substituted (C1-C40)alkyl, substituted (C1-C40)heteroalkyl, substituted (C1-C40)acyl, substituted (C2-C40)alkenyl, substituted (C2-C40)alkynyl, substituted aryl(C1-C40)alkyl, substituted aryl(C1-C40)acyl, (C1-C40)alkylsulfonyl or -C(NH)-NH2;</li><li>m is, independently for each occurrence, 1, 2, 3, 4, 5, 6 or 7;</li><li>n is, independently for each occurrence, 1, 2, 3, 4 or 5;</li><li>s is, independently for each occurrence, 1, 2, 3, 4, 5, 6 or 7;</li><li>t is, independently for each occurrence, 1, 2, 3, 4, 5, 6 or 7; and</li><li>X1, X2, X3, X4, and X5 each is, independently for each occurrence, H, F, Cl, Br, I, (C1-10)alkyl, substituted (C1-10)alkyl, (C2-10)alkenyl, substituted (C2-10)alkenyl, (C2-10)alkynyl, substituted (C2-110)alkynyl, aryl, substituted aryl, OH, NH2, NO2, or CN;</li><li>provided that <ol id="ol0004" compact="compact"><li>(I). when R4 is (C1-C40)acyl, aryl(C1-C40)acyl, substituted (C1-C40)acyl, substituted aryl(C1-C40)acyl, (C1-C40)alkylsulfonyl or -C(NH)-NH2, then R5 is H, (C1-C40)alkyl, (C1-C40)heteroalkyl, (C2-C40)alkenyl, (C2-C40)alkynyl, aryl(C1-C40)alkyl, substituted (C1-C40)alkyl, substituted (C1-C40)heteroalkyl, substituted (C2-C40)alkenyl, substituted (C2-C40)alkynyl or substituted aryl(C1-C40)alkyl;</li><li>(II). when R2 is (C1-C30)acyl, aryl(C1-C30)acyl, substituted (C1-C30)acyl or substituted aryl(C1-C30)acyl, then R3 is H, (C1-C30)alkyl, (C1-C30)heteroalkyl, (C2-C30)alkenyl, (C2-C30)alkynyl, aryl(C1-C30)alkyl, substituted (C1-C30)alkyl, substituted (C1-C30)heteroalkyl, substituted (C2-C30)alkenyl, substituted (C2-C30)alkynyl or substituted aryl(C1-C30)alkyl;</li><li>(III). either A3 or A8 or both must be present in said compound;</li><li>(IV). when A2 is Cys, D-Cys, hCys, D-hCys, Pen or D-Pen, then A9 is Cys, D-Cys, hCys, D-hCys, Pen or D-Pen;</li><li>(V). when A2 is Asp or Glu, then A9 is Dab, Dap, Orn or Lys;</li><li>(VI). when A8 is Ala or Gly, then A1 is not Nle; and</li><li>(VII). when A1 is deleted, then R2 and R3 cannot both be H;</li></ol></li></ul> or a pharmaceutically acceptable salt thereof.</li><li>2. A compound according to paragraph 1, wherein: <ul id="ul0017" list-style="none" compact="compact"><li>A1 is A6c, Gaba, Nle, Met, Phe, D-Phe, D-2-Nal, hPhe, Chg, D-Chg, Cha, hCha, hPro, hLeu, Nip, β-hMet or Oic;</li><li>A2 is Cys, D-Cys, hCys, D-hCys, Pen, D-Pen, Asp or Glu;</li><li>A3 is Gly, Ala, D-Ala, D-Glu, β-Ala, Gaba, Aib or deleted;</li><li>A4 is His;</li><li>A5 is D-Phe, D-1-Nal, D-2-Nal, D-Trp, D-Bal or D-(Et)Tyr;</li><li>A6 is Arg or hArg;</li><li>A7 is Trp, Bip, D-Trp, 1-Nal or 2-Nal;</li><li>A8 is A6c, Ala, β-Ala, Gaba, Apn or Ahx;</li><li>A9 is Cys, D-Cys, hCys, D-hCys, Pen, D-Pen or Lys; and</li><li>A10 is Thr or deleted;</li></ul> or a pharmaceutically acceptable salt thereof.</li><li>3. A compound according to paragraph 2, wherein: R2 and R3 is, independently for each occurrence, H, acyl, n-propanoyl or n-butanoyl; or a pharmaceutically acceptable salt thereof.</li><li>4. A compound according paragraph 1, wherein: <ul id="ul0018" list-style="none" compact="compact"><li>A1 is Acc, Arg, D-Arg, Cha, D-Cha, hCha, Chg, D-Chg, Gaba, Ile, Leu, hLeu, β-hMet, 2-Nal, D-2-Nal, Nip, Nle, Oic, Phe, D-Phe, hPhe, hPro, Val or deleted;</li><li>A2 is Cys, D-Cys, Pen or Asp;</li><li>A3 is Gly, Ala, β-Ala, Gaba, Aib, D-Ala, D-Abu, D-Cha, D-Ile, D-Leu, D-Tle, D-Val or deleted;</li><li>A4 is His or 3-Pal;</li><li>A5 is D-Phe, D-2-Nal or D-(Et)Tyr;</li><li>A6 is Arg or hArg;</li><li>A7 is Trp, 1-Nal, 2-Nal, Bal, Bip or D-Trp;</li><li>A8 is Gly, D-Ala, Acc, Ala, β-Ala, Gaba, Apn, Ahx, Aha or deleted;</li><li>A9 is Cys, D-Cys, Pen or Lys; and</li><li>A10 is Thr or deleted;</li><li>provided that either A3 or A8 is deleted, but not both;</li></ul> or a pharmaceutically acceptable salt thereof.</li><li>5. A compound according to paragraph 4, wherein said compound is: <ul id="ul0019" list-style="none" compact="compact"><li>Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-β-Ala-Lys)-NH2; SEQ ID NO:1</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-A6c-Lys)-NH2; SEQ ID NO:1</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-NH2; SEQ ID NO:2</li><li>D-Phe-c(Cys-His-D-Phe-Arg-Trp-Ala-D-Cys)-Thr-NH2; SEQ ID NO:3</li><li>D-Phe-c(Cys-His-D-Phe-Arg-Trp-β-Ala-D-Cys)-Thr-NH2; SEQ ID NO:3</li><li>D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-Thr-NH2; SEQ ID NO:3</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH2; SEQ ID NO:2</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Apn-Lys)-NH2; SEQ ID NO:4</li><li>Ac-A6c-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:5</li><li>Ac-D-2-Nal-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:6</li><li>Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:6</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:6</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:7</li><li>Ac-Nle-c(Cys-β-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:7</li><li>Ac-Nle-c(Cys-Gaba-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:7</li><li>Ac-Nle-c(Cys-Aib-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:7</li><li>Ac-Nle-c(Cys-Gly-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:7</li><li>Ac-Nle-c(D-Cys-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:8</li><li>Ac-Nle-c(D-Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:8</li><li>Ac-Nle-c(D-Cys-β-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:8</li><li>Ac-Nle-c(D-Cys-Gaba-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:8</li><li>Ac-Nle-c(D-Cys-Aib-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:8</li><li>Ac-Nle-c(D-Cys-Gly-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:8</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2; SEQ ID NO:9</li><li>Ac-Nle-c(Cys-β-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2; SEQ ID NO:9</li><li>Ac-Nle-c(Cys-Gaba-His-D-Phe-Arg-Trp-D-Cys)-NH2; SEQ ID NO:9</li><li>Ac-Nle-c(Cys-Aib-His-D-Phe-Arg-Trp-D-Cys)-NH2;SEQ ID NO:9</li><li>Ac-Nle-c(Cys-Gly-His-D-Phe-Arg-Trp-D-Cys)-NH2;SEQ ID NO:9</li><li>Ac-Nle-c(D-Cys-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2; SEQ ID NO:10</li><li>Ac-Nle-c(D-Cys-D-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2; SEQ ID NO:10</li><li>Ac-Nle-c(D-Cys-β-Ala-His-D-Phe-Arg-Trp-D-Cys)-NH2; SEQ ID NO:10</li><li>Ac-Nle-c(D-Cys-Gaba-His-D-Phe-Arg-Trp-D-Cys)-NH2; SEQ ID NO:10</li><li>Ac-Nle-c(D-Cys-Aib-His-D-Phe-Arg-Trp-D-Cys)-NH2; SEQ ID NO:10</li><li>Ac-Oic-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:11</li><li>Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2;SEQ ID NO:11</li><li>Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:11</li><li>Ac-D-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:11</li><li>Ac-Nip-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:11</li><li>Ac-hPro-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:11</li><li>Ac-hLeu-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:11</li><li>Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:11</li><li>Ac-Phe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:11</li><li>Ac-D-Phe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:11</li><li>Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:11</li><li>n-butanoyl-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:12</li><li>Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:11</li><li>Ac-β-hMet-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:11</li><li>Ac-Gaba-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:11</li><li>Ac-Cha-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2; SEQ ID NO:13</li><li>Ac-hCha-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2; SEQ ID NO:13</li><li>Ac-Leu-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2; SEQ ID NO:13</li><li>Ac-hLeu-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2; SEQ ID NO:13</li><li>Ac-Phe-c(Asp-His-D-Phe-Arg-D-Trp-Ala-Lys)-NH2; SEQ ID NO:13</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-D-Ala-Lys)-NH2; SEQ ID NO:14</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-β-Ala-Lys)-NH2; SEQ ID NO:14</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Gaba-Lys)-NH2; SEQ ID NO:14</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Aha-Lys)-NH2; SEQ ID NO:14</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-D-Trp-Apn-Lys)-NH2; SEQ ID NO:14</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Apn-Cys)-NH2; SEQ ID NO:15</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Gaba-Cys)-NH2; SEQ ID NO:15</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-NH2; SEQ ID NO:15</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-β-Ala-Cys)-NH2; SEQ ID NO:15</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-D-Ala-Cys)-NH2; SEQ ID NO:15</li><li>Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2; SEQ ID NO:16</li><li>Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-2-Nal-Cys)-NH2; SEQ ID NO:16</li><li>Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-1-Nal-Cys)-NH2; SEQ ID NO:16</li><li>n-butanoyl-Nle-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Cys)-NH2; SEQ ID NO:17</li><li>n-butanoyl-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:17</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Cys)-NH2; SEQ ID NO:18</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-1-Nal-Cys)-NH2; SEQ ID NO:18</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Bal-Cys)-NH2; SEQ ID NO:18</li><li>Ac-Nle-c(Cys-D-Glu-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:61</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-D-Ala-Lys)-NH2;SEQ ID NO:19</li><li>Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Bal-Cys)-NH2; SEQ ID NO:20</li><li>Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:21</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;SEQ ID NO:22</li><li>Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2; SEQ ID NO:22</li><li>D-Phe-c(Cys-His-D-Phe-hArg-Trp-β-Ala-D-Cys)-Thr-NH2; SEQ ID NO:23</li><li>D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Thr-NH2; SEQ ID NO:24</li><li>D-Phe-c(Cys-His-D-Phe-Arg-Bip-β-Ala-D-Cys)-Thr-NH2; SEQ ID NO:25</li><li>D-Phe-c(Cys-His-D(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-NH2; SEQ ID NO:24</li><li>D-Phe-c(Cys-His-D-Phe-hArg-Bip-β-Ala-D-Cys)-Thr-NH2; SEQ ID NO:26</li><li>D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-NH2; SEQ ID NO:26</li><li>Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH2; SEQ ID NO:27</li><li>Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Trp-Lys)-NH2;SEQ ID NO:28</li><li>Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Bal-Lys)-NH2; SEQ ID NO:28</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-OH; SEQ ID NO:29</li><li>Ac-Nle-c(Cys-D-Abu-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:30</li><li>Ac-Nle-c(Cys-D-Val-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:30</li><li>Ac-Nle-c(Cys-D-Ile-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:30</li><li>Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:30</li><li>Ac-Nle-c(Cys-D-Tle-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:30</li><li>Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:30</li><li>Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:31</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2; SEQ ID NO:32</li><li>Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2; SEQ ID NO:32</li><li>Ac-Leu-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:33</li><li>Ac-Cha-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:33</li><li>Ac-Ile-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:33</li><li>Ac-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:33</li><li>Ac-Val-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:33</li><li>Ac-2-Nal-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:33</li><li>Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:34</li><li>Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:34</li><li>Ac-Nle-c(Cys-3-Pal-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:35</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH; SEQ ID NO:36</li><li>Ac-Nle-c(Cys-His-Phe-Arg-D-Trp-Gaba-Cys)-NH2; SEQ ID NO:37</li><li>Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Ala-Lys)-NH2; SEQ ID NO:38</li><li>Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-β-Ala-Lys)-NH2; SEQ ID NO:38</li><li>Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:39</li><li>Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Ahx-Cys)-NH2;SEQ ID NO:39</li><li>Ac-hPhe-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:40</li><li>Ac-Cha-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:40</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-β-Ala-Lys)-OH; SEQ ID NO:41</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-OH; SEQ ID NO:42</li><li>D-Phe-c(Cys-His-D-Phe-Arg-Trp-Ala-D-Cys)-Thr-OH; SEQ ID NO:43</li><li>D-Phe-c(Cys-His-D-Phe-Arg-Trp-β-Ala-D-Cys)-Thr-OH; SEQ ID NO:43</li><li>D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-Thr-OH; SEQ ID NO:43</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-OH; SEQ ID NO:42</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Apn-Lys)-OH; SEQ ID NO:41</li><li>Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH; SEQ ID NO:44</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH; SEQ ID NO:44</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH; SEQ ID NO:29</li><li>Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH; SEQ ID NO:44</li><li>Ac-D-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH; SEQ ID NO:44</li><li>Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH; SEQ ID NO:44</li><li>Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH; SEQ ID NO:44</li><li>Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-OH;SEQ ID NO:44</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Gaba-Cys)-OH; SEQ ID NO:45</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-Ahx-Cys)-OH; SEQ ID NO:45</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-β-Ala-Cys)-OH; SEQ ID NO:45</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-D-Ala-Cys)-OH; SEQ ID NO:45</li><li>Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-OH; SEQ ID NO:46</li><li>Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-2-Nal-Cys)-OH; SEQ ID NO:46</li><li>Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-1-Nal-Cys)-OH; SEQ ID NO:46</li><li>Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Bal-Cys)-OH; SEQ ID NO:46</li><li>Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH; SEQ ID NO:47</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-OH; SEQ ID NO:29</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-OH; SEQ ID NO:48 or</li><li>Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2; SEQ ID NO:49</li><li>or a pharmaceutically acceptable salt thereof.</li></ul></li><li>6. A compound according to paragraph 5, wherein said compound is: <ul id="ul0020" list-style="none" compact="compact"><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2;SEQ ID NO:7</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2;SEQ ID NO:22</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2; SEQ ID NO:32</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH; SEQ ID NO:29</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-OH; SEQ ID NO:29 or</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-OH; SEQ ID NO:48</li><li>or a pharmaceutically acceptable salt thereof.</li></ul></li><li>7. A compound according paragraph 1, wherein: <ul id="ul0021" list-style="none" compact="compact"><li>A1 is Arg, D-Arg, Cha, hCha, Chg, D-Chg, Ile, Leu, 2-Nal, Nle, Phe, D-Phe, hPhe, Val or deleted;</li><li>A2 is Cys, Pen or Asp;</li><li>A3 is D-Ala, D-Abu, D-Cha, D-Ile, D-Leu, D-Tle, D-Val or deleted;</li><li>A4 is His or 3-Pal;</li><li>A5 is D-Phe, D-2-Nal or D-(Et)Tyr;</li><li>A6 is Arg or hArg;</li><li>A7 is Trp, 2-Nal, Bal, Bip or D-Trp;</li><li>A8 is Gly, Ala, β-Ala, Gaba, Apn, Ahx or deleted;</li><li>A9 is Cys, D-Cys, Pen or Lys;</li><li>A10 is Thr or deleted; and</li><li>R2 and R3 is, independently for each occurrence, H or acyl;</li></ul> or a pharmaceutically acceptable salt thereof.</li><li>8. A compound according to paragraph 7, wherein said compound is: <ul id="ul0022" list-style="none" compact="compact"><li>Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:50</li><li>Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:50</li><li>Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2; SEQ ID NO:51</li><li>Ac-D-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2; SEQ ID NO:52</li><li>Ac-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2; SEQ ID NO:52</li><li>Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2; SEQ ID NO:51</li><li>Ac-D-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH2; SEQ ID NO:53</li><li>Ac-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH2; SEQ ID NO:53</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:7</li><li>D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Thr-NH2; SEQ ID NO:24</li><li>Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH2; SEQ ID NO:27</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2; SEQ ID NO:32</li><li>Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:34</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-β-Ala-Lys)-NH2; SEQ ID NO:1</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Ahx-Cys)-NH2; SEQ ID NO:2</li><li>D-Phe-c(Cys-His-D-Phe-Arg-Trp-β-Ala-D-Cys)-Thr-NH2; SEQ ID NO:3</li><li>D-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-D-Cys)-Thr-NH2; SEQ ID NO:3</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Apn-Cys)-NH2; SEQ ID NO:2</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Apn-Lys)-NH2; SEQ ID NO:4</li><li>Ac-Cha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:6</li><li>Ac-Nle-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:6</li><li>Ac-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:11</li><li>Ac-hCha-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:11</li><li>Ac-D-Chg-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:11</li><li>Ac-hPhe-c(Asp-His-D-Phe-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:11</li><li>Ac-Nle-c(Cys-His-D-Phe-Arg-D-Trp-β-Ala-Cys)-NH2; SEQ ID NO:15</li><li>Ac-Nle-c(Pen-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:21</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2; SEQ ID NO:22</li><li>D-Phe-c(Cys-His-D-Phe-hArg-Trp-β-Ala-D-Cys)-Thr-NH2; SEQ ID NO:23</li><li>D-Phe-c(Cys-His-D-Phe-Arg-Bip-β-Ala-D-Cys)-Thr-NH2; SEQ ID NO:25</li><li>D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Trp-β-Ala-D-Cys)-Thr-NH2; SEQ ID NO:24</li><li>D-Phe-c(Cys-His-D-Phe-hArg-Bip-β-Ala-D-Cys)-Thr-NH2; SEQ ID NO:26</li><li>D-Phe-c(Cys-His-D-(Et)Tyr-hArg-Bip-β-Ala-D-Cys)-Thr-NH2; SEQ ID NO:26</li><li>Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Trp-Lys)-NH2; SEQ ID NO:28</li><li>Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Bal-Lys)-NH2; SEQ ID NO:28</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-OH; SEQ ID NO:29</li><li>Ac-Nle-c(Cys-D-Abu-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:30</li><li>Ac-Nle-c(Cys-D-Val-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:30</li><li>Ac-Nle-c(Cys-D-Ile-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:30</li><li>Ac-Nle-c(Cys-D-Leu-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:30</li><li>Ac-Nle-c(Cys-D-Tle-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:30</li><li>Ac-Nle-c(Cys-D-Cha-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:30</li><li>Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:31</li><li>Ac-Nle-c(Pen-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2; SEQ ID NO:32</li><li>Ac-Leu-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:33</li><li>Ac-Cha-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:33</li><li>Ac-Ile-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:33</li><li>Ac-Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:33</li><li>Ac-Val-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:33</li><li>Ac-2-Nal-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:33</li><li>Phe-c(Cys-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:34</li><li>Ac-Nle-c(Cys-3-Pal-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:35</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-OH; SEQ ID NO:36</li><li>Ac-Nle-c(Cys-His-Phe-Arg-D-Trp-Gaba-Cys)-NH2; SEQ ID NO:37</li><li>Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2; SEQ ID NO:16</li><li>Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-2-Nal-Cys)-NH2; SEQ ID NO:16</li><li>Ac-Nle-c(Cys-D-Ala-His-D-2-Nal-Arg-Bal-Cys)-NH2; SEQ ID NO:20</li><li>Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-Ala-Lys)-NH2; SEQ ID NO:38</li><li>Ac-Nle-c(Asp-His-D-2-Nal-Arg-Trp-β-Ala-Lys)-NH2; SEQ ID NO:38</li><li>Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:39</li><li>Ac-Nle-c(Cys-His-D-2-Nal-Arg-Trp-Ahx-Cys)-NH2; SEQ ID NO:39</li><li>Ac-hPhe-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:40</li><li>Ac-Cha-c(Asp-His-D-2-Nal-Arg-Trp-Gaba-Lys)-NH2; SEQ ID NO:40 or</li><li>Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2; SEQ ID NO:49</li><li>or a pharmaceutically acceptable salt thereof.</li></ul></li><li>9. A compound according to paragraph 1, wherein: A1 is Arg, D-Arg, hArg or D-hArg; or a pharmaceutically acceptable salt thereof.</li><li>10. A compound according to paragraph 9, wherein A2 is Cys, D-Cys, hCys, D-hCys, Pen, D-Pen, Asp or Glu; A3 is Gly, Ala, D-Ala, D-Glu, β-Ala, Gaba, Aib or deleted; A4 is His; A5 is D-Phe, D-1-Nal, D-2-Nal, D-Trp, D-Bal or D-(Et)Tyr; A6 is Arg or hArg; A7 is Trp, Bip, D-Trp, 1-Nal or 2-Nal; A8 is A6c, Ala, β-Ala, Gaba, Apn or Ahx; A9 is Cys, D-Cys, hCys, D-hCys, Pen, D-Pen or Lys; A10 is Thr or deleted; or a pharmaceutically acceptable salt thereof.</li><li>11. A compound according to paragraph 10, wherein: R2 and R3 is, independently for each occurrence, H, acyl, n-propanoyl or n-butanoyl; or a pharmaceutically acceptable salt thereof.</li><li>12. A compound according to paragraph 11, wherein A2 is Cys or Asp; A3 is D-Ala or deleted; A4 is His; A5 is D-Phe or D-2-Nal; A6 is Arg; A7 is Trp; A8 is Ala, Gaba or deleted; A9 is Cys, Pen or Lys; A10 is deleted; or a pharmaceutically acceptable salt thereof.</li><li>13. A compound according to paragraph 12, wherein: R2 and R3 is, independently for each occurrence, H or acyl; or a pharmaceutically acceptable salt thereof.</li><li>14. A compound according to paragraph 13, wherein said compound is: <ul id="ul0023" list-style="none" compact="compact"><li>Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:50</li><li>Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:50</li><li>Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2; SEQ ID NO:51</li><li>Ac-D-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2; SEQ ID NO:52</li><li>Ac-Arg-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2; SEQ ID NO:52</li><li>Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2; SEQ ID NO:51</li><li>Ac-D-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH2; SEQ ID NO:53</li><li>Ac-Arg-c(Asp-His-D-Phe-Arg-Trp-Ala-Lys)-NH2; SEQ ID NO:53 or</li><li>Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2; SEQ ID NO:49</li></ul> or pharmaceutically acceptable salts thereof.</li><li>15. A compound according to paragraph 14, wherein said compound is: <ul id="ul0024" list-style="none" compact="compact"><li>Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:50</li><li>Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2; SEQ ID NO:51 or</li><li>Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2; SEQ ID NO:49</li></ul> or a pharmaceutically acceptable salt thereof.</li><li>16. A compound according to paragraph 15, wherein said compound is: Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2; SEQ ID NO:50 or a pharmaceutically acceptable salt thereof.</li><li>17. A compound according to paragraph 15, wherein said compound is: Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2; SEQ ID NO:51 or a pharmaceutically acceptable salt thereof.</li><li>18. A compound according to paragraph 15, wherein said compound is: Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2; SEQ ID NO:49 or a pharmaceutically acceptable salt thereof.</li><li>19. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of paragraphs 1 to 18, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.</li><li>20. A pharmaceutical composition according to paragraph 19, wherein said compound is a selective melanocortin-4 receptor agonist or a pharmaceutically acceptable salt thereof.</li><li>21. A pharmaceutical composition according to paragraph 20, wherein said compound is a selective melanocortin-4 receptor agonist or a pharmaceutically acceptable salt thereof with a functional activity characterized by an EC50 at least 15-fold more selective for the human melanocortin 4 receptor than for the human melanocortin-1 receptor, the human melanocortin-3 receptor and the human melanocortin-5 receptor.</li><li>22. A pharmaceutical composition according to paragraph 21, wherein the functional activity of the melanocortin-4 receptor agonist is characterized by an EC50 at least 17-fold more selective for the human melanocortin-4 receptor than for the human melanocortin-3 receptor.</li><li>23. A pharmaceutical composition according to paragraph 21, wherein the functional activity of the melanocortin-4 receptor agonist is characterized by an EC50 at least 90-fold more selective for the human melanocortin-4 receptor than for the human melanocortin-3 receptor.</li><li>24. A pharmaceutical composition according to paragraph 21, wherein the functional activity of the melanocortin-4 receptor agonist is characterized by an EC50 at least 200-fold more selective for the human melanocortin-4 receptor than for the human melanocortin-5 receptor.</li><li>25. A pharmaceutical composition according to paragraph 21, wherein the functional activity of the melanocortin-4 receptor agonist is characterized by an EC50 at least 3000-fold more selective for the human melanocortin-4 receptor than for the human melanocortin-5 receptor.</li><li>26. A pharmaceutical composition according to paragraph 19 useful for treating an acute or chronic inflammatory disease or medical condition wherein said disease or condition is selected from the group consisting of general inflammation, inflammatory bowel disease, brain inflammation, sepsis and septic shock.</li><li>27. A pharmaceutical composition according to paragraph 19 useful for treating a disease or medical condition with an autoimmune component wherein said disease or condition is selected from the group consisting of rheumatoid arthritis, gouty arthritis and multiple sclerosis.</li><li>28. A pharmaceutical composition according to paragraph 19 useful for treating a metabolic disease or medical condition accompanied by weight gain wherein said disease or condition is selected from the group consisting of obesity, feeding disorders and Prader-Willi Syndrome.</li><li>29. A pharmaceutical composition according to paragraph 28, wherein obesity is treated.</li><li>30. A pharmaceutical composition according to paragraph 28, wherein a feeding disorder is treated.</li><li>31. A pharmaceutical composition according to paragraph 19 useful for decreasing food intake.</li><li>32. A pharmaceutical composition according to paragraph 19 useful for decreasing body weight.</li><li>33. A pharmaceutical composition according to paragraph 19 useful for decreasing food intake and decreasing body weight.</li><li>34. A pharmaceutical composition according to paragraph 31 useful for decreasing food intake wherein said compound is selected from the group consisting of Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2 SEQ ID NO:32, Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 SEQ ID NO:50, Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 SEQ ID NO:50, Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2 SEQ ID NO:51, Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 SEQ ID NO:7, D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Thr-NH2 SEQ ID NO:24, Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2 SEQ ID NO:22 and Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2 SEQ ID NO:49, or a pharmaceutically acceptable salt thereof.</li><li>35. A pharmaceutical composition according to paragraph 34 useful for decreasing food intake wherein said compound is Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 SEQ ID NO:50, or a pharmaceutically acceptable salt thereof.</li><li>36. A pharmaceutical composition according to paragraph 34 useful for decreasing food intake wherein said compound is Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2 SEQ ID NO:49, or a pharmaceutically acceptable salt thereof.</li><li>37. A pharmaceutical composition according to paragraph 34 useful for decreasing food intake wherein said compound is Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2 SEQ ID NO:51, or a pharmaceutically acceptable salt thereof.</li><li>38. A pharmaceutical composition according to paragraph 32 useful for decreasing body weight wherein said compound is selected from the group consisting of Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2 SEQ ID NO:32, Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 SEQ ID NO:50, Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 SEQ ID NO:50, Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2 SEQ ID NO:51, Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 SEQ ID NO:7, D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Thr-NH2 SEQ ID NO:24, Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2 SEQ ID NO:22 and Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2 SEQ ID NO:49, or a pharmaceutically acceptable salt thereof.</li><li>39. A pharmaceutical composition according to paragraph 38 useful for decreasing food intake wherein said compound is Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 SEQ ID NO:50, or a pharmaceutically acceptable salt thereof.</li><li>40. A pharmaceutical composition according to paragraph 38 useful for decreasing food intake wherein said compound is Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2 SEQ ID NO:49, or a pharmaceutically acceptable salt thereof.</li><li>41. A pharmaceutical composition according to paragraph 38 useful for decreasing food intake wherein said compound is Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2 SEQ ID NO:51, or a pharmaceutically acceptable salt thereof.</li><li>42. A pharmaceutical composition according to paragraph 33 useful for decreasing food intake and decreasing body weight wherein said compound is selected from the group consisting of Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2 SEQ ID NO:32, Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 SEQ ID NO:50, Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 SEQ ID NO:50, Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2 SEQ ID NO:51, Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 SEQ ID NO:7, D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Thr-NH2 SEQ ID NO:24, Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2 SEQ ID NO:22 and Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2 SEQ ID NO:49, or a pharmaceutically acceptable salt thereof.</li><li>43. A pharmaceutical composition according to paragraph 42 useful for decreasing food intake wherein said compound is Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 SEQ ID NO:50, or a pharmaceutically acceptable salt thereof.</li><li>44. A pharmaceutical composition according to paragraph 42 useful for decreasing food intake wherein said compound is Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2 SEQ ID NO:49, or a pharmaceutically acceptable salt thereof.</li><li>45. A pharmaceutical composition according to paragraph 42 useful for decreasing food intake wherein said compound is Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2 SEQ ID NO:51, or a pharmaceutically acceptable salt thereof.</li><li>46. A pharmaceutical composition according to paragraph 19 useful for treating a metabolic disease or medical condition accompanied by weight loss wherein said disease or condition is selected from the group consisting of anorexia, bulimia, AIDS wasting, cachexia, cancer cachexia and wasting in frail elderly.</li><li>47. A pharmaceutical composition according to paragraph 46 useful for treating anorexia.</li><li>48. A pharmaceutical composition according to paragraph 46 useful for treating bulimia.</li><li>49. A pharmaceutical composition according to paragraph 46 useful for treating AIDS wasting or wasting in frail elderly.</li><li>50. A pharmaceutical composition according to paragraph 46 useful for treating cachexia or cancer cachexia.</li><li>51. A pharmaceutical composition according to paragraph 19 useful for treating a neoplastic disease or medical condition wherein said disease or condition is selected from the group consisting of skin cancer and cancer cachexia.</li><li>52. A pharmaceutical composition according to paragraph 19 useful for treating a reproductive or sexual medical condition wherein said disease or condition is selected from the group consisting of endometriosis, uterine bleeding, sexual dysfunction, erectile dysfunction and decreased sexual response in females.</li><li>53. A pharmaceutical composition according to paragraph 19 useful for treating a disease or medical condition resulting from treatment or insult to an organism wherein said disease or condition is selected from the group consisting of organ transplant rejection, ischemia and reperfusion injury, wounding and spinal cord injury, and weight loss due to a medical procedure selected from the group consisting of chemotherapy, radiation therapy, temporary or permanent immobilization and dialysis.</li><li>54. A pharmaceutical composition according to paragraph 19 useful for treating a cardiovascular disease or medical condition wherein said disease or condition is selected from the group consisting of hemorrhagic shock, cardiogenic shock, hypovolemic shock, cardiovascular disorders and cardiac cachexia.</li><li>55. A pharmaceutical composition according to paragraph 19 useful for treating a pulmonary disease or medical condition wherein said disease or condition is selected from the group consisting of acute respiratory distress syndrome, pulmonary fibrosis, chronic obstructive pulmonary disease and asthma.</li><li>56. A pharmaceutical composition according to paragraph 19 useful for treating a disease or medical condition wherein said disease or condition is selected from the group consisting of enhanced immune tolerance and allergies.</li><li>57. A pharmaceutical composition according to paragraph 19 useful for treating a dermatological disease or medical condition wherein said disease or condition is selected from the group consisting of psoriasis, skin pigmentation depletion, acne and keloid formation.</li><li>58. A pharmaceutical composition according to paragraph 19 useful for treating a behavioral or central nervous system or neuronal disease or medical condition wherein said disease or condition is selected from the group consisting of anxiety, depression, memory dysfunction and neuropathic pain.</li><li>59. A pharmaceutical composition according to paragraph 19 useful for treating a renal disease or medical condition wherein said disease or condition is selected from the group consisting of renal cachexia and natriuresis.</li><li>60. A pharmaceutical composition according to paragraph 19 useful for modulating ovarian weight, placental development, prolactin secretion, FSH secretion, intrauterine fetal growth, parturition, spermatogenesis, thyroxin release, aldosterone synthesis and release, body temperature, blood pressure, heart rate, vascular tone, brain blood flow, blood glucose levels, sebum secretion, pheromone secretion, motivation, learning and behavior, pain perception, neuroprotection and nerve growth, bone metabolism, bone formation and bone development.</li><li>61. A pharmaceutical composition according to paragraph 19 useful for modulating bone metabolism, bone formation and bone development.</li><li>62. A pharmaceutical composition according to paragraph 19 useful for inhibiting alcohol consumption, for reducing alcohol consumption, for treating alcoholism, or for treating alcohol abuse.</li><li>63. A pharmaceutical composition according to paragraph 62 useful for inhibiting alcohol consumption wherein said compound of said pharmaceutical composition is a selective melanocortin 4 receptor agonist.</li><li>64. A pharmaceutical composition according to paragraph 62 useful for reducing alcohol consumption wherein said compound of said pharmaceutical composition is a selective melanocortin 4 receptor agonist.</li><li>65. A pharmaceutical composition according to paragraph 62 useful for treating alcoholism wherein said compound of said pharmaceutical composition is a selective melanocortin 4 receptor agonist.</li><li>66. A pharmaceutical composition according to paragraph 62 useful for treating alcohol abuse wherein said compound of said pharmaceutical composition is a selective melanocortin 4 receptor agonist.</li><li>67. A pharmaceutical composition according to paragraph 63 useful for inhibiting alcohol consumption wherein said compound of said pharmaceutical composition is a selective melanocortin 4 receptor agonist exhibiting a functional activity characterized by an EC50 at least 15- fold more selective for the human melanocortin 4 receptor than for the human melanocortin 1 receptor, the human melanocortin 3 receptor and the human melanocortin 5 receptor.</li><li>68. A pharmaceutical composition according to paragraph 67 useful for inhibiting alcohol consumption wherein said compound of said pharmaceutical composition is a selective melanocortin 4 receptor agonist exhibiting a function activity characterized by an EC50 at least 17-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 3 receptor.</li><li>69. A pharmaceutical composition according to paragraph 67 useful for inhibiting alcohol consumption wherein said compound of said pharmaceutical composition is a selective melanocortin 4 receptor agonist exhibiting a function activity characterized by an EC50 at least 90-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 3 receptor.</li><li>70. A pharmaceutical composition according to paragraph 67 useful for inhibiting alcohol consumption wherein said compound of said pharmaceutical composition is a selective melanocortin 4 receptor agonist exhibiting a function activity characterized by an EC50 at least 200-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 5 receptor.</li><li>71. A pharmaceutical composition according to paragraph 67 useful for inhibiting alcohol consumption wherein said compound of said pharmaceutical composition is a selective melanocortin 4 receptor agonist exhibiting a function activity characterized by an EC50 at least 3000-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 5 receptor.</li><li>72. The use of a therapeutically effective amount of a melanocortin 4 receptor agonist according to any one of paragraphs 1 to 18, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament useful to inhibit alcohol consumption in a subject in need of such treatment.</li><li>73. The use of a therapeutically effective amount of a melanocortin 4 receptor agonist of according to any one of paragraphs 1 to 18, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament useful to reduce alcohol consumption in a subject in need of such treatment.</li><li>74. The use of a therapeutically effective amount of a melanocortin 4 receptor agonist according to any one of paragraphs 1 to 18, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament useful to treat alcoholism in a subject in need of such treatment.</li><li>75. The use of a therapeutically effective amount of a melanocortin 4 receptor agonist according to any one of paragraphs 1 to 18, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament useful to treat alcohol abuse in a subject in need of such treatment.</li><li>76. A method of eliciting an agonist or antagonist effect from a melanocortin receptor in a subject in need thereof which comprises administering to said subject a therapeutically effective amount of a compound according to any one of paragraphs 1 to 18, or a pharmaceutically acceptable salt thereof.</li><li>77. A method according to paragraph 76, wherein said compound is a selective melanocortin 4 receptor agonist.</li><li>78. A method according to paragraph 77, wherein said compound is a selective melanocortin 4 receptor agonist with a functional activity characterized by an EC50 at least 15- fold more selective for the human melanocortin 4 receptor than for the human melanocortin 1 receptor, the human melanocortin 3 receptor and the human melanocortin 5 receptor.</li><li>79. A method according to paragraph 78, wherein the functional activity of the melanocortin 4 receptor agonist is characterized by an EC50 at least 17-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 3 receptor.</li><li>80. A method according to paragraph 78, wherein the functional activity of the melanocortin 4 receptor agonist is characterized by an EC50 at least 90-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 3 receptor.</li><li>81. A method according to paragraph 78, wherein the functional activity of the melanocortin 4 receptor agonist is characterized by an EC50 at least 200-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 5 receptor.</li><li>82. A method according to paragraph 78, wherein the functional activity of the melanocortin 4 receptor agonist is characterized by an EC50 at least 3000-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 5 receptor.</li><li>83. A method of treating an acute or chronic inflammatory disease or medical condition by eliciting an agonist or antagonist effect from a melanocortin receptor according to paragraph 76, wherein said disease or condition is selected from the group consisting of general inflammation, inflammatory bowel disease, brain inflammation, sepsis and septic shock.</li><li>84. A method of treating a disease or medical condition with an autoimmune component by eliciting an agonist or antagonist effect from a melanocortin receptor according to paragraph 76, wherein said disease or condition is selected from the group consisting of rheumatoid arthritis, gouty arthritis and multiple sclerosis.</li><li>85. A method of treating a metabolic disease or medical condition accompanied by weight gain by eliciting an agonist or antagonist effect from a melanocortin receptor according to paragraph 76, wherein said disease or condition is selected from the group consisting of obesity, feeding disorders and Prader-Willi Syndrome.</li><li>86. A method according to paragraph 85, wherein obesity is treated.</li><li>87. A method according to paragraph 85, wherein a feeding disorder is treated.</li><li>88. A method of decreasing food intake according to paragraph 76.</li><li>89. A method of decreasing body weight according to paragraph 76.</li><li>90. A method of decreasing food intake and decreasing body weight by eliciting an agonist or antagonist effect from a melanocortin receptor according to paragraph 76.</li><li>91. A method of decreasing food intake by eliciting an agonist or antagonist effect from a melanocortin receptor according to paragraph 88 wherein said compound is Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2 SEQ ID NO:32, Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 SEQ ID NO:50, Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 SEQ ID NO:50, Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2 SEQ ID NO:51, Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 SEQ ID NO:7, D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Thr-NH2 SEQ ID NO:24, Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2 SEQ ID NO:22 or Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2 SEQ ID NO:49, or a pharmaceutically acceptable salt thereof.</li><li>92. A method according to paragraph 91, wherein said compound is Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 SEQ ID NO:50, or a pharmaceutically acceptable salt thereof.</li><li>93. A method according to paragraph 91, wherein said compound is Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2 SEQ ID NO:49, or a pharmaceutically acceptable salt thereof.</li><li>94. A method according to paragraph 91, wherein said compound is Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2 SEQ ID NO:51, or a pharmaceutically acceptable salt thereof.</li><li>95. A method of decreasing body weight by eliciting an agonist or antagonist effect from a melanocortin receptor according to paragraph 89 wherein said compound is Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2 SEQ ID NO:32, Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 SEQ ID NO:50, Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 SEQ ID NO:50, Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2 SEQ ID NO:51, Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 SEQ ID NO:7, D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Thr-NH2 SEQ ID NO:24, Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2 SEQ ID NO:22 or Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2 SEQ ID NO:49, or a pharmaceutically acceptable salt thereof.</li><li>96. A method according to paragraph 95, wherein said compound is Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 SEQ ID NO:50, or a pharmaceutically acceptable salt thereof.</li><li>97. A method according to paragraph 95, wherein said compound is Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2 SEQ ID NO:49, or a pharmaceutically acceptable salt thereof.</li><li>98. A method according to paragraph 95, wherein said compound is Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2 SEQ ID NO:51, or a pharmaceutically acceptable salt thereof.</li><li>99. A method of decreasing food intake and decreasing body weight by eliciting an agonist or antagonist effect from a melanocortin receptor according to paragraph 90 wherein said compound is Ac-Nle-c(Cys-His-D-Phe-Arg-Trp-Gaba-Pen)-NH2 SEQ ID NO:32, Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 SEQ ID NO:50, Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 SEQ ID NO:50, Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2 SEQ ID NO:51, Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 SEQ ID NO:7, D-Phe-c(Cys-His-D-(Et)Tyr-Arg-Trp-β-Ala-D-Cys)-Thr-NH2 SEQ ID NO:24, Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2 SEQ ID NO:22, or Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2 SEQ ID NO:49, or a pharmaceutically acceptable salt thereof.</li><li>100. A method according to paragraph 99, wherein said compound is 22493 Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 SEQ ID NO:50, or a pharmaceutically acceptable salt thereof.</li><li>101. A method according to paragraph 99, wherein said compound is Ac-Arg-c(Cys-D-Ala-His-D-2-Nal-Arg-Trp-Cys)-NH2 SEQ ID NO:49, or a pharmaceutically acceptable salt thereof.</li><li>102. A method according to paragraph 99, wherein said compound is Ac-D-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Pen)-NH2 SEQ ID NO:51, or a pharmaceutically acceptable salt thereof.</li><li>103. A method of treating a metabolic disease or medical condition accompanied by weight loss by eliciting an agonist or antagonist effect from a melanocortin receptor according to paragraph 76, wherein said disease or condition is selected from the group consisting of anorexia, bulimia, AIDS wasting, cachexia, cancer cachexia and wasting in frail elderly.</li><li>104. A method according to paragraph 103, wherein anorexia is treated.</li><li>105. A method according to paragraph 103, wherein bulimia is treated.</li><li>106. A method according to paragraph 103, wherein AIDS wasting or wasting in frail elderly is treated.</li><li>107. A method according to paragraph 103, wherein cachexia or cancer cachexia is treated.</li><li>108. A method of treating a neoplastic disease or medical condition by eliciting an agonist or antagonist effect from a melanocortin receptor according to paragraph 76, wherein said disease or condition is selected from the group consisting of skin cancer and cancer cachexia.</li><li>109. A method of treating a reproductive or sexual medical condition by eliciting an agonist or antagonist effect from a melanocortin receptor according to paragraph 76, wherein said disease or condition is selected from the group consisting of endometriosis, uterine bleeding, sexual dysfunction, erectile dysfunction and decreased sexual response in females.</li><li>110. A method of treating a disease or medical condition resulting from treatment or insult to an organism by eliciting an agonist or antagonist effect from a melanocortin receptor according to paragraph 76, wherein said disease or condition is selected from the group consisting of organ transplant rejection, ischemia and reperfusion injury, wounding and spinal cord injury, and weight loss due to a medical procedure selected from the group consisting of chemotherapy, radiation therapy, temporary or permanent immobilization and dialysis.</li><li>111. A method of treating a cardiovascular disease or medical condition by eliciting an agonist or antagonist effect from a melanocortin receptor according to paragraph 76, wherein said disease or condition is selected from the group consisting of hemorrhagic shock, cardiogenic shock, hypovolemic shock, cardiovascular disorders and cardiac cachexia.</li><li>112. A method of treating a pulmonary disease or medical condition by eliciting an agonist or antagonist effect from a melanocortin receptor according to paragraph 76, wherein said disease or condition is selected from the group consisting of acute respiratory distress syndrome, pulmonary fibrosis, chronic obstructive pulmonary disease and asthma.</li><li>113. A method of treating a disease or medical condition by eliciting an agonist or antagonist effect from a melanocortin receptor according to paragraph 76, wherein said disease or condition is selected from the group consisting of enhanced immune tolerance and allergies.</li><li>114. A method of treating a dermatological disease or medical condition by eliciting an agonist or antagonist effect from a melanocortin receptor according to paragraph 76, wherein said disease or condition is selected from the group consisting of psoriasis, skin pigmentation depletion, acne and keloid formation.</li><li>115. A method of treating a behavioral or central nervous system or neuronal disease or medical condition by eliciting an agonist or antagonist effect from a melanocortin receptor according to paragraph 76, wherein said disease or condition is selected from the group consisting of anxiety, depression, memory dysfunction and neuropathic pain.</li><li>116. A method of treating a renal disease or medical condition by eliciting an agonist or antagonist effect from a melanocortin receptor according to paragraph 76, wherein said disease or condition is selected from the group consisting of renal cachexia and natriuresis.</li><li>117. A method of modulating ovarian weight, placental development, prolactin secretion, FSH secretion, intrauterine fetal growth, parturition, spermatogenesis, thyroxin release, aldosterone synthesis and release, body temperature, blood pressure, heart rate, vascular tone, brain blood flow, blood glucose levels, sebum secretion, pheromone secretion, motivation, learning and behavior, pain perception, neuroprotection and nerve growth by eliciting an agonist or antagonist effect from a melanocortin receptor according to paragraph 76.</li><li>118. A method of modulating bone metabolism, bone formation and bone development by eliciting an agonist or antagonist effect from a melanocortin receptor according to paragraph 76.</li><li>119. A method of inhibiting alcohol consumption, reducing alcohol consumption, treating alcoholism, or treating alcohol abuse by eliciting an agonist or antagonist effect from a melanocortin receptor according to paragraph 76.</li><li>120. A method of inhibiting alcohol consumption according to paragraph 119, wherein said compound of said pharmaceutical composition is a selective melanocortin 4 receptor agonist.</li><li>121. A method of reducing alcohol consumption according to paragraph 119, wherein said compound of said pharmaceutical composition is a selective melanocortin 4 receptor agonist.</li><li>122. A method of treating alcoholism according to paragraph 119, wherein said compound of said pharmaceutical composition is a selective melanocortin 4 receptor agonist.</li><li>123. A method of treating alcohol abuse according to paragraph 119, wherein said compound of said pharmaceutical composition is a selective melanocortin 4 receptor agonist.</li><li>124. A method of inhibiting alcohol consumption according to paragraph 120, wherein said compound of said pharmaceutical composition is a selective melanocortin 4 receptor agonist with a functional activity characterized by an EC50 at least 15- fold more selective for the human melanocortin 4 receptor than for the human melanocortin 1 receptor, the human melanocortin 3 receptor and the human melanocortin 5 receptor.</li><li>125. A method according to paragraph 124, wherein the functional activity of the melanocortin 4 receptor agonist is characterized by an EC50 at least 17-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 3 receptor.</li><li>126. A method according to paragraph 124, wherein the functional activity of the melanocortin 4 receptor agonist is characterized by an EC50 at least 90-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 3 receptor.</li><li>127. A method according to paragraph 124, wherein the functional activity of the melanocortin 4 receptor agonist is characterized by an EC50 at least 200-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 5 receptor.</li><li>128. A method according to paragraph 124, wherein the functional activity of the melanocortin 4 receptor agonist is characterized by an EC50 at least 3000-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 5 receptor.</li><li>129. The use of a therapeutically effective amount of a melanocortin 4 receptor agonist or antagonist according to any one of paragraphs 1-18, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament useful to treat a disease or condition selected from the group consisting of general inflammation, inflammatory bowel disease, brain inflammation, sepsis, septic shock, rheumatoid arthritis, gouty arthritis, multiple sclerosis, a metabolic disease or medical condition accompanied by weight gain, obesity, feeding disorders, Prader-Willi Syndrome, a metabolic disease or medical condition accompanied by weight loss, anorexia, bulimia, AIDS wasting, cachexia, cancer cachexia, wasting in frail elderly, skin cancer, endometriosis, uterine bleeding, sexual dysfunction, erectile dysfunction, decreased sexual response in females, organ transplant rejection, ischemia and reperfusion injury, wounding and spinal cord injury, weight loss due to a medical procedure selected from the group consisting of chemotherapy, radiation therapy, temporary or permanent immobilization and dialysis, hemorrhagic shock, cardiogenic shock, hypovolemic shock, cardiovascular disorders, cardiac cachexia, acute respiratory distress syndrome, pulmonary fibrosis, chronic obstructive pulmonary disease, asthma, enhanced immune tolerance, allergies, psoriasis, skin pigmentation depletion, acne, keloid formation, anxiety, depression, memory dysfunction, neuropathic pain, renal cachexia and natriuresis.</li><li>130. The use of a therapeutically effective amount of a melanocortin 4 receptor agonist or antagonist according to any one of paragraphs 1-18, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament useful to modulate ovarian weight, placental development, prolactin secretion, FSH secretion, intrauterine fetal growth, parturition, spermatogenesis, thyroxin release, aldosterone synthesis and release, body temperature, blood pressure, heart rate, vascular tone, brain blood flow, blood glucose levels, sebum secretion, pheromone secretion, motivation, learning and behavior, pain perception, neuroprotection, nerve growth, bone metabolism, bone formation and bone development.</li><li>131. A compound according to formula II: (R2R3)-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-NH2 wherein: <ul id="ul0025" list-style="none" compact="compact"><li>A1 is Nle or deleted;</li><li>A2 is Cys or Asp;</li><li>A3 is Glu or D-Ala;</li><li>A4 is His;</li><li>A5 is D-Phe;</li><li>A6 is Arg;</li><li>A7 is Trp, 2-Nal or Bal;</li><li>A8 is Gly, Ala, D-Ala, β-Ala, Gaba or Apn;</li><li>A9 is Cys or Lys;</li><li>each of R2 and R3 is independently selected from the group consisting of H or (C1-C6) acyl;</li><li>provided that <ol id="ol0005" compact="compact"><li>(I). when R2 is (C1-C6)acyl, then R3 is H; and</li><li>(II). when A2 is Cys, then A9 is Cys,</li></ol></li></ul> or a pharmaceutically acceptable salt thereof.</li><li>132. A compound according to paragraph 131, wherein said compound is: <ul id="ul0026" list-style="none" compact="compact"><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gly-Cys)-NH2; SEQ ID NO:54</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-D-Ala-Cys)-NH2; SEQ ID NO:54</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-β-Ala-Cys)-NH2; SEQ ID NO:54</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:54</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Apn-Cys)-NH2; SEQ ID NO:54</li><li>Ac-c(Cys-Glu-His-D-Phe-Arg-Trp-Ala-Cys)-NH2; SEQ ID NO:55</li><li>Ac-c(Cys-Glu-His-D-Phe-Arg-2-Nal-Ala-Cys)-NH2; SEQ ID NO:55</li><li>Ac-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Ala-Cys)-NH2;SEQ ID NO:56</li><li>Ac-c(Cys-D-Ala-His-D-Phe-Arg-2-Nal-Ala-Cys)-NH2; SEQ ID NO:56</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Ala-Cys)-NH2; SEQ ID NO:57</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-β-Ala-Cys)-NH2; SEQ ID NO:57</li><li>Ac-Nle-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Gaba-Cys)-NH2; SEQ ID NO:57 or</li><li>Ac-Nle-c(Asp-D-Ala-His-D-Phe-Arg-Bal-Ala-Lys)-NH2; SEQ ID NO:58 or</li></ul> a pharmaceutically acceptable salt thereof.</li><li>133. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of paragraphs 131 or 132, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.</li><li>134. A pharmaceutical composition according to paragraph 133, wherein said compound is a selective melanocortin 4 receptor agonist, or a pharmaceutically acceptable salt thereof.</li><li>135. A pharmaceutical composition according to paragraph 134, wherein said compound is a selective melanocortin 4 receptor agonist, or a pharmaceutically acceptable salt thereof, with a functional activity characterized by an EC50 at least 15-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 1 receptor, the human melanocortin 3 receptor and the human melanocortin 5 receptor.</li><li>136. A pharmaceutical composition according to paragraph 135, wherein the functional activity of the melanocortin 4 receptor agonist is characterized by an EC50 at least 17-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 3 receptor.</li><li>137. A pharmaceutical composition according to paragraph 135, wherein the functional activity of the melanocortin 4 receptor agonist is characterized by an EC50 at least 90-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 3 receptor.</li><li>138. A pharmaceutical composition according to paragraph 135, wherein the functional activity of the melanocortin 4 receptor agonist is characterized by an EC50 at least 200-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 5 receptor.</li><li>139. A pharmaceutical composition according to paragraph 135, wherein the functional activity of the melanocortin 4 receptor agonist is characterized by an EC50 at least 3000-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 5 receptor.</li><li>140. A pharmaceutical composition according to paragraph 133 useful for treating an acute or chronic inflammatory disease or medical condition wherein said disease or condition is selected from the group consisting of general inflammation, inflammatory bowel disease, brain inflammation, sepsis and septic shock.</li><li>141. A pharmaceutical composition according to paragraph 133 useful for treating a disease or medical condition with an autoimmune component wherein said disease or condition is selected from the group consisting of rheumatoid arthritis, gouty arthritis and multiple sclerosis.</li><li>142. A pharmaceutical composition according to paragraph 133 useful for treating a metabolic disease or medical condition accompanied by weight gain wherein said disease or condition is selected from the group consisting of obesity, feeding disorders and Prader-Willi Syndrome.</li><li>143. A pharmaceutical composition according to paragraph 142, wherein obesity is treated.</li><li>144. A pharmaceutical composition according to paragraph 142, wherein a feeding disorder is treated.</li><li>145. A pharmaceutical composition according to paragraph 133 useful for decreasing food intake.</li><li>146. A pharmaceutical composition according to paragraph 133 useful for decreasing body weight.</li><li>147. A pharmaceutical composition according to paragraph 133 useful for decreasing food intake and decreasing body weight.</li><li>148. A pharmaceutical composition according to paragraph 133 useful for treating a metabolic disease or medical condition accompanied by weight loss wherein said disease or condition is selected from the group consisting of anorexia, bulimia, AIDS wasting, cachexia, cancer cachexia and wasting in frail elderly.</li><li>149. A pharmaceutical composition according to paragraph 148 useful for treating anorexia.</li><li>150. A pharmaceutical composition according to paragraph 148 useful for treating bulimia.</li><li>151. A pharmaceutical composition according to paragraph 148 useful for treating AIDS wasting or wasting in frail elderly.</li><li>152. A pharmaceutical composition according to paragraph 148 useful for treating cachexia or cancer cachexia.</li><li>153. A pharmaceutical composition according to paragraph 133 useful for treating a neoplastic disease or medical condition wherein said disease or condition is selected from the group consisting of skin cancer and cancer cachexia.</li><li>154. A pharmaceutical composition according to paragraph 133 useful for treating a reproductive or sexual medical condition wherein said disease or condition is selected from the group consisting of endometriosis, uterine bleeding, sexual dysfunction, erectile dysfunction and decreased sexual response in females.</li><li>155. A pharmaceutical composition according to paragraph 133 useful for treating a disease or medical condition resulting from treatment or insult to an organism wherein said disease or condition is selected from the group consisting of organ transplant rejection, ischemia and reperfusion injury, wounding and spinal cord injury, and weight loss due to a medical procedure selected from the group consisting of chemotherapy, radiation therapy, temporary or permanent immobilization and dialysis.</li><li>156. A pharmaceutical composition according to paragraph 133 useful for treating a cardiovascular disease or medical condition wherein said disease or condition is selected from the group consisting of hemorrhagic shock, cardiogenic shock, hypovolemic shock, cardiovascular disorders and cardiac cachexia.</li><li>157. A pharmaceutical composition according to paragraph 133 useful for treating a pulmonary disease or medical condition wherein said disease or condition is selected from the group consisting of acute respiratory distress syndrome, pulmonary fibrosis, chronic obstructive pulmonary disease and asthma.</li><li>158. A pharmaceutical composition according to paragraph 133 useful for treating a disease or medical condition wherein said disease or condition is selected from the group consisting of enhanced immune tolerance and allergies.</li><li>159. A pharmaceutical composition according to paragraph 133 useful for treating a dermatological disease or medical condition wherein said disease or condition is selected from the group consisting of psoriasis, skin pigmentation depletion, acne and keloid formation.</li><li>160. A pharmaceutical composition according to paragraph 133 useful for treating a behavioral or central nervous system or neuronal disease or medical condition wherein said disease or condition is selected from the group consisting of anxiety, depression, memory dysfunction and neuropathic pain.</li><li>161. A pharmaceutical composition according to paragraph 133 useful for treating a renal disease or medical condition wherein said disease or condition is selected from the group consisting of renal cachexia and natriuresis.</li><li>162. A pharmaceutical composition according to paragraph 133 useful for modulating ovarian weight, placental development, prolactin secretion, FSH secretion, intrauterine fetal growth, parturition, spermatogenesis, thyroxin release, aldosterone synthesis and release, body temperature, blood pressure, heart rate, vascular tone, brain blood flow, blood glucose levels, sebum secretion, pheromone secretion, motivation, learning and behavior, pain perception, neuroprotection and nerve growth.</li><li>163. A pharmaceutical composition according to paragraph 133 useful for modulating bone metabolism, bone formation and bone development.</li><li>164. A pharmaceutical composition according to paragraph 133 useful for inhibiting alcohol consumption, for reducing alcohol consumption, for treating alcoholism, or for treating alcohol abuse.</li><li>165. A pharmaceutical composition according to paragraph 164 useful for inhibiting alcohol consumption wherein said compound of said pharmaceutical composition is a selective melanocortin 4 receptor agonist.</li><li>166. A pharmaceutical composition according to paragraph 164 useful for reducing alcohol consumption wherein said compound of said pharmaceutical composition is a selective melanocortin 4 receptor agonist.</li><li>167. A pharmaceutical composition according to paragraph 164 useful for treating alcoholism wherein said compound of said pharmaceutical composition is a selective melanocortin 4 receptor agonist.</li><li>168. A pharmaceutical composition according to paragraph 164 useful for treating alcohol abuse wherein said compound of said pharmaceutical composition is a selective melanocortin 4 receptor agonist.</li><li>169. A pharmaceutical composition according to paragraph 165 useful for inhibiting alcohol consumption wherein said compound of said pharmaceutical composition is a selective melanocortin 4 receptor agonist exhibiting a functional activity characterized by an EC50 at least 15- fold more selective for the human melanocortin 4 receptor than for the human melanocortin 1 receptor, the human melanocortin 3 receptor and the human melanocortin 5 receptor.</li><li>170. A pharmaceutical composition according to paragraph 169 useful for inhibiting alcohol consumption wherein said compound of said pharmaceutical composition is a selective melanocortin 4 receptor agonist exhibiting a function activity characterized by an EC50 at least 17-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 3 receptor.</li><li>171. A pharmaceutical composition according to paragraph 169 useful for inhibiting alcohol consumption wherein said compound of said pharmaceutical composition is a selective melanocortin 4 receptor agonist exhibiting a function activity characterized by an EC50 at least 90-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 3 receptor.</li><li>172. A pharmaceutical composition according to paragraph 169 useful for inhibiting alcohol consumption wherein said compound of said pharmaceutical composition is a selective melanocortin 4 receptor agonist exhibiting a function activity characterized by an EC50 at least 200-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 5 receptor.</li><li>173. A pharmaceutical composition according to paragraph 169 useful for inhibiting alcohol consumption wherein said compound of said pharmaceutical composition is a selective melanocortin 4 receptor agonist exhibiting a function activity characterized by an EC50 at least 3000-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 5 receptor.</li><li>174. The use of a therapeutically effective amount of a melanocortin 4 receptor agonist according to any one of paragraphs 131 or 132, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament useful to inhibit alcohol consumption in a subject in need of such treatment.</li><li>175. The use of a therapeutically effective amount of a melanocortin 4 receptor agonist of according to any one of paragraphs 131 or 132, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament useful to reduce alcohol consumption in a subject in need of such treatment.</li><li>176. The use of a therapeutically effective amount of a melanocortin 4 receptor agonist according to any one of paragraphs 131 or 132, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament useful to treat alcoholism in a subject in need of such treatment.</li><li>177. The use of a therapeutically effective amount of a melanocortin 4 receptor agonist according to c any one of paragraphs 131 or 132, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament useful to treat alcohol abuse in a subject in need of such treatment.</li><li>178. A method of eliciting an agonist or antagonist effect from a melanocortin receptor in a subject in need thereof which comprises administering to said subject a therapeutically effective amount of a compound according to any one of paragraphs 131 or 132, or a pharmaceutically acceptable salt thereof.</li><li>179. A method according to paragraph 178, wherein said compound is a selective melanocortin 4 receptor agonist.</li><li>180. A method according to paragraph 179, wherein said compound is a selective melanocortin 4 receptor agonist with a functional activity characterized by an EC50 at least 15- fold more selective for the human melanocortin 4 receptor than for the human melanocortin 1 receptor, the human melanocortin 3 receptor and the human melanocortin 5 receptor.</li><li>181. A method according to paragraph 180, wherein the functional activity of the melanocortin 4 receptor agonist is characterized by an EC50 at least 17-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 3 receptor.</li><li>182. A method according to paragraph 180, wherein the functional activity of the melanocortin 4 receptor agonist is characterized by an EC50 at least 90-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 3 receptor.</li><li>183. A method according to paragraph 180, wherein the functional activity of the melanocortin 4 receptor agonist is characterized by an EC50 at least 200-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 5 receptor.</li><li>184. A method according to paragraph 180, wherein the functional activity of the melanocortin 4 receptor agonist is characterized by an EC50 at least 3000-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 5 receptor.</li><li>185. A method of treating an acute or chronic inflammatory disease or medical condition by eliciting an agonist or antagonist effect from a melanocortin receptor according to paragraph 178, wherein said disease or condition is selected from the group consisting of general inflammation, inflammatory bowel disease, brain inflammation, sepsis and septic shock.</li><li>186. A method of treating a disease or medical condition with an autoimmune component by eliciting an agonist or antagonist effect from a melanocortin receptor according to paragraph 178, wherein said disease or condition is selected from the group consisting of rheumatoid arthritis, gouty arthritis and multiple sclerosis.</li><li>187. A method of treating a metabolic disease or medical condition accompanied by weight gain by eliciting an agonist or antagonist effect from a melanocortin receptor according to paragraph 178, wherein said disease or condition is selected from the group consisting of obesity, feeding disorders and Prader-Willi Syndrome.</li><li>188. A method according to paragraph 187, wherein obesity is treated.</li><li>189. A method according to paragraph 187 wherein a feeding disorder is treated.</li><li>190. A method of decreasing food intake according to paragraph 178.</li><li>191. A method of decreasing body weight according to paragraph 178.</li><li>192. A method of decreasing food intake and decreasing body weight by eliciting an agonist or antagonist effect from a melanocortin receptor according to paragraph 178.</li><li>193. A method of treating a metabolic disease or medical condition accompanied by weight loss by eliciting an agonist or antagonist effect from a melanocortin receptor according to paragraph 178, wherein said disease or condition is selected from the group consisting of anorexia, bulimia, AIDS wasting, cachexia, cancer cachexia and wasting in frail elderly.</li><li>194. A method according to paragraph 193, wherein anorexia is treated.</li><li>195. A method according to paragraph 193, wherein bulimia is treated.</li><li>196. A method according to paragraph 193, wherein AIDS wasting or wasting in frail elderly is treated.</li><li>197. A method according to paragraph 193, wherein cachexia or cancer cachexia is treated.</li><li>198. A method of treating a neoplastic disease or medical condition by eliciting an agonist or antagonist effect from a melanocortin receptor according to paragraph 178, wherein said disease or condition is selected from the group consisting of skin cancer and cancer cachexia.</li><li>199. A method of treating a reproductive or sexual medical condition by eliciting an agonist or antagonist effect from a melanocortin receptor according to paragraph 178, wherein said disease or condition is selected from the group consisting of endometriosis, uterine bleeding, sexual dysfunction, erectile dysfunction and decreased sexual response in females.</li><li>200. A method of treating a disease or medical condition resulting from treatment or insult to an organism by eliciting an agonist or antagonist effect from a melanocortin receptor according to paragraph 178, wherein said disease or condition is selected from the group consisting of organ transplant rejection, ischemia and reperfusion injury, wounding and spinal cord injury, and weight loss due to a medical procedure selected from the group consisting of chemotherapy, radiation therapy, temporary or permanent immobilization and dialysis.</li><li>201. A method of treating a cardiovascular disease or medical condition by eliciting an agonist or antagonist effect from a melanocortin receptor according to paragraph 178, wherein said disease or condition is selected from the group consisting of hemorrhagic shock, cardiogenic shock, hypovolemic shock, cardiovascular disorders and cardiac cachexia.</li><li>202. A method of treating a pulmonary disease or medical condition by eliciting an agonist or antagonist effect from a melanocortin receptor according to paragraph 178, wherein said disease or condition is selected from the group consisting of acute respiratory distress syndrome, pulmonary fibrosis, chronic obstructive pulmonary disease and asthma.</li><li>203. A method of treating a disease or medical condition by eliciting an agonist or antagonist effect from a melanocortin receptor according to paragraph 178, wherein said disease or condition is selected from the group consisting of enhanced immune tolerance and allergies.</li><li>204. A method of treating a dermatological disease or medical condition by eliciting an agonist or antagonist effect from a melanocortin receptor according to paragraph 178, wherein said disease or condition is selected from the group consisting of psoriasis, skin pigmentation depletion, acne and keloid formation.</li><li>205. A method of treating a behavioral or central nervous system or neuronal disease or medical condition by eliciting an agonist or antagonist effect from a melanocortin receptor according to paragraph 178, wherein said disease or condition is selected from the group consisting of anxiety, depression, memory dysfunction and neuropathic pain.</li><li>206. A method of treating a renal disease or medical condition by eliciting an agonist or antagonist effect from a melanocortin receptor according to paragraph 178, wherein said disease or condition is selected from the group consisting of renal cachexia and natriuresis.</li><li>207. A method of modulating ovarian weight, placental development, prolactin secretion, FSH secretion, intrauterine fetal growth, parturition, spermatogenesis, thyroxin release, aldosterone synthesis and release, body temperature, blood pressure, heart rate, vascular tone, brain blood flow, blood glucose levels, sebum secretion, pheromone secretion, motivation, learning and behavior, pain perception, neuroprotection and nerve growth by eliciting an agonist or antagonist effect from a melanocortin receptor according to paragraph 178.</li><li>208. A method of modulating bone metabolism, bone formation and bone development by eliciting an agonist or antagonist effect from a melanocortin receptor according to paragraph 178.</li><li>209. A method of inhibiting alcohol consumption, reducing alcohol consumption, treating alcoholism, or treating alcohol abuse by eliciting an agonist or antagonist effect from a melanocortin receptor according to paragraph 178.</li><li>210. A method of inhibiting alcohol consumption according to paragraph 209, wherein said compound of said pharmaceutical composition is a selective melanocortin 4 receptor agonist.</li><li>211. A method of reducing alcohol consumption according to paragraph 209, wherein said compound of said pharmaceutical composition is a selective melanocortin 4 receptor agonist.</li><li>212. A method of treating alcoholism according to paragraph 209, wherein said compound of said pharmaceutical composition is a selective melanocortin 4 receptor agonist.</li><li>213. A method of treating alcohol abuse according to paragraph 209, wherein said compound of said pharmaceutical composition is a selective melanocortin 4 receptor agonist.</li><li>214. A method of inhibiting alcohol consumption according to paragraph 210, wherein said compound of said pharmaceutical composition is a selective melanocortin 4 receptor agonist with a functional activity characterized by an EC50 at least 15- fold more selective for the human melanocortin 4 receptor than for the human melanocortin 1 receptor, the human melanocortin 3 receptor and the human melanocortin 5 receptor.</li><li>215. A method according to paragraph 214, wherein the functional activity of the melanocortin 4 receptor agonist is characterized by an EC50 at least 17-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 3 receptor.</li><li>216. A method according to paragraph 214, wherein the functional activity of the melanocortin 4 receptor agonist is characterized by an EC50 at least 90-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 3 receptor.</li><li>217. A method according to paragraph 214, wherein the functional activity of the melanocortin 4 receptor agonist is characterized by an EC50 at least 200-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 5 receptor.</li><li>218. A method according to paragraph 214, wherein the functional activity of the melanocortin 4 receptor agonist is characterized by an EC50 at least 3000-fold more selective for the human melanocortin 4 receptor than for the human melanocortin 5 receptor.</li><li>219. The use of a therapeutically effective amount of a melanocortin 4 receptor agonist or antagonist according to any one of paragraphs 131 or 132, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament useful to treat a disease or condition selected from the group consisting of general inflammation, inflammatory bowel disease, brain inflammation, sepsis, septic shock, rheumatoid arthritis, gouty arthritis, multiple sclerosis, a metabolic disease or medical condition accompanied by weight gain, obesity, feeding disorders, Prader-Willi Syndrome, a metabolic disease or medical condition accompanied by weight loss, anorexia, bulimia, AIDS wasting, cachexia, cancer cachexia, wasting in frail elderly, skin cancer, endometriosis, uterine bleeding, sexual dysfunction, erectile dysfunction, decreased sexual response in females, organ transplant rejection, ischemia and reperfusion injury, wounding and spinal cord injury, weight loss due to a medical procedure selected from the group consisting of chemotherapy, radiation therapy, temporary or permanent immobilization and dialysis, hemorrhagic shock, cardiogenic shock, hypovolemic shock, cardiovascular disorders, cardiac cachexia, acute respiratory distress syndrome, pulmonary fibrosis, chronic obstructive pulmonary disease, asthma, enhanced immune tolerance, allergies, psoriasis, skin pigmentation depletion, acne, keloid formation, anxiety, depression, memory dysfunction, neuropathic pain, renal cachexia and natriuresis.</li><li>220. The use of a therapeutically effective amount of a melanocortin 4 receptor agonist or antagonist according to any one of paragraphs 131 or 132, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament useful to modulate ovarian weight, placental development, prolactin secretion, FSH secretion, intrauterine fetal growth, parturition, spermatogenesis, thyroxin release, aldosterone synthesis and release, body temperature, blood pressure, heart rate, vascular tone, brain blood flow, blood glucose levels, sebum secretion, pheromone secretion, motivation, learning and behavior, pain perception, neuroprotection, nerve growth, bone metabolism, bone formation and bone development.</li></ol><img file="EP3925614A2_D0255.tif" /><img file="EP3925614A2_D0256.tif" /><img file="EP3925614A2_D0257.tif" /><img file="EP3925614A2_D0258.tif" /><img file="EP3925614A2_D0259.tif" /><img file="EP3925614A2_D0260.tif" /><img file="EP3925614A2_D0261.tif" /><img file="EP3925614A2_D0262.tif" /><img file="EP3925614A2_D0263.tif" /><img file="EP3925614A2_D0264.tif" /><img file="EP3925614A2_D0265.tif" /><img file="EP3925614A2_D0266.tif" /><img file="EP3925614A2_D0267.tif" /><img file="EP3925614A2_D0268.tif" /><img file="EP3925614A2_D0269.tif" /><img file="EP3925614A2_D0270.tif" /><img file="EP3925614A2_D0271.tif" /><img file="EP3925614A2_D0272.tif" /><img file="EP3925614A2_D0273.tif" /><img file="EP3925614A2_D0274.tif" /><img file="EP3925614A2_D0275.tif" /><img file="EP3925614A2_D0276.tif" /><img file="EP3925614A2_D0277.tif" /><img file="EP3925614A2_D0278.tif" /><img file="EP3925614A2_D0279.tif" /><img file="EP3925614A2_D0280.tif" /><img file="EP3925614A2_D0281.tif" /><img file="EP3925614A2_D0282.tif" /><img file="EP3925614A2_D0283.tif" /><img file="EP3925614A2_D0284.tif" /><img file="EP3925614A2_D0285.tif" /><img file="EP3925614A2_D0286.tif" /><img file="EP3925614A2_D0287.tif" /><img file="EP3925614A2_D0288.tif" /><img file="EP3925614A2_D0289.tif" /><img file="EP3925614A2_D0290.tif" /><img file="EP3925614A2_D0291.tif" /><img file="EP3925614A2_D0292.tif" /><img file="EP3925614A2_D0293.tif" /><img file="EP3925614A2_D0294.tif" /><img file="EP3925614A2_D0295.tif" />

Contents5

303 sheets

Sheet 1
Sheet 2
Sheet 3
Sheet 4
Sheet 5
Sheet 6
Sheet 7
Sheet 8
Sheet 9
Sheet 10
Sheet 11
Sheet 12
Sheet 13
Sheet 14
Sheet 15
Sheet 16
Sheet 17
Sheet 18
Sheet 19
Sheet 20
Sheet 21
Sheet 22
Sheet 23
Sheet 24
Sheet 25
Sheet 26
Sheet 27
Sheet 28
Sheet 29
Sheet 30
Sheet 31
Sheet 32
Sheet 33
Sheet 34
Sheet 35
Sheet 36
Sheet 37
Sheet 38
Sheet 39
Sheet 40
Sheet 41
Sheet 42
Sheet 43
Sheet 44
Sheet 45
Sheet 46
Sheet 47
Sheet 48
Sheet 49
Sheet 50
Sheet 51
Sheet 52
Sheet 53
Sheet 54
Sheet 55
Sheet 56
Sheet 57
Sheet 58
Sheet 59
Sheet 60
Sheet 61
Sheet 62
Sheet 63
Sheet 64
Sheet 65
Sheet 66
Sheet 67
Sheet 68
Sheet 69
Sheet 70
Sheet 71
Sheet 72
Sheet 73
Sheet 74
Sheet 75
Sheet 76
Sheet 77
Sheet 78
Sheet 79
Sheet 80
Sheet 81
Sheet 82
Sheet 83
Sheet 84
Sheet 85
Sheet 86
Sheet 87
Sheet 88
Sheet 89
Sheet 90
Sheet 91
Sheet 92
Sheet 93
Sheet 94
Sheet 95
Sheet 96
Sheet 97
Sheet 98
Sheet 99
Sheet 100
Sheet 101
Sheet 102
Sheet 103
Sheet 104
Sheet 105
Sheet 106
Sheet 107
Sheet 108
Sheet 109
Sheet 110
Sheet 111
Sheet 112
Sheet 113
Sheet 114
Sheet 115
Sheet 116
Sheet 117
Sheet 118
Sheet 119
Sheet 120
Sheet 121
Sheet 122
Sheet 123
Sheet 124
Sheet 125
Sheet 126
Sheet 127
Sheet 128
Sheet 129
Sheet 130
Sheet 131
Sheet 132
Sheet 133
Sheet 134
Sheet 135
Sheet 136
Sheet 137
Sheet 138
Sheet 139
Sheet 140
Sheet 141
Sheet 142
Sheet 143
Sheet 144
Sheet 145
Sheet 146
Sheet 147
Sheet 148
Sheet 149
Sheet 150
Sheet 151
Sheet 152
Sheet 153
Sheet 154
Sheet 155
Sheet 156
Sheet 157
Sheet 158
Sheet 159
Sheet 160
Sheet 161
Sheet 162
Sheet 163
Sheet 164
Sheet 165
Sheet 166
Sheet 167
Sheet 168
Sheet 169
Sheet 170
Sheet 171
Sheet 172
Sheet 173
Sheet 174
Sheet 175
Sheet 176
Sheet 177
Sheet 178
Sheet 179
Sheet 180
Sheet 181
Sheet 182
Sheet 183
Sheet 184
Sheet 185
Sheet 186
Sheet 187
Sheet 188
Sheet 189
Sheet 190
Sheet 191
Sheet 192
Sheet 193
Sheet 194
Sheet 195
Sheet 196
Sheet 197
Sheet 198
Sheet 199
Sheet 200
Sheet 201
Sheet 202
Sheet 203
Sheet 204
Sheet 205
Sheet 206
Sheet 207
Sheet 208
Sheet 209
Sheet 210
Sheet 211
Sheet 212
Sheet 213
Sheet 214
Sheet 215
Sheet 216
Sheet 217
Sheet 218
Sheet 219
Sheet 220
Sheet 221
Sheet 222
Sheet 223
Sheet 224
Sheet 225
Sheet 226
Sheet 227
Sheet 228
Sheet 229
Sheet 230
Sheet 231
Sheet 232
Sheet 233
Sheet 234
Sheet 235
Sheet 236
Sheet 237
Sheet 238
Sheet 239
Sheet 240
Sheet 241
Sheet 242
Sheet 243
Sheet 244
Sheet 245
Sheet 246
Sheet 247
Sheet 248
Sheet 249
Sheet 250
Sheet 251
Sheet 252
Sheet 253
Sheet 254
Sheet 255
Sheet 256
Sheet 257
Sheet 258
Sheet 259
Sheet 260
Sheet 261
Sheet 262
Sheet 263
Sheet 264
Sheet 265
Sheet 266
Sheet 267
Sheet 268
Sheet 269
Sheet 270
Sheet 271
Sheet 272
Sheet 273
Sheet 274
Sheet 275
Sheet 276
Sheet 277
Sheet 278
Sheet 279
Sheet 280
Sheet 281
Sheet 282
Sheet 283
Sheet 284
Sheet 285
Sheet 286
Sheet 287
Sheet 288
Sheet 289
Sheet 290
Sheet 291
Sheet 292
Sheet 293
Sheet 294
Sheet 295
Sheet 296
Sheet 297
Sheet 298
Sheet 299
Sheet 300
Sheet 301
Sheet 302
Sheet 303

Every citation, both ways

Citations
Document	Relation	Office	Cited during
US1613874A	Cites	United States of America	Applicant
WO2005060985A1	Cites	World Intellectual Property Organization (WIPO)	Applicant
US5595760A	Cites	United States of America	Applicant
US5672659A	Cites	United States of America	Applicant
US5821221A	Cites	United States of America	Applicant
US5916883A	Cites	United States of America	Applicant
US6350430B1	Cites	United States of America	Applicant
US6525019B2	Cites	United States of America	Applicant
US6600015B2	Cites	United States of America	Applicant
US6613874B1	Cites	United States of America	Applicant
US6639123B1	Cites	United States of America	Applicant
US6713487B2	Cites	United States of America	Applicant
US6720324B2	Cites	United States of America	Applicant
CONE, R. D. ET AL., RECENT PROG. HORM. RES., vol. 51, 1996, pages 287 - 318	Non-patent	–	Applicant
CONE, R. D. ET AL., ANN. N.Y. ACAD. SCI., vol. 680, 1993, pages 342 - 363	Non-patent	–	Applicant
TATRO, J. B. ET AL., ENDOCRINOL, vol. 121, 1987, pages 1900 - 1907	Non-patent	–	Applicant
MOUNTJOY, K. G. ET AL., SCIENCE, vol. 257, 1992, pages 1248 - 1251	Non-patent	–	Applicant
CHHAJLANI, V. ET AL., FEBS LETT., vol. 309, 1992, pages 417 - 420	Non-patent	–	Applicant
GANTZ, I. ET AL., J. BIOL. CHEM., vol. 268, 1993, pages 15174 - 15179	Non-patent	–	Applicant
DE WIED, D. ET AL., METHODS ACHIEV. EXP. PATHOL., vol. 15, 1991, pages 167 - 199	Non-patent	–	Applicant
DE WIED, D. ET AL., PHYSIOL. REV., vol. 62, 1982, pages 977 - 1059	Non-patent	–	Applicant
GUBER, K.A. ET AL., AM. J. PHYSIOL., vol. 257, 1989, pages R681 - R694	Non-patent	–	Applicant
WALKER J.M. ET AL., SCIENCE, vol. 210, 1980, pages 1247 - 1249	Non-patent	–	Applicant
MURPHY, M. T. ET AL., SCIENCE, vol. 221, 1983, pages 192 - 193	Non-patent	–	Applicant
ELLERKMANN, E. ET AL., ENDOCRINOL, vol. 130, 1992, pages 133 - 138	Non-patent	–	Applicant
VERSTEEG, D. H. G. ET AL., LIFE SCI., vol. 38, 1986, pages 835 - 840	Non-patent	–	Applicant
GIRAUDO, S. Q. ET AL., BRAIN RES., vol. 809, 1998, pages 302 - 306	Non-patent	–	Applicant
FAROOQI, 1. S. ET AL., NE J MED., vol. 348, 2003, pages 1085 - 1095	Non-patent	–	Applicant
MACNEIL, D. J. ET AL., EU. J. PHARM., vol. 450, 2002, pages 141 - 109	Non-patent	–	Applicant
KASK, A. ET AL., NEUROREPORT, vol. 10, 1999, pages 707 - 711	Non-patent	–	Applicant
CATANIA, A. ET AL., PHARM. REV., vol. 56, 2004, pages 1 - 29	Non-patent	–	Applicant
GETTING, S. J. ET AL., CURR. OPIN. INVESTIG. DRUGS, vol. 2, 2001, pages 1064 - 1069	Non-patent	–	Applicant
FEHM, H. L. ET AL., J. CLIN. ENDO. & METAB., vol. 6, 2001, pages 1144 - 1148	Non-patent	–	Applicant
HANSEN, M. J. ET AL., BRAIN RES., vol. 1039, 2005, pages 137 - 145	Non-patent	–	Applicant
WESSELLS, H. ET AL., NEUROSCIENCE, vol. 118, 2003, pages 755 - 762	Non-patent	–	Applicant
WESSELLS, H. ET AL., UROLOGY, vol. 56, 2000, pages 641 - 646	Non-patent	–	Applicant
SHADIACK, A. M. ET AL., SOCIETY FOR NEUROSCIENCE ABSTRACT, 2003	Non-patent	–	Applicant
WESSELLS, H. ET AL., J. UROLOGY, vol. 160, 1998, pages 389 - 393	Non-patent	–	Applicant
ROSEN, R. C. ET AL., INT. J. IMPOTENCE RES., vol. 16, 2004, pages 135 - 142	Non-patent	–	Applicant
DUMONT, L. M. ET AL., PEPTIDES, vol. 26, 2005, pages 1929 - 1935	Non-patent	–	Applicant
FOURCROY, J. L., DRUGS, vol. 63, 2003, pages 1445 - 1457	Non-patent	–	Applicant
MIONI, C. ET AL., EU. J. PHARM., vol. 477, 2003, pages 227 - 234	Non-patent	–	Applicant
SHARMA H. S. ET AL., ACTA. NEROCHIR. SUPPL., vol. 86, 2003, pages 399 - 405	Non-patent	–	Applicant
SHARMA H.S., ANN. N.Y. ACAD. SCI., vol. 1053, 2005, pages 407 - 421	Non-patent	–	Applicant
HARRIS, R. B. ET AL., PHYSIOL. BEHAV., vol. 73, 2001, pages 599 - 608	Non-patent	–	Applicant
MARKISON, S. ET AL., ENDOCRINOLOGY, vol. 146, 2005, pages 2766 - 2773	Non-patent	–	Applicant
LUGER, T. A. ET AL., PATHOBIOLOGY, vol. 67, 1999, pages 318 - 321	Non-patent	–	Applicant
HATTA, N. ET AL., J. INVEST. DERMATOL., vol. 116, 2001, pages 564 - 570	Non-patent	–	Applicant
BOHM, M. ET AL., J. INVEST. DERMATOL., vol. 118, 2002, pages 533 - 539	Non-patent	–	Applicant
STURM, R.A., MELANOMA RES., vol. 12, 2002, pages 405 - 416	Non-patent	–	Applicant
BASTIENS, M. T. ET AL., AM. J. HUM. GENET., vol. 68, 2001, pages 884 - 894	Non-patent	–	Applicant
PONTILLO, J. ET AL., BIOORGANIC & MED. CHEM. LTRS., vol. 15, 2005, pages 2541 - 2546	Non-patent	–	Applicant
BEDNAREK, M. A. ET AL., EXPERT OPINION THER. PATENTS, vol. 14, 2004, pages 327 - 336	Non-patent	–	Applicant
VOISEY, J. ET AL., CURR. DRUG TARGETS, vol. 4, 2003, pages 586 - 597	Non-patent	–	Applicant
BERTOLINI, A. ET AL., J. ENDOCRINOL. INVEST., vol. 4, 1981, pages 241 - 251	Non-patent	–	Applicant
VRINTEN, D. ET AL., J. NEUROSCIENCE, vol. 20, 2000, pages 8131 - 8137	Non-patent	–	Applicant
NAVARRO, M. ET AL., ALCOHOL CLIN. EXP. RES., vol. 29, 2005, pages 949 - 957	Non-patent	–	Applicant
STEWART, J.M. ET AL.: "Solid Phase Synthesis", 1984, PIERCE CHEMICAL CO.	Non-patent	–	Applicant
SCHNOLZER ET AL., INT. J. PEPTIDE PROTEIN RES., vol. 40, 1992, pages 180	Non-patent	–	Applicant

99 members in 21 offices

This recordMember, by publication datePriority claim11 more offices are in the list below

Priority claims9

Priority claims
Document	Office	Kind	Date
69777905P	United States of America	–	2005-07-08
69777905	United States of America	P	2005-07-08
74885005P	United States of America	–	2005-12-09
74885005	United States of America	P	2005-12-09
17202836	European Patent Office (EPO)	A	2006-07-10
12188784	European Patent Office (EPO)	A	2006-07-10
10182566	European Patent Office (EPO)	A	2006-07-10
06786665	European Patent Office (EPO)	A	2006-07-10
2006026586	United States of America	W	2006-07-10

Members99

Family members, oldest first
Document	Office	Kind
AU2006269261A1	Australia	A1	2007-01-18
CA2614615A1	Canada	A1	2007-01-18
CA2793119A1	Canada	A1	2007-01-18
CA3044795A1	Canada	A1	2007-01-18
CA3228910A1	Canada	A1	2007-01-18
WO2007008704A2	World Intellectual Property Organization (WIPO)	A2	2007-01-18
WO2007008704A3	World Intellectual Property Organization (WIPO)	A3	2007-10-11
IL188545A0	Israel	A0	2008-04-13
IL188545D0	Israel	D0	2008-04-13
EP1915167A2	European Patent Office (EPO)	A2	2008-04-30
KR20080049711A	Republic of Korea	A	2008-06-04
CN101257916A	China	A	2008-09-03
JP2009500427A	Japan	A	2009-01-08
RU2008104803A	Russian Federation	A	2009-08-20
AU2009230799A1	Australia	A1	2009-11-19
AU2006269261B2	Australia	B2	2009-12-17
RU2380372C2	Russian Federation	C2	2010-01-27
KR20100016120A	Republic of Korea	A	2010-02-12
CN101676298A	China	A	2010-03-24
NZ565217A	New Zealand	A	2010-03-26
EP1915167A4	European Patent Office (EPO)	A4	2010-04-07
JP2010090130A	Japan	A	2010-04-22
IL201732A0	Israel	A0	2010-06-16
IL201732D0	Israel	D0	2010-06-16
SG163585A1	Singapore	A1	2010-08-30
EP2236151A1	European Patent Office (EPO)	A1	2010-10-06
US2010279922A1	United States of America	A1	2010-11-04
KR100997177B1	Republic of Korea	B1	2010-11-29
RU2009131092A	Russian Federation	A	2011-02-20
EP2286825A2	European Patent Office (EPO)	A2	2011-02-23
EP2286825A3	European Patent Office (EPO)	A3	2011-07-27
JP4734411B2	Japan	B2	2011-07-27
US2011183886A1	United States of America	A1	2011-07-28
IL188545A	Israel	A	2011-08-31
HK1149190A	Hong Kong, China	A	2011-09-30
HK1149190A1	Hong Kong, China	A1	2011-09-30
US8039435B2	United States of America	B2	2011-10-18
RU2439079C2	Russian Federation	C2	2012-01-10
AU2009230799B2	Australia	B2	2012-02-09
EP2236151B1	European Patent Office (EPO)	B1	2012-05-23
PT2236151E	Portugal	E	2012-07-02
DK2236151T3	Denmark	T3	2012-07-09
NZ580806A	New Zealand	A	2012-07-27
ES2386862T3	Spain	T3	2012-09-03
CA2614615C	Canada	C	2012-10-16
PL2236151T3	Poland	T3	2012-10-31
EP2548568A2	European Patent Office (EPO)	A2	2013-01-23
KR101232201B1	Republic of Korea	B1	2013-02-12
CN101257916B	China	B	2013-04-03
EP2548568A3	European Patent Office (EPO)	A3	2013-07-17
JP2013253090A	Japan	A	2013-12-19
CN103755786A	China	A	2014-04-30
JP2015232003A	Japan	A	2015-12-24
JP5889513B2	Japan	B2	2016-03-22
CN103755786B	China	B	2016-05-11
IL201732A	Israel	A	2016-07-31
JP5965520B2	Japan	B2	2016-08-03
CN105837661A	China	A	2016-08-10
EP2286825B1	European Patent Office (EPO)	B1	2016-09-28
US9458195B2	United States of America	B2	2016-10-04
US2016368962A1	United States of America	A1	2016-12-22
PT2286825T	Portugal	T	2017-01-02
DK2286825T3	Denmark	T3	2017-01-09
ES2604328T3	Spain	T3	2017-03-06
PL2286825T3	Poland	T3	2017-06-30
HUE031731T2	Hungary	T2	2017-07-28
IL246392A	Israel	A	2017-07-31
US2017240595A1	United States of America	A1	2017-08-24
US9850280B2	United States of America	B2	2017-12-26
EP2548568B1	European Patent Office (EPO)	B1	2018-01-10
DK2548568T3	Denmark	T3	2018-03-12
PT2548568T	Portugal	T	2018-03-21
ES2663916T3	Spain	T3	2018-04-17
US2018105557A1	United States of America	A1	2018-04-19
PL2548568T3	Poland	T3	2018-06-29
EP3354273A1	European Patent Office (EPO)	A1	2018-08-01
HUE037147T2	Hungary	T2	2018-08-28
US2018305406A1	United States of America	A1	2018-10-25
CA2793119C	Canada	C	2019-07-23
HK1258965A	Hong Kong, China	A	2019-11-22
HK1258965A1	Hong Kong, China	A1	2019-11-22
US2020095281A1	United States of America	A1	2020-03-26
EP3354273B1	European Patent Office (EPO)	B1	2021-03-24
DK3354273T3	Denmark	T3	2021-06-28
PT3354273T	Portugal	T	2021-06-28
PL3354273T3	Poland	T3	2021-10-11
SI3354273T1	Slovenia	T1	2021-10-29
ES2877349T3	Spain	T3	2021-11-16
HUE055154T2	Hungary	T2	2021-11-29
NL301150I1	Netherlands (Kingdom of the)	I1	2021-12-08
EP3925614A2This record	European Patent Office (EPO)	A2	2021-12-22
HUS2100054I1	Hungary	I1	2021-12-28
FR21C1060I1	France	I1	2022-01-21
EP3925614A3	European Patent Office (EPO)	A3	2022-03-23
US2022127305A1	United States of America	A1	2022-04-28
NL301150I2	Netherlands (Kingdom of the)	I2	2022-11-24
FR21C1060I2	France	I2	2022-12-02
CN105837661B	China	B	2024-10-15
CN119119190A	China	A	2024-12-13

18 legal events, as 2 offices reported them to INPADOC

Over the term

Point at a mark for the event

Events

Legal events, newest first
	Event	Code	Office
2026-03-11	First examination report despatched17Q	17Q	EP
2026-02-06	Information on the status of an ep patent application or granted ep patentGrantedSTATUS: EXAMINATION IS IN PROGRESSSTAA	STAA	EP
2025-08-20	Party data changed (applicant data changed or rights of an application transferred)RAP3	RAP3	EP
2023-08-16	Opt-out of the competence of the unified patent court (upc) registeredP01	P01	EP
2022-10-26	Request for examination filed17P	17P	EP
2022-10-26	Designated contracting states (corrected)RBV	RBV	EP
2022-09-23	Information on the status of an ep patent application or granted ep patentGrantedSTATUS: REQUEST FOR EXAMINATION WAS MADESTAA	STAA	EP
2022-09-09	Requests to designate patent in hong kongDE	DE	HK
2022-03-23	Designated contracting statesAK	AK	EP
2022-03-23	Information provided on ipc code assigned before grantRIC1	RIC1	EP
2022-02-18	Search report despatchedORIGINAL CODE: 0009013PUAL	PUAL	EP
2021-12-22	Divisional application: reference to earlier applicationAC	AC	EP
2021-12-22	Divisional application: reference to earlier applicationAC	AC	EP
2021-12-22	Divisional application: reference to earlier applicationAC	AC	EP
2021-12-22	Divisional application: reference to earlier applicationAC	AC	EP
2021-12-22	Designated contracting statesAK	AK	EP
2021-11-19	Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI	PUAI	EP
2021-11-19	Information on the status of an ep patent application or granted ep patentGrantedSTATUS: THE APPLICATION HAS BEEN PUBLISHEDSTAA	STAA	EP